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1. Preamble
Guidelines summarize and evaluate available evidence with the aim
of assisting health professionals in proposing the best management
strategies for an individual patient with a given condition. Guidelines
and their recommendations should facilitate decision making of health
professionals in their daily practice. However, the final decisions con-
cerning an individual patient must be made by the responsible health
professional(s) in consultation with the patient and caregiver as ap-
propriate. (see Table 1)
A great number of guidelines have been issued in recent years by the
European Society of Cardiology (ESC) and its partners such as European
Atherosclerosis Society (EAS), as well as by other societies and orga-
nisations. Because of their impact on clinical practice, quality criteria
for the development of guidelines have been established in order to
make all decisions transparent to the user. The recommendations for
formulating and issuing ESC Guidelines can be found on the ESC
website (http://www.escardio.org/Guidelines-&-Education/Clinical-
Practice-Guidelines/Guidelines-development/Writing-ESC-Guidelines).
The ESC Guidelines represent the official position of the ESC on a given
topic and are regularly updated.
The ESC carries out a number of registries which are essential to
assess diagnostic/therapeutic processes, use of resources and adherence
to Guidelines. These registries aim at providing a better understanding
of medical practice in Europe and around the world, based on data
collected during routine clinical practice.
The guidelines are developed together with derivative educational
material addressing the cultural and professional needs for cardiologists
and allied professionals. Collecting high-quality observational data, at
appropriate time interval following the release of ESC Guidelines, will
help evaluate the level of implementation of the Guidelines, checking in
priority the key end points defined with the ESC Guidelines and
Education Committees and Task Force members in charge.
The Members of this Task Force were selected by the ESC and EAS,
including representation from relevant ESC sub-specialty groups, in order
to represent professionals involved with the medical care of patients with
this pathology. Selected experts in the field from both societies under-
took a comprehensive review of the published evidence for management
of a given condition according to ESC Committee for Practice Guidelines
(CPG) policy. A critical evaluation of diagnostic and therapeutic proce-
dures was performed, including assessment of the risk–benefit ratio. The
level of evidence and the strength of the recommendation of particular
management options were weighed and graded according to predefined
ESC scales, as outlined in the tables below.
The experts of the writing and reviewing panels provided declara-
tion of interest forms for all relationships that might be perceived as
real or potential sources of conflicts of interest. These forms were
compiled into one file and can be found on the ESC website (http://
www.escardio.org/guidelines). Any changes in declarations of interest
that arise during the writing period were notified to the ESC and EAS
Chairpersons and updated. The Task Force received its entire financial
support from the ESC and EAS without any involvement from the
healthcare industry.
The ESC CPG supervises and coordinates the preparation of new
Guidelines. The Committee is also responsible for the endorsement pro-
cess of these Guidelines. The ESC Guidelines undergo extensive review by
the CPG and external experts. After appropriate revisions the Guidelines
are approved by all the experts involved in the Task Force. The finalized
document is approved by the CPG and EAS for publication in the
European Heart Journal and Atherosclerosis Journal. The Guidelines were
developed after careful consideration of the scientific and medical
knowledge and the evidence available at the time of their dating.
The task of developing ESC/EAS Guidelines also includes the creation
of educational tools and implementation programmes for the re-
commendations including condensed pocket guideline versions, summary
slides, booklets with essential messages, summary cards for non-specia-
lists and an electronic version for digital applications (smartphones, etc.).
These versions are abridged and thus, for more detailed information, the
user should always access the full text version of the Guidelines, which is
freely available via the ESC and EAS websites and hosted on their jour-
nals’ websites (EHJ and Atherosclerosis Journal). The National Cardiac
Societies of the ESC are encouraged to endorse, translate and implement
all ESC Guidelines. Implementation programmes are needed because it
has been shown that the outcome of disease may be favourably influenced
by the thorough application of clinical recommendations.
Health professionals are encouraged to take the ESC/EAS Guidelines
fully into account when exercising their clinical judgment, as well as in
the determination and the implementation of preventive, diagnostic or
therapeutic medical strategies. However, the ESC/EAS Guidelines do
not override in any way whatsoever the individual responsibility of
F. Mach, et al.
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Abbreviations and acronyms
ABI Ankle–brachial index
ACCELERATE Assessment of Clinical Effects of Cholesteryl Ester
Transfer Protein Inhibition with Evacetrapib in Patients at
a High-Risk for Vascular Outcomes
ACCORD Action to Control Cardiovascular Risk in Diabetes
ACS Acute coronary syndrome
ALT Alanine aminotransferase
ANGPTL3Angiopoietin-like protein 3
Apo Apolipoprotein
ART Antiretroviral treatment
ASCEND A Study of Cardiovascular Events iN Diabetes
ASCOT-LLA Anglo-Scandinavian Cardiac Outcomes Trial – Lipid-
Lowering Arm
ASCVD Atherosclerotic cardiovascular disease
ASSIGN CV risk estimation model from the Scottish Intercollegiate
Guidelines Network
AURORA A study to evaluate the Use of Rosuvastatin in subjects On
Regular haemodialysis: an Assessment of survival and
cardiovascular events
b.i.d. Twice a day (bis in die)
BIOSTAT-CHF BIOlogy Study to TAilored Treatment in Chronic
Heart Failure
BIP Bezafibrate Infarction Prevention
BMI Body mass index
BP Blood pressure
CABG Coronary artery bypass graft surgery
CAC Coronary artery calcium
CAD Coronary artery disease
CANTOS Canakinumab Antiinflammatory Thrombosis Outcome
Study
CETP Cholesteryl ester transfer protein
CHD Coronary heart disease
CI Confidence interval
CIID Chronic immune-mediated inflammatory diseases
CIRT Cardiovascular Inflammation Reduction Trial
CK Creatine kinase
CKD Chronic kidney disease
COM-B Capability, Opportunity and Motivation
CORONA Controlled Rosuvastatin Multinational Trial in Heart
Failure
CPG Committee for Practice Guidelines
CT Computed tomography
CTT Cholesterol Treatment Trialists
CV Cardiovascular
CVD Cardiovascular disease
CYP Cytochrome P450
4D Die Deutsche Diabetes Dialyse Studie
dal-OUTCOMES Effects of Dalcetrapib in Patients with a Recent
Acute Coronary Syndrome
DASH Dietary Approaches to Stop Hypertension
DGAT-2 Diacylglycerol acyltransferase-2
DHA Docosahexaenoic acid
DM Diabetes mellitus
EAPC European Association of Preventive Cardiology
EAS European Atherosclerosis Society
EBBIGHAUS Evaluating PCSK9 Binding Antibody Influence on
Cognitive Health in High Cardiovascular Risk Subjects
eGFR Estimated glomerular filtration rate
EMA European Medicines Agency
EPA Eicosapentaenoic acid
ESC European Society of Cardiology
EVOLVE EpanoVa fOr Lowering Very high triglyceridEs
EVOPACSEVOlocumab for early reduction of LDL-cholesterol levels
in patients with Acute Coronary Syndromes
FCH Familial combined hyperlipidaemia
FCS Familial chylomicronaemia syndrome
FDA US Food and Drug Administration
FH Familial hypercholesterolaemia
FIELD Fenofibrate Intervention and Event Lowering in Diabetes
FOCUS Fixed-Dose Combination Drug for Secondary
Cardiovascular Prevention
FOURIER Further Cardiovascular Outcomes Research with PCSK9
Inhibition in Subjects with Elevated Risk
GFR Glomerular filtration rate
GI Gastrointestinal
GISSI Gruppo Italiano per lo Studio della Sopravvivenza
nell'Infarto Miocardico
HbA1c Glycated haemoglobin
HeFH Heterozygous familial hypercholesterolaemia
HDL High-density lipoprotein
HDL-C High-density lipoprotein cholesterol
HF Heart failure
HHS Helsinki Heart Study
HIV Human immunodeficiency virus
HMG-CoAHydroxymethylglutaryl-coenzyme A
HoFH Homozygous familial hypercholesterolaemia
HPS2-THRIVE Heart Protection Study 2-Treatment of HDL to
Reduce the Incidence of Vascular Events
HR Hazard ratio
HTG Hypertriglyceridaemia
IDEA L Incremental Decrease In End-points Through Aggressive
Lipid-lowering
IDL Intermediate-density lipoproteins
IL Interleukin
ILLUMINATE Investigation of Lipid Level Management to
Understand its Impact in Atherosclerotic Events
IMPROVE-IT Improved Reduction of Outcomes: Vytorin Efficacy
International Trial
IPD Individual participant data
JUPITER Justification for the Use of Statins in Prevention: an
Intervention Trial Evaluating Rosuvastatin
KDIGO Kidney Disease: Improving Global Outcomes
LCAT Lecithin cholesterol acyltransferase
LDL Low-density lipoprotein
LDL-C Low-density lipoprotein cholesterol
LDLR Low-density lipoprotein receptor
LEAD Lower extremity arterial disease
LEADER Lower Extremity Arterial Disease Event Reduction
LPL Lipoprotein lipase
Lp(a) Lipoprotein(a)
mAb Monoclonal antibody
MACE Major adverse cardiovascular events
MESA Multi-Ethnic Study of Atherosclerosis
MetS Metabolic syndrome
MI Myocardial infarction
mRNA Messenger RNA
MTP Microsomal triglyceride transfer protein
NAFLD Non-alcoholic fatty liver disease
NNT Number needed to treat
NPC1L1 Niemann-Pick C1-like protein 1
NSTE-ACS Non-ST elevation acute coronary syndrome
o.d. Once a day (omni die)
ODYSSEY Outcomes Evaluation of Cardiovascular Outcomes After
an Acute Coronary Syndrome During Treatment With
Alirocumab
PAD Peripheral arterial disease
PCI Percutaneous coronary intervention
PCSK9 Proprotein convertase subtilisin/kexin type 9
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health professionals to make appropriate and accurate decisions in
consideration of each patient's health condition and in consultation
with that patient or the patient's caregiver where appropriate and/or
necessary. It is also the health professional's responsibility to verify the
rules and regulations applicable in each country to drugs and devices at
the time of prescription.
2. Introduction
The previous ESC/EAS lipid Guidelines were published in August
2016 [1]. The emergence of a substantial body of evidence over the last
few years has required new, up-to-date Guidelines.
New evidence has confirmed that the key initiating event in ather-
ogenesis is the retention of low-density lipoprotein (LDL) cholesterol
(LDL-C) and other cholesterol-rich apolipoprotein (Apo) B-containing li-
poproteins within the arterial wall [2]. Several recent placebo-controlled
clinical studies have shown that the addition of either ezetimibe or anti-
proprotein convertase subtilisin/kexin type 9 (PCSK9) monoclonal anti-
bodies (mAbs) to statin therapy provides a further reduction in athero-
sclerotic cardiovascular disease (ASCVD) risk, which is directly and po-
sitively correlated with the incrementally achieved absolute LDL-C
reduction. Furthermore, these clinical trials have clearly indicated that
the lower the achieved LDL-C values, the lower the risk of future cardi-
ovascular (CV) events, with no lower limit for LDL-C values, or ‘J’-curve
effect. In addition, studies of the clinical safety of these very low achieved
LDL-C values have proved reassuring, albeit monitoring for longer periods
is required. For raising high-density lipoprotein (HDL) cholesterol (HDL-
C), recent studies have indicated that the currently available therapies do
not reduce the risk of ASCVD. Finally, human Mendelian randomization
studies have demonstrated the critical role of LDL-C, and other choles-
terol-rich ApoB-containing lipoproteins, in atherosclerotic plaque forma-
tion and related subsequent CV events. Thus, there is no longer an ‘LDL-C
hypothesis’, but established facts that increased LDL-C values are causally
related to ASCVD, and that lowering LDL particles and other ApoB-con-
taining lipoproteins as much as possible reduces CV events.
In order to be aligned with these new findings, the ESC/EAS Task
Force members who have written these Guidelines have proposed new
LDL-C goals, as well as a revised CV risk stratification, which are
especially relevant to high- and very-high-risk patients.
These novel ESC/EAS Guidelines on lipids provide important new
advice on patient management, which should enable more clinicians to
efficiently and safely reduce CV risk through lipid modification (see
Table 2).
2.1. What is new in the 2019 guidelines?
New recommendations, and new and revised concepts, are pre-
sented in Table 3.
3. What is cardiovascular disease prevention?
3.1. Definition and rationale
Cardiovascular disease (CVD), of which ASCVD is the major com-
ponent, is responsible for> 4 million deaths in Europe each year. It
kills more women (2.2 million) than men (1.8 million), although CV
deaths before the age of 65 years are more common in men (490 000 vs.
193 000) [3]. Prevention is defined as a co-ordinated set of actions,
either at the population or individual level, aimed at eradicating and
eliminating are synonymous or minimizing the impact of CV diseases
and their related disabilities. More patients are surviving their first CVD
event and are at high-risk of recurrences. In addition, the prevalence of
some risk factors, notably diabetes (DM) and obesity, is increasing. The
importance of ASCVD prevention remains undisputed and should be
delivered at the general population level by promoting healthy lifestyle
behaviour [4], and at the individual level by tackling unhealthy life-
styles and by reducing increased levels of causal CV risk factors, such as
LDL cholesterol or blood pressure (BP) levels.
3.2. Development of the joint Task Force guidelines for the management of
dyslipidaemias
The present Guidelines represent an evidence-based consensus of
the European Task Force, including the ESC and the EAS.
By appraising the current evidence and identifying remaining
knowledge gaps in the management of dyslipidaemias, the Task Force
has formulated recommendations to guide action in clinical practice to
prevent ASCVD by modifying plasma lipid levels.
PPAR-α Peroxisome proliferator-activated receptor-α
PREDIMED Prevención con Dieta Mediterránea
PROCAM Prospective Cardiovascular Munster Study
PROMINENT Pemafibrate to Reduce Cardiovascular OutcoMes by
Reducing Triglycerides IN PatiENts With DiabeTes
PUFA Polyunsaturated fatty acid
PURE Prospective Urban Rural Epidemiology
RA Rheumatoid arthritis
RCT Randomized controlled trial
REDUCE-IT Reduction of Cardiovascular Events with EPA-
Intervention Trial
REVEAL Randomized EValuation of the Effects of Anacetrapib
Through Lipid modification
RR Relative risk
RYR Red yeast rice
SAMS Statin-associated muscle symptoms
SBP Systolic blood pressure
SCORE Systematic Coronary Risk Estimation
SEAS Simvastatin and Ezetimibe in Aortic Stenosis
SECURE-PCI Statins Evaluation in Coronary Procedures and
Revascularization
SFA Saturated fatty acid
SHARP Study of Heart and Renal Protection
siRNA Small interfering RNA
SMI Severe mental illness
SPARCL Stroke Prevention by Aggressive Reduction in Cholesterol
Levels
STAREE STAtin Therapy for Reducing Events in the Elderly
STEMI ST-elevation myocardial infarction
STRENGTH Outcomes Study to Assess STatin Residual Risk
Reduction with EpaNova in HiGh CV Risk PatienTs with
Hypertriglyceridemia
TC Total cholesterol
T1DM Type 1 diabetes mellitus
T2DM Type 2 diabetes mellitus
TGs Triglycerides
TIA Transient ischaemic attack
TIMI Thrombolysis In Myocardial Infarction
TNF Tumour necrosis factor
TNT Treating to New Targets
TRL Triglyceride-rich lipoprotein
ULN Upper limit of normal
VA-HIT Veterans Affairs High Density Lipoprotein Intervention
Trial
VITAL VITamin D and OmegA-3 Trial
VLDL Very low-density lipoprotein
WHO World Health Organization
WOSCOPS West of Scotland Coronary Prevention Study
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This document has been developed for healthcare professionals to
facilitate informed communication with individuals about their CV risk
and the benefits of adopting and sustaining a healthy lifestyle, and of
early modification of their lipid-related CV risk. In addition, the
Guidelines provide tools for healthcare professionals to promote up-to-
date intervention strategies, integrate these strategies into national or
regional prevention frameworks, and to translate them into locally
delivered healthcare services, in line with the recommendations of the
World Health Organization (WHO) Global Status Report on
Noncommunicable Diseases 2014 [5].
A lifetime approach to CV risk should be considered [1]. This im-
plies that—apart from improving lifestyle habits and reducing risk
factor levels in patients with established ASCVD, and in those at in-
creased risk of developing ASCVD—people of all ages should be en-
couraged to adopt or sustain a healthy lifestyle.
4. Total cardiovascular risk
4.1. Total cardiovascular risk estimation
CV risk in the context of these Guidelines means the likelihood of a
person developing an atherosclerotic CV event over a defined period of
time. Total CVD risk expresses the combined effect of a number of risk
factors on this risk estimate. In these Guidelines, we address the lipid-related
contribution to total CV risk and how to manage it at the clinical level.
4.1.1. Rationale for assessing total cardiovascular disease risk
All current guidelines on the prevention of ASCVD in clinical
practice recommend the assessment of total CVD risk. Prevention of
ASCVD in a given person should relate to his or her total CV risk: the
higher the risk, the more intense the action should be.
Many risk assessment systems are available and have been com-
prehensively reviewed (Supplementary Table 1 in the Supplementary
Data). Most guidelines use one of these risk assessment systems [6–8].
Ideally, risk charts should be based on country-specific cohort data.
These are not available for most countries. The SCORE (Systematic
Coronary Risk Estimation) system can be recalibrated for use in dif-
ferent populations by adjusting for secular changes in CVD mortality
and risk factor prevalence. Calibrated country-specific versions are
available for many European countries and can be found at http://
www.heartscore.org. These are now being updated to provide recali-
brated, contemporaneous country-specific charts for all European
Table 1
Classes of recommendations.
Table 2
Levels of evidence.
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Table 3
New recommendations, and new and revised concepts.
(continued on next page)
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Table 3 (continued)
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countries. Other risk estimation systems—using both fatal and non-fatal
events—can also be recalibrated, but the process is easier and scienti-
fically more robust for mortality than for total events. The European
Guidelines on CVD prevention in clinical practice (both the 2012 [9]
and 2016 [10] versions) recommend the use of the SCORE system be-
cause it is based on large, representative European cohort data sets and
because it is relatively straightforward to recalibrate for individual
countries.
Fig. 1. Systematic Coronary Risk Estimation chart for European populations at high cardiovascular disease risk. The 10-year risk of fatal cardiovascular disease in
populations at high cardiovascular disease risk based on the following risk factors: age, gender, smoking, systolic blood pressure, and total cholesterol. To convert the
risk of fatal cardiovascular disease to risk of total (fatal + non-fatal) cardiovascular disease, multiply by 3 in men and by 4 in women, and slightly less in older
people. Note: the Systematic Coronary Risk Estimation chart is for use in people without overt cardiovascular disease, diabetes (type 1 and 2), chronic kidney disease,
familial hypercholesterolaemia, or very high levels of individual risk factors because such people are already at high-risk and need intensive risk factor management.
Cholesterol: 1 mmoL/L = 38.67 mg/dL. The SCORE risk charts presented above differ slightly from those in the 2016 European Society of Cardiology/European
Atherosclerosis Society Guidelines for the management of dyslipidaemias and the 2016 European Guidelines on cardiovascular disease prevention in clinical practice,
in that: (i) age has been extended from age 65 to 70; (ii) the interaction between age and each of the other risk factors has been incorporated, thus reducing the
overestimation of risk in older persons in the original Systematic Coronary Risk Estimation charts; and (iii) the cholesterol band of 8 mmoL/L has been removed, since
such persons will qualify for further evaluation in any event. SCORE = Systematic Coronary Risk Estimation.
ACS= acute coronary syndrome; ApoB=apolipoprotein B; ASCVD= atherosclerotic cardiovascular disease; CAC= coronary artery calcium; CHD= coronary heart
disease; CT= computed tomography; CV= cardiovascular; CVD= cardiovascular disease; DM=diabetes mellitus; FH= familial hypercholesterolaemia;
HDL=high-density lipoprotein; LDL-C= low-density lipoproteins cholesterol; Lp(a)= lipoprotein(a); PCSK9=proprotein convertase subtilisin/kexin type 9;
PUFAs=polyunsaturated fatty acids; RCTs= randomized controlled trials; T1DM= type 1 diabetes mellitus; T2DM= type 2 diabetes mellitus; TGs= triglycerides.
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Persons with documented ASCVD, type 1 or type 2 DM (T1DM and
T2DM, respectively), very high levels of individual risk factors, or
chronic kidney disease (CKD) are generally at very-high or high total
CV risk. No risk estimation models are needed for such persons; they all
need active management of all risk factors. For other, apparently
healthy people, the use of a risk estimation system such as SCORE,
which estimates the 10 year cumulative risk of a first fatal athero-
sclerotic event, is recommended to estimate total CV risk, since many
people have several risk factors that, in combination, may result in high
levels of total CV risk.
Risk estimates have been produced as charts for high- and low-risk
regions in Europe (Fig. 1 and 2) [11]. All International Classification of
Diseases codes that are related to deaths from vascular origin caused by
atherosclerosis are included. The reasons for retaining a system that
estimates fatal as opposed to total fatal + non-fatal events are that non-
fatal events are dependent on definition, developments in diagnostic
tests, and methods of ascertainment, all of which can vary, resulting in
very variable multipliers to convert fatal to total events. In addition,
Fig. 2. Systematic Coronary Risk Estimation chart for European populations at low cardiovascular disease risk. The 10-year risk of fatal cardiovascular disease in
populations at low cardiovascular disease risk based on the following risk factors: age, gender, smoking, systolic blood pressure, and total cholesterol. To convert the
risk of fatal cardiovascular disease to risk of total (fatal + non-fatal) cardiovascular disease, multiply by 3 in men and by 4 in women, and slightly less in older
people. Note: the Systematic Coronary Risk Estimation chart is for use in people without overt cardiovascular disease, diabetes (type 1 and 2), chronic kidney disease,
familial hypercholesterolaemia, or very high levels of individual risk factors because such people are already at high-risk and need intensive risk factor management.
Cholesterol: 1 mmoL/L = 38.67 mg/dL. The SCORE risk charts presented above differ slightly from those in the 2016 European Society of Cardiology/European
Atherosclerosis Society Guidelines for the management of dyslipidaemias and the 2016 European Guidelines on cardiovascular disease prevention in clinical practice,
in that: (i) age has been extended from age 65 to 70; (ii) the interaction between age and each of the other risk factors has been incorporated, thus reducing the
overestimation of risk in older persons in the original Systematic Coronary Risk Estimation charts; and (iii) the cholesterol band of 8 mmoL/L has been removed since
such persons will qualify for further evaluation in any event. SCORE = Systematic Coronary Risk Estimation.
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total event charts, in contrast to those based on mortality, are more
difficult to recalibrate to suit different populations. That said, work is in
progress to produce regional total event charts .
The SCORE data indicate that the total CVD event risk is about three
times higher than the risk of fatal CVD for men, so a SCORE risk of 5%
translates into a CVD risk of ∼15% of total (fatal + non-fatal) CVD
endpoints; the multiplier is higher in women and lower in older people.
Clinicians often ask for thresholds to trigger certain interventions.
This is problematic since risk is a continuum and there is no threshold
at which, for example, a drug is automatically indicated. This is true for
Box 1
How to use the risk estimation charts
To estimate a person's 10-year risk of CVD death, find the table for his/her gender, smoking status, and age. Within the table, find the cell
nearest to the person's BP and TC. Risk estimates will need to be adjusted upwards as the person approaches the next age category.
Risk is initially assessed on the level of TC and systolic BP before treatment, if known. The longer the treatment and the more effective it is,
the greater the reduction in risk, but in general it will not be more than about one-third of the baseline risk. For example, for a person on
antihypertensive drug treatment in whom the pre-treatment BP is not known, if the total CV SCORE risk is 6%, then the pre-treatment total CV
risk may have been 9%.
Low-risk persons should be offered advice to maintain their low-risk status. While no threshold is universally applicable, the intensity of
advice should increase with increasing risk.
The charts may be used to give some indication of the effects of reducing risk factors, given that there is apparently a time lag before the
risk reduces. In general, people who stop smoking halve their cumulative risk over a relatively short period of time.
BP=blood pressure; CV= cardiovascular; CVD= cardiovascular disease; SCORE = Systematic Coronary Risk Estimation; TC= total cholesterol.
Box 2
Risk estimation charts for different countries
The low-risk charts should be considered for use in Austria, Belgium, Cyprus, Denmark, Finland, France, Germany, Greece, Iceland, Ireland,
Israel, Italy, Luxembourg, Netherlands, Norway, Malta, Portugal, Slovenia, Spain, Sweden, Switzerland, and the UK.
The high-risk charts should be considered for use in Albania, Algeria, Armenia, Bosnia and Herzegovina, Croatia, Czech Republic, Estonia,
Hungary, Latvia, Lebanon, Libya, Lithuania, Montenegro, Morocco, Poland, Romania, Serbia, Slovakia, Tunisia, and Turkey.
Some countries have a cardiovascular disease mortality rate> 350/100 000, and the high-risk chart may underestimate risk. These are
Azerbaijan, Belarus, Bulgaria, Egypt, Georgia, Kazakhstan, Kyrgyzstan, Macedonia, Republic of Moldova, Russian Federation, Syria, Tajikistan,
Turkmenistan, Ukraine, and Uzbekistan.
See http://apps.who.int/gho/data/node.home.
Box 3
Qualifiers
The charts can assist in risk assessment and management, but must be interpreted in light of the clinician's knowledge and experience, and of
the patient's pre-test likelihood of CVD.
Risk will be overestimated in countries with decreasing CVD mortality, and underestimated in countries in which mortality is increasing.
This is dealt with by recalibration (http://www.heartscore.org/en_GB/).
Risk estimates are lower in women than in men. However, risk is only deferred in women; the risk of a 60-year-old woman is similar to that
of a 50-year-old man. Ultimately, more women die from CVD than men.
Relative risks may be unexpectedly high in young persons, even if absolute risk levels are low. The relative risk chart (Supplementary
Fig. 1) and the estimated risk age (Supplementary Fig. 2) may be helpful in identifying and counselling such persons.
CVD= cardiovascular disease.
Box 4
Factors modifying Systematic Coronary Risk Estimation risks
Social deprivation: the origin of many of the causes of CVD.
Obesity and central obesity as measured by the body mass index and waist circumference, respectively.
Physical inactivity.
Psychosocial stress including vital exhaustion.
Family history of premature CVD (men:< 55 years and women:< 60 years).
Chronic immune-mediated inflammatory disorder.
Major psychiatric disorders.
Treatment for human immunodeficiency virus infection.
Atrial fibrillation.
Left ventricular hypertrophy.
Chronic kidney disease.
Obstructive sleep apnoea syndrome.
Non-alcoholic fatty liver disease.
CVD= cardiovascular disease.
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all continuous risk factors such as plasma cholesterol or systolic BP
(SBP). Therefore, the goals that are proposed in this document reflect
this concept.
A particular problem relates to young people with high levels of risk
factors; a low absolute risk may conceal a very high relative risk re-
quiring at least intensive lifestyle advice. To motivate young people (i.e.
aged< 40 years) not to delay changing their unhealthy lifestyle, an
estimate of their relative risk—illustrating that lifestyle changes can
reduce relative risk substantially—may be helpful (Supplementary
Fig. 1).
Another approach to this problem is to use CV risk age. The risk age
of a person with several CV risk factors is the age of a person with the
same level of risk but with ideal levels of risk factors. Thus, a high-risk
40-year-old would have a risk age ≥65 years. Risk age can be estimated
visually by looking at the SCORE chart (as illustrated in Supplementary
Fig. 2). In this chart, the risk age of a person with risk factors is defined
as the age at which a person with ideal risk factor levels would reach
the same risk level. Ideal risk factors are non-smoking, total cholesterol
(TC) ≤4 mmoL/L (≤155 mg/dL), and SBP ≤120mmHg. Risk age is
also automatically calculated as part of the latest revision of HeartScore
(http://www.HeartScore.org).
Risk age has been shown to be independent of the CV endpoint used
[6,8], can be used in any population regardless of baseline risk or secular
changes in mortality, and therefore avoids the need for recalibration.
Lifetime risk is another approach to illustrate the impact of risk
factors that may be useful in younger people [12]. The greater the
burden of risk factors, the higher the lifetime risk. This approach pro-
duces higher risk figures for younger people because of their longer
exposure times. Therefore, it is more useful as a way of illustrating risk
than as a guide to treatment, because therapeutic trials have been based
on a fixed follow-up period and not on lifetime risk.
Another problem relates to older people. In some age categories, the
majority of people, especially males, will have estimated 10 year cu-
mulative CV death risks exceeding the 5–10% level, based on age only,
even when other CV risk factor levels are relatively low. Therefore, be-
fore initiating treatment in the elderly, clinicians should evaluate pa-
tients carefully. The relative strengths of risk factors vary with age and
SCORE overestimates risk in older people (that is, those aged>65 years)
[11]. These Guidelines include illustrative charts for older people (see
Figs. 1 and 2). While older people benefit from smoking cessation, and
control of hypertension and hyperlipidaemia (see section 9.3), clinical
judgement is required to avoid side effects from overmedication.
The additional impact of HDL-C on risk estimation is illustrated in
Supplementary Figs. 3 and 4; HDL-C can be used to increase the ac-
curacy of the risk evaluation. In these charts, HDL-C is used categori-
cally. The electronic version of SCORE, HeartScore (http://www.
heartscore.org/en_GB/), has been modified to take HDL-C into con-
sideration as a continuous variable. Clinicians should be aware that at
extremely high values [above ∼2.3 mmoL/L (90 mg/dL)] of HDL-C
there appears to be an increased risk of ASCVD, so at such levels HDL-C
cannot be used as a risk predictor.
Box 5
Risk estimation: key messages
In apparently healthy persons, CVD risk is most frequently the result of multiple, interacting risk factors. This is the basis for total CV risk
estimation and management.
Risk factor screening including the lipid profile should be considered in men>40 years old, and in women>50 years of age or post-
menopausal.
A risk estimation system such as SCORE can assist in making logical management decisions, and may help to avoid both under- and
overtreatment.
Certain individuals declare themselves to be at high or very high CVD risk without needing risk scoring, and all risk factors require
immediate attention. This is true for patients with documented CVD, older individuals with long-standing DM, familial hypercholesterolaemia,
chronic kidney disease, carotid or femoral plaques, coronary artery calcium score> 100, or extreme Lp(a) elevation.
All risk estimation systems are relatively crude and require attention to qualifying statements.
Additional factors affecting risk can be accommodated in electronic risk estimation systems such as HeartScore (www.heartscore.org).
The total risk approach allows flexibility; if optimal control cannot be achieved with one risk factor, trying harder with the other factors can
still reduce risk.
CV= cardiovascular; CVD= cardiovascular disease; DM=diabetes mellitus; SCORE = Systematic Coronary Risk Estimation.
Table 4
Cardiovascular risk categories.
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4.1.2. How to use the risk estimation charts
Use of the low- or the high-risk SCORE charts will depend on the
CVD mortality experience in each country. While any cut-off point is
arbitrary and open to debate, in these Guidelines, the cut-off point for
calling a country ‘low CVD risk’ is based on WHO data derived from the
Global Burden of Disease Study.
Countries are categorized as low-risk if their age-adjusted 2016 CVD
mortality rate was<150/100 000 (for men and women together)
(http://www.who.int/healthinfo/global_burden_disease/estimates/en/
). Countries with a CVD mortality rate of ≥150/100 000 or more are
considered to be at high-risk.
Boxes 1 to 5 summarize the main points regarding the risk estima-
tion charts and their use.
Social deprivation and psychosocial stress set the scene for in-
creased risk [13]. For those at moderate risk, other factors—including
metabolic factors such as increased ApoB, lipoprotein(a) [Lp(a)], tri-
glycerides (TGs), or C-reactive protein; the presence of albuminuria; the
presence of atherosclerotic plaque in the carotid or femoral arteries; or
the coronary artery calcium (CAC) score—may improve risk classifi-
cation. Many other biomarkers are also associated with increased CVD
risk, although few of these have been shown to be associated with
appreciable reclassification. Total CV risk will also be higher than in-
dicated in the SCORE charts in asymptomatic persons with abnormal
markers of subclinical atherosclerotic vascular damage. Reclassification
is of value in people identified as being at moderate CV risk by using
markers such as CAC score> 100 Agatston units, ankle–brachial index
(ABI)< 0.9 or> 1.40, carotid–femoral pulse wave velocity> 10 m/s,
or the presence of plaques at carotid or femoral ultrasonography. In
studies comparing these markers, CAC had the best reclassification
ability [14–16].
Some factors such as a high HDL-C up to 2.3 mmoL/L (90mg/dL)
[17] or a family history of longevity can also be associated with lower
risk.
4.2. Risk levels
A total CV risk estimate is part of a continuum. The cut-off points
that are used to define high-risk are, in part, both arbitrary and based
on the risk levels at which benefit is evident in clinical trials. In clinical
practice, consideration should be given to practical issues in relation to
the local healthcare systems. Not only should those at high risk be
identified and managed, but those at moderate risk should also receive
professional advice regarding lifestyle changes; in some cases, drug
therapy will be needed to reduce atherosclerotic risk.
Low-risk people should be given advice to help them maintain this
status. Thus, the intensity of preventive actions should be tailored to the
patient's total CV risk. The strongest driver of total CV risk is age, which
can be considered as ‘exposure time’ to risk factors.
For these reasons, the Task Force suggests the following categories
of risk and LDL-C goals, based on the best available evidence and in an
ideal setting with unlimited resources. These categories represent a
counsel of perfection, but these ideals are for guidance only and prac-
tical decision-making must be based on what is appropriate to the local
situation.
With these considerations, we propose the levels of total CV risk
presented in Table 4.
4.2.1. Role of non-invasive cardiovascular imaging techniques in the
assessment of total cardiovascular disease risk
Non-invasive imaging techniques can detect the presence, estimate
the extent, and evaluate the clinical consequences of atherosclerotic
vascular damage. Detection of coronary artery calcification with non-
contrast computed tomography (CT) gives a good estimate of the
atherosclerotic burden and is strongly associated with CV events [18]. A
recent meta-analysis from the US Preventive Services Task Force sum-
marized the available evidence on the value of non-traditional risk
factors for risk prediction, and found that, although there are no ran-
domized trials showing that the use of CAC reduces health outcomes,
nevertheless it improves both discrimination and reclassification [19].
Assessment of carotid or femoral plaque burden with ultrasound has also
been demonstrated to be predictive of CV events, comparable to CAC
[20–23], while the measurement of the carotid intima–media thickness is
inferior to CAC score and carotid plaque detection [16,24,25].
In asymptomatic patients at low or moderate risk who would be
eligible for statin therapy (see Table 5), assessment of ASCVD with
imaging may have an impact on medical treatment, both from the
physician's and the patient's points of view. Data from the Multi-Ethnic
Study of Atherosclerosis (MESA) showed that 41–57% of individuals
who would be eligible for statin therapy had a CAC score of zero and
the rate of atherosclerotic CVD events in the 10 year follow-up period
was low (1.5–4.9%) [26]. In contrast, the rates of ASCVD and coronary
heart disease (CHD) events in individuals with a CAC score> 100
Agatston were 18.9 and 12.7 per 1000 person-years, respectively [18].
Compared with a strategy of treating all patients, the use of CAC score
to guide long-term statin therapy has been shown to be cost-effective
[27]. Note that CAC score is often very low in patients younger than 45
years of age with severe familial hypercholesterolaemia (FH), including
homozygous FH (HoFH), and has low specificity in this population.
Assessment of coronary luminal stenosis>50% and plaque compo-
sition with coronary CT angiography also provides incremental prog-
nostic value over traditional risk stratification models [28]. As a result, in
asymptomatic individuals with moderate risk, the presence of a CAC
score>100 Agatston, and carotid or femoral plaque burden on ultra-
sonography, may reclassify them to a higher risk category. Therefore, the
use of methods to detect these markers should be of interest in that group
(see Recommendations for cardiovascular imaging for risk assessment of
atherosclerotic cardiovascular disease below) [14–16]. Overall, CAC score
assessment with CT should be considered in individuals at low or mod-
erate risk in whom the respective LDL-C goal is not achieved with life-
style intervention alone, and pharmacological therapy is an option (see
Table 5). The use of imaging techniques to determine the presence and
extent of atherosclerotic vascular damage in low-risk individuals not
being considered for statin therapy is not justified due to low prognostic
yield, and the associated costs and radiation hazards when measuring
CAC score, particularly among low-risk women [29]. Of note, CAC score
is increased following statin treatment; therefore, the CAC scores of
statin-treated patients should be interpreted with caution.
Recommenda tions for cardiovascular imaging for risk assessment of athero-
sclerotic cardiovascular disease.
CAC= coronary artery calcium; CT= computed tomography;
CV= cardiovascular.
a Class of recommendation.
b Level of evidence.
4.2.2. Risk-based intervention strategies
Table 5 presents suggested intervention strategies as a function of
total CV risk and LDL-C level. This graded approach is based on evi-
dence from multiple meta-analyses and individual randomized
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controlled trials (RCTs), which show a consistent and graded reduction
in ASCVD risk in response to reductions in TC and LDL-C levels (see
Recommendations for cardiovascular disease risk estimation below)
[31–41]. These data are consistent in showing that, since the relative
risk reduction is proportional to the absolute reduction in LDL-C and
the absolute reduction in LDL-C resulting from a particular drug re-
gimen depends only on baseline LDL-C, at any given level of baseline
risk the higher the initial LDL-C level the greater the absolute reduction
in risk. Advice on individual drug treatments is given in section 8.
Recommendations for cardiovascular disease risk estimation.
CKD= chronic kidney disease; CV= cardiovascular; CVD= cardiovascular
disease; DM=diabetes mellitus; FH= familial hypercholesterolaemia; LDL-
C= low-density lipoprotein cholesterol; SCORE = Systematic Coronary Risk
Estimation.
a Class of recommendation.
b Level of evidence.
5. Lipids and lipoproteins
5.1. Biological role of lipids and lipoproteins
Lipoproteins in plasma transport lipids to tissues for energy utili-
zation, lipid deposition, steroid hormone production, and bile acid
formation. Lipoproteins consist of esterified and unesterified choles-
terol, TGs, and phospholipids and protein components named apoli-
poproteins that act as structural components, ligands for cellular re-
ceptor binding, and enzyme activators or inhibitors.
There are six major lipoproteins in blood: chylomicrons, very low-
density lipoprotein (VLDL), intermediate-density lipoprotein (IDL),
LDL; Lp(a), and HDL (Table 6 and Supplementary Fig. 5).
5.2. Role of lipids and lipoproteins in the pathophysiology of atherosclerosis
All ApoB-containing lipoproteins< 70 nm in diameter, including
smaller TG-rich lipoproteins and their remnant particles, can cross the
endothelial barrier, especially in the presence of endothelial dysfunc-
tion, where they can become trapped after interaction with extra-
cellular structures such as proteoglycans [42]. ApoB-containing lipo-
proteins retained in the arterial wall provoke a complex process that
leads to lipid deposition and the initiation of an atheroma [43].
Continued exposure to ApoB-containing lipoproteins leads to addi-
tional particles being retained over time in the artery wall, and to the
growth and progression of atherosclerotic plaques. On average, people
with higher concentrations of plasma ApoB-containing lipoproteins will
retain more particles and accumulate lipids faster, resulting in more
rapid growth and the progression of atherosclerotic plaques.
Because atherosclerotic plaques grow over time as additional ApoB-
containing lipoprotein particles are retained, the size of the total
atherosclerotic plaque burden is likely to be determined by both the
concentration of circulating LDL-C and other ApoB-containing lipo-
proteins, and by the total duration of exposure to these lipoproteins.
Therefore, a person's total atherosclerotic plaque burden is likely to be
proportional to the cumulative exposure to these lipoproteins [44].
Eventually, the increase of the atherosclerotic plaque burden along
with changes in the composition of the plaque reaches a critical point at
which disruption of a plaque can result, with the formation of an
overlying thrombus that acutely obstructs blood flow resulting in un-
stable angina, myocardial infarction (MI), or death. Therefore, the risk
of experiencing an acute ASCVD event rises rapidly as more ApoB-
containing lipoproteins become retained and the atherosclerotic plaque
burden increases. This provides the rationale for encouraging a healthy
lifestyle to maintain low levels of ApoB-containing lipoproteins
throughout life to slow the progression of atherosclerosis; it also ex-
plains the motivation to recommend treatment to lower LDL-C and
other ApoB-containing lipoproteins, for both the primary prevention of
ASCVD and the secondary prevention of recurrent CV events [44].
5.3. Evidence for the causal effects of lipids and lipoproteins on the risk of
atherosclerotic cardiovascular disease
5.3.1. Low-density lipoprotein cholesterol and risk of atherosclerosis
Plasma LDL-C is a measure of the cholesterol mass carried by LDL
particles, by far the most numerous of the ApoB-containing lipopro-
teins, and is an estimate of the concentration of circulating LDL.
Numerous epidemiological studies, Mendelian randomization studies,
and RCTs have consistently demonstrated a log-linear relationship be-
tween the absolute changes in plasma LDL-C and the risk of ASCVD
[34,45–50]. The remarkable consistency among these studies, in addi-
tion to biological and experimental evidence, provides compelling
evidence that LDL-C is causally associated with the risk of ASCVD, and
that lowering LDL-C reduces the risk of ASCVD proportionally to the
absolute achieved reduction in LDL-C [2,51].
Furthermore, Mendelian randomization studies have demonstrated
that long-term exposure to lower LDL-C levels is associated with a much
lower risk of CV events as compared with shorter-term exposure to lower
LDL-C (as achieved, for example, in randomized trials) [48,52]. These
data provide strong support for the concept that LDL particles have both
a causal and cumulative effect on the risk of ASCVD. Therefore, the effect
of LDL-C on the risk of ASCVD appears to be determined by both the
absolute magnitude and the total duration of exposure to LDL-C [2].
The clinical benefit of lowering LDL-C is determined by the reduc-
tion in circulating LDL particles as estimated by ApoB, which is usually
mirrored by a reduction of cholesterol carried by those particles [2,53].
Therefore, the clinical benefit of therapies that lower LDL-C by reducing
LDL particle mass will be proportional to the absolute reduction in LDL-
C, because—on average—the reduction in LDL-C and LDL particles will
be concordant [34,50,54,55]. In contrast, the clinical benefit of thera-
pies that lower LDL-C by a mechanism that may dramatically modify
their composition may not be proportional to the observed absolute
reduction in LDL-C, but instead would be expected to be proportional to
the absolute change in LDL particle concentration as measured by a
reduction in ApoB [2,53].
5.3.2. Triglyceride-rich lipoproteins and risk of atherosclerosis
TG-rich VLDL particles and their remnants carry most of the circu-
lating TGs. Therefore, the plasma TG concentration reflects the con-
centration of circulating ApoB-containing TG-rich lipoproteins.
Elevated plasma TG levels are associated with an increasing risk of
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ASCVD, but this association becomes null after adjusting for non-HDL-
C, an estimate of the total concentration of all ApoB-containing lipo-
proteins [45]. Similarly, lowering TG with fibrates reduces the risk of
CV events by the same amount as LDL-C-lowering therapies when
measured per unit change of non-HDL-C [50], suggesting that the effect
of plasma TGs on ASCVD is mediated by changes in the concentration of
TG-rich lipoproteins as estimated by non-HDL-C.
Mendelian randomization studies also suggest that the association
between plasma TGs and the risk of CHD may be causal; however, this
evidence must be interpreted with caution because nearly all variants
associated with TGs are also associated with HDL-C, LDL-C, or Lp(a)
[56–59]. A recent Mendelian randomization study demonstrated that
TG-lowering lipoprotein lipase (LPL) variants and LDL-C-lowering LDL
receptor variants had the same effect on the risk of ASCVD per unit
change of ApoB, suggesting that all ApoB-containing lipoproteins have
the same effect on the risk of CHD [53]. Together, these studies strongly
suggest that the causal effect of TG-rich lipoproteins and their remnants
on the risk of ASCVD is determined by the circulating concentration of
ApoB-containing particles, rather than by the TG content itself.
5.3.3. High-density lipoprotein cholesterol and risk of atherosclerosis
The inverse association between plasma HDL-C and the risk of
ASCVD is among the most consistent and reproducible associations in
observational epidemiology [45,60]. In contrast, Mendelian randomi-
zation studies do not provide compelling evidence that HDL-C is cau-
sally associated with the risk of ASCVD [49,61,62]. However, this
evidence must be interpreted with caution because most genetic
variants associated with HDL-C are also associated with directionally
opposite changes in TGs, LDL-C, or both, thus making estimates of the
effect of HDL-C on the risk of ASCVD very difficult using the Mendelian
randomization study design. Furthermore, there is no evidence from
randomized trials that therapeutically increasing plasma HDL-C reduces
the risk of CV events [63–67]. In the Effects of Dalcetrapib in Patients
with a Recent Acute Coronary Syndrome (dal-OUTCOMES) trial,
treatment with the cholesteryl ester transfer protein (CETP) inhibitor
dalcetrapib increased HDL-C without any effect on LDL-C or ApoB, but
did not reduce the risk of major CV events [65]. Similarly, in the As-
sessment of Clinical Effects of Cholesteryl Ester Transfer Protein In-
hibition with Evacetrapib in Patients at a High-Risk for Vascular Out-
comes (ACCELERATE) and Randomized Evaluation of the Effects of
Anacetrapib Through Lipid Modification (REVEAL) trials, treatment
with CETP inhibitors more than doubled HDL-C levels, but did not
appear to reduce the risk of ASCVD events beyond that expected from
the modest reductions in ApoB levels [2,63,64]. Furthermore, several
randomized trials have shown that directly infused HDL mimetics in-
crease plasma HDL-C concentrations, but do not reduce the progression
of atherosclerosis as measured by intravascular ultrasound [68,69].
Therefore, there is currently no randomized trial or genetic evidence
to suggest that raising plasma HDL-C is likely to reduce the risk of
ASCVD events. Whether therapies that alter the function of HDL par-
ticles will reduce the risk of ASCVD is unknown.
5.3.4. Lipoprotein(a) and risk of atherosclerosis
Lp(a) is an LDL particle with an Apo(a) moiety covalently bound to
Table 5
Intervention strategies as a function of total cardiovascular risk and untreated low-density lipoprotein choles-terol levels.
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its ApoB component [70]. It is < 70 nm in diameter and can freely flux
across the endothelial barrier, where it can become—similarly to
LDL—retained within the arterial wall and thus may increase the risk of
ASCVD. Pro-atherogenic effects of Lp(a) have also been attributed to
pro-coagulant effects as Lp(a) has a similar structure to plasminogen,
and it has pro-inflammatory effects most likely related to the oxidized
phospholipid load carried by Lp(a) [71].
Higher plasma Lp(a) concentrations are associated with an increased
risk of ASCVD, but it appears to be a much weaker risk factor for most
people than LDL-C [72,73]. In contrast, Mendelian randomization studies
have consistently demonstrated that lifelong exposure to higher Lp(a)
levels is strongly and causally associated with an increased risk of ASCVD
[74,75]. While randomized trials evaluating therapies that lower Lp(a)
by 20–30% (including niacin and CETP inhibitors) have not provided
evidence that lowering Lp(a) reduces the risk of ASCVD beyond that
which would be expected from the observed reduction in ApoB-con-
taining lipoproteins, recent data with PCSK9 inhibitors have suggested a
possible role for Lp(a) lowering in reducing CV risk [76].
This conflicting evidence appears to have been reconciled by a re-
cent Mendelian randomization study that showed that the causal effect
of Lp(a) on the risk of ASCVD is proportional to the absolute change in
plasma Lp(a) levels. Importantly, this study also suggested that people
with extremely high Lp(a) levels> 180 mg/dL (> 430 nmoL/L) may
have an increased lifetime risk of ASCVD similar to that of people with
heterozygous FH (HeFH). Because about 90% of a person's Lp(a) level is
inherited, extremely elevated Lp(a) may represent a new inherited lipid
disorder that is associated with extremely high lifetime risk of ASCVD
and is two-fold more prevalent than HeFH [77]. However, this study
[77] and another based on the Heart Protection Study 2-Treatment of
HDL to Reduce the Incidence of Vascular Events (HPS2-THRIVE) trial
[78] have shown that large absolute changes in Lp(a) may be needed to
produce a clinically meaningful reduction in the risk of ASCVD events.
5.4. Laboratory measurement of lipids and lipoproteins
Measurement of lipids and lipoproteins is used to estimate the risk
of ASCVD and guide therapeutic decision-making. Quantification of
plasma lipids can be performed on whole plasma and quantification of
lipoproteins can be achieved by measuring their protein component.
Operationally, lipoproteins are classified based on their hydrated den-
sity (see Table 6).
5.4.1. Lipoprotein measurement
Given the central causal role of ApoB-containing lipoproteins in the
initiation and progression of atherosclerosis, direct measurement of the
circulating concentration of atherogenic ApoB-containing lipoproteins to
both estimate risk and guide treatment decisions would be ideal. Because
all ApoB-containing lipoproteins—including VLDL, TG-rich remnant
particles, and LDL—contain a single ApoB molecule, quantitation of
ApoB directly estimates the number of atherogenic particles in plasma.
Standardized, automated, accurate, and inexpensive methods to
measure ApoB are available. Fasting is not required because even in the
post-prandial state, ApoB48-containing chylomicrons typically re-
present< 1% of the total concentration of circulating ApoB-containing
lipoproteins. Furthermore, the analytical performances of ApoB mea-
surement methods are superior to the measurement or calculation of
LDL-C and non-HDL-C [79].
5.4.2. Lipid measurements
In clinical practice, the concentration of plasma lipoproteins is not
usually measured directly but is instead estimated by measuring their
cholesterol content. TC in humans is distributed primarily among three
major lipoprotein classes: VLDL, LDL, and HDL. Smaller amounts of
cholesterol are also contained in two minor lipoprotein classes: IDL and
Lp(a). A standard serum lipid profile measures the concentration of TC
and HDL-C, as well as TG. With these values, the LDL-C concentration
can be estimated.
Plasma LDL-C can be measured directly using enzymatic techniques
or preparative ultracentrifugation, but in clinical medicine it is most
often calculated using the Friedewald formula:
LDL-C=TC−HDL-C− (TG/2.2) in mmol/L
or
LDL-C=TC−HDL-C− (TG/5) in mg/dL
Although convenient, the Friedewald calculated value of LDL-C has
several well-established limitations: (i) methodological errors may accu-
mulate since the formula necessitates three separate analyses of TC, TGs,
and HDL-C; and (ii) a constant cholesterol/TG ratio in VLDL is assumed.
With high TG values (>4.5 mmoL/L or>400mg/dL) the formula cannot
be used. This should especially be considered in non-fasting samples.
To overcome the problems associated with calculated LDL-C, direct
enzymatic methods for the measurement of LDL-C have been devel-
oped. These methods are commercially available as ready to use tools
for automatic analysis. The definition of LDL-C by the Friedewald
equation and by direct measurement is the same: non-HDL-C – VLDL-C,
representing the sum of the cholesterol carried by the biochemically
defined LDL, IDL, and Lp(a) subfractions.
For the general population, calculated LDL-C and direct LDL-C show
very strong correlations [80–83]. However, calculated LDL-C has been
found to underestimate LDL-C at concentrations of TG≥2 mmoL/L
(177 mg/dL) [81,82]. Equally, at very low levels of LDL-C, calculated
LDL-C may be misleading, especially in the presence of high TG
[81,84–86]. To avoid some of the problems with the Friedewald for-
mula, a number of modifications for the calculation of LDL-C have been
suggested, but it remains to be proved whether these modifications are
superior to Friedewald's formula for the estimation of CV risk
[81,85–87]. It is important to note that direct LDL-C measurements also
have limitations, including systematic bias and inaccuracy in patients
with dyslipidaemia, especially for high TG levels [88–90].
As an alternative calculated LDL-C, non-HDL-C can be calculated as
TC – HDL-C and is a measure of the TC carried by all atherogenic ApoB-
containing lipoproteins, including TG-rich particles in VLDL and their
remnants [100].
Several methods for the determination of Lp(a) are available. The
complex molecular structure of Lp(a) and the variation in size of Apo(a)
has been a challenge in the development of analytical methods for Lp
(a). Available methods are, to a varying degree, influenced by the Apo
(a) isoform [91]. Furthermore, the concentration of Lp(a) is reported as
either a molar concentration (nmol/L) or as a mass (mg/dL) by the
various assays, and conversion between molar and mass concentrations
has been found to be both size- and concentration-dependent [91–93].
Therefore, standardization between assays is needed to establish a re-
liable and reproducible method for the quantification of Lp(a) mass or
particle number [92].
5.4.3. Fasting or non-fasting?
Traditionally, blood sampling for lipid analyses has been re-
commended in the fasting state. Recent systematic studies comparing
fasting and non-fasting samples have suggested that the difference is
small for most lipid parameters [85,94–100]. Non-fasting sampling has
been used in large population-based studies [100]. In most studies, non-
fasting samples display a higher TG level of ∼0.3 mmoL/L (27 mg/dL)
[100,101]. On average, and for most individuals, this increment will be
of no clinical significance. Indeed, a number of guidelines recommend
non-fasting sampling [100,102,103].
For general risk screening, non-fasting samples seem to have at least the
same prognostic value as fasting samples [104]. The practical advantages
of non-fasting samples, including better patient acceptability, outweigh the
potential imprecision in some patients, although the determination of some
key analytes, such as fasting glucose, may be compromised. Furthermore,
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even if non-fasting sampling can be used in most cases, in patients with
metabolic syndrome (MetS), DM, or hypertriglyceridaemia (HTG), calcu-
lated LDL-C should be interpreted with caution.
5.5. Recommendations for measuring lipids and lipoproteins to estimate risk
of atherosclerotic cardiovascular disease
Measurement of plasma TC is needed to calculate risk using SCORE,
while the inclusion of plasma HDL-C level can improve risk estimation
using the online SCORE calculator. Therefore, both TC and HDL-C
should be measured to estimate a person's risk of ASCVD using SCORE,
or one of the other risk calculators (almost all of which also include
measurements of TC and HDL-C).
Plasma LDL-C should be measured to estimate the risk of ASCVD
that can be modified with LDL-C-lowering therapies, and to identify
whether markedly elevated LDL-C levels are present that may suggest a
lifetime high-risk of ASCVD due to lifelong cumulative exposure to high
levels of atherogenic lipoproteins, such as in FH. Plasma LDL-C can be
either calculated or measured directly.
Plasma TG should be assessed to identify people who may have a
greater modifiable risk of ASCVD than is reflected by LDL-C, due to the
presence of an increased concentration of atherogenic ApoB-containing
TG-rich lipoproteins and their remnants, and to identify people in
whom calculated and directly measured LDL-C may underestimate the
risk of ASCVD by underestimating either the concentration of circu-
lating LDL particles or the cholesterol content carried by those particles,
such as those with very low levels of LDL. This may be especially re-
levant in patients with DM or MetS.
In general, LDL-C, non-HDL-C, and ApoB concentrations are very
highly correlated. As a result, under most circumstances, they provide
very similar information about ASCVD risk [45,105–108]. However,
under certain circumstances—including among people with elevated TG
levels, DM, obesity, or very low achieved LDL-C levels—the calculated or
directly measured LDL-C level may underestimate both the total con-
centration of cholesterol carried by LDL and, more importantly, under-
estimate the total concentration of ApoB-containing lipoproteins, thus
underestimating the risk of ASCVD. In around 20% of patients there may
be discordance between measured LDL-C and ApoB levels [85,109].
Considering the potential inaccuracy of LDL-C in dyslipidaemia,
among patients with DM or high TG levels, and in patients with very
low LDL-C levels, measurement of both ApoB and non-HDL-C is re-
commended as part of routine lipid analysis for risk evaluation in pa-
tients with elevated plasma TGs. Because ApoB provides an accurate
estimate of the total concentration of atherogenic particles under all
circumstances, it is the preferred measurement to further refine the
estimate of ASCVD risk that is modifiable by lipid-lowering therapy.
Lp(a) has a similar structure to plasminogen and binds to the plas-
minogen receptor, leading to increased thrombosis (pro-thrombotic
factor). Measurement of Lp(a) should be considered at least once in
each person's lifetime, if available, to identify people who have in-
herited an extremely elevated level of Lp(a) ≥180 mg/dL (≥430
nmoL/L) and therefore have a very high lifetime risk of ASCVD that is
approximately equivalent to the risk associated with HeFH. In addition,
this strategy can identify people with less-extreme Lp(a) elevations who
may be at a higher risk of ASCVD, which is not reflected by the SCORE
system, or by other lipid or lipoprotein measurements. Measurement of
Lp(a) has been shown to provide clinically significant improved risk
reclassification under certain conditions, and therefore should be con-
sidered in patients who have an estimated 10-year risk of ASCVD that is
close to the threshold between high and moderate risk [110–112].
Recommendations for measuring lipids and lipoproteins to estimate
the risk of ASCVD are summarized below.
6. Treatment targets and goals
In previous EAS/ESC Guidelines for the management of dyslipi-
daemias [1,113] and other major guidelines on the treatment of blood
cholesterol to reduce atherosclerotic CV risk in adults [40,114], the
importance of LDL-C lowering to prevent ASCVD is strongly empha-
sized. The European Task Force felt that limiting the current knowledge
on CV prevention only to results from RCTs reduces the exploitation of
the potential that is available for the prevention of ASCVD. It is the
concordance of the conclusions from many different approaches (from
basic science, clinical observations, genetics, epidemiology, RCTs, etc.)
that contributes to the understanding of the causes of ASCVD and to the
Recommendations for lipid analyses for cardiovascular disease risk estimation.
Apo= apolipoprotein; ASCVD=atherosclerotic cardiovascular disease; CV= cardiovascular; CVD= cardiovascular disease; DM=diabetes mellitus; HDL-
C=high-density lipoprotein cholesterol; LDL-C= low-density lipoprotein cholesterol; Lp(a)= lipoprotein(a); SCORE = Systematic Coronary Risk Estimation;
TC= total cholesterol; TG= triglyceride.
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potential of prevention. The Task Force is aware of the limitations of
some of the sources of evidence and accepts that RCTs have not ex-
amined different LDL-C goals systematically, but felt that it was ap-
propriate to look at the totality of the evidence. Particular consideration
was given to results from meta-analyses confirming the dose-dependent
reduction in ASCVD with LDL-C-lowering agents; the greater the ab-
solute LDL-C reduction, the greater the CV risk reduction
[35,36,50,115]. The benefits related to LDL-C reduction are not specific
for statin therapy [33]. No level of LDL-C below which benefit ceases or
harm occurs has been defined.
There is considerable individual variability in the LDL-C response to
dietary and drug treatments [31], which is traditionally taken to sup-
port a tailored approach to management. Total CV risk reduction should
be individualized, and this can be more specific if goals are defined. The
use of goals can also aid patient–doctor communication. It is judged
that a goal approach may facilitate adherence to treatment, although
this consensus opinion has not been fully tested. For all these reasons,
the European Task Force retains a goal approach to lipid management
and treatment goals are tailored to the total CV risk level. There is also
evidence suggesting that lowering of LDL-C beyond the goals that were
set in the previous EAS/ESC Guidelines is associated with fewer ASCVD
events [34,116,117]. Therefore, it seems appropriate to reduce LDL-C
to as low a level as possible, at least in patients at very high CV risk, and
for this reason a minimum 50% reduction is suggested for LDL reduc-
tion, together with reaching the tailored goal.
The lipid goals are part of a comprehensive CV risk reduction
strategy and are summarized in Table 7. The rationales for the non-lipid
targets are given in the 2016 ESC Joint Prevention Guidelines [10].
The targeted approach to lipid management is primarily aimed at
reducing atherosclerotic risk by substantially lowering LDL-C to levels
that have been achieved in recent large-scale trials of PCSK-9 inhibitors.
Therefore, for patients at very high CV risk, whether in secondary
prevention or (rarely) in primary prevention, LDL-C reduction of ≥50%
from baseline and an LDL-C goal of< 1.4 mmoL/L (< 55 mg/dL) are
recommended. For patients with ASCVD who experience a second
vascular event within 2 years (not necessarily of the same type as the
first event) while taking maximally tolerated statin-based therapy, an
LDL-C goal< 1.0 mmoL/L (< 40 mg/dL) may be considered
[119,120]. For people at high CV risk, an LDL-C reduction of ≥50%
from baseline and an LDL-C goal< 1.8 mmoL/L (< 70 mg/dL) are
recommended. In patients at moderate CV risk, an LDL-C goal< 2.6
mmoL/L (< 100 mg/dL) should be considered, while for low-risk in-
dividuals a goal of< 3.0 mmoL/L (< 116 mg/dL) may be considered
(see Recommendations for treatment goals for low-density lipoprotein cho-
lesterol below and Supplementary Table 2).
Table 7
Treatment targets and goals for cardiovascular disease prevention.
Smoking No exposure to tobacco in any form.
Diet Healthy diet low in saturated fat with a focus on wholegrain products, vegetables, fruit, and fish.
Physical activity 3.5–7 h moderately vigorous physical activity per week or 30–60 min most days.
Body weight BMI 20–25 kg/m2, and waist circumference < 94 cm (men) and <80 cm (women).
Blood pressure < 140/90mmHg.a
LDL-C Very-high risk in primary or secondary prevention:
A therapeutic regimen that achieves ≥50% LDL-C reduction from baselineb and an LDL-C goal of < 1.4 mmoL/L (< 55 mg/dL).
No current statin use: this is likely to require high-intensity LDL-lowering therapy.
Current LDL-lowering treatment: an increased treatment intensity is required.
High risk: A therapeutic regimen that achieves ≥50% LDL-C reduction from baselineb and an LDL-C goal of < 1.8 mmoL/L (< 70 mg/dL).
Moderate risk:
A goal of < 2.6 mmoL/L (< 100 mg/dL).
Low risk:
A goal of < 3.0 mmoL/L (< 116 mg/dL).
Non-HDL-C Non-HDL-C secondary goals are <2.2, 2.6, and 3.4 mmoL/L (< 85, 100, and 130 mg/dL) for very-high-, high-, and moderate-risk people, respectively.
ApoB ApoB secondary goals are <65, 80, and 100 mg/dL for very-high-, high-, and moderate-risk people, respectively.
Triglycerides No goal, but < 1.7 mmoL/L (< 150 mg/dL) indicates lower risk and higher levels indicate a need to look for other risk factors.
Diabetes HbA1c: < 7% (<53 mmoL/mol).
Apo= apolipoprotein; BMI=body mass index; HbA1c=glycated haemoglobin; HDL-C=high-density lipoprotein cholesterol; LDL-C= low-density lipoprotein
cholesterol.
a Lower treatment targets are recommended for most treated hypertensive patients, provided that the treatment is well tolerated [118].
b The term ‘baseline’ refers to the LDL-C level in a person not taking any lipid-lowering medication, or to the extrapolated baseline value for those who are on
current treatment.
Table 6
Physical and chemical characteristics of human plasma lipoproteins.
Density (g/mL) Diameter TGs (%) Cholesteryl PLs (%) Cholesterol (%) Apolipoproteins
(nm) esters (%) Major Others
Chylomicrons <0.95 80–100 90–95 2–4 2–6 1 ApoB-48 ApoA-I, A-II, A-IV, A-V
VLDL 0.95–1.006 30–80 50–65 8–14 12–16 4–7 ApoB-100 ApoA-I, C-II, C-III, E, A-V
IDL 1.006–1.019 25–30 25–40 20–35 16–24 7–11 ApoB-100 ApoC-II, C-III, E
LDL 1.019–1.063 20–25 4–6 34–35 22–26 6–15 ApoB-100
HDL 1.063–1.210 8–13 7 10–20 55 5 ApoA-I ApoA-II, C-III, E, M
Lp(a) 1.006–1.125 25–30 4–8 35–46 17–24 6–9 Apo(a) ApoB-100
Apo= apolipoprotein; HDL=high-density lipoprotein; IDL= intermediate-density lipoprotein; LDL= low-density lipoprotein; Lp(a)= lipoprotein(a);
PLs= phospholipids; TGs= triglycerides; VLDL= very low-density lipoprotein.
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Table 8
Impact of specific lifestyle changes on lipid levels.
The magnitude of the effect (+++ =>10%, ++ = 5–10%, + =<5%) and the level of evidence refer to the impact of each dietary modification on plasma
levels of a specific lipoprotein class.
HDL-C=high-density lipoprotein cholesterol; LDL-C= low-density lipoprotein cholesterol; TC= total cholesterol; TG= triglyceride.
Recommendations for treatment goals for low-density lipoprotein cholesterol.
ASCVD= atherosclerotic cardiovascular disease; FH= familial hypercholesterolaemia; LDL-C= low-density lipoprotein cholesterol.
a Class of recommendation.
b Level of evidence.
c For definitions see Table 4.
d The term ‘baseline’ refers to the LDL-C level in a person not taking any LDL-C-lowering medication. In people who are taking LDL-C-lowering medication(s), the
projected baseline (untreated) LDL-C levels should be estimated, based on the average LDL-C-lowering efficacy of the given medication or combination of medi-
cations.
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Secondary goals have also been defined by inference for non-HDL-C
and for ApoB; they receive a moderate grading, as they have not been
extensively studied in RCTs. The specific goal for non-HDL-C should be
0.8 mmoL/L (30 mg/dL) higher than the corresponding LDL-C goal; the
adjustment of lipid-lowering therapy in accordance with these sec-
ondary goals may be considered in patients at very high CV risk after
achievement of an LDL-C goal, although the clinical advantages of this
approach with respect to outcomes remain to be addressed. When
secondary targets are used the recommendations are: (i) non-HDL-
C< 2.2 mmoL/L (< 85 mg/dL),< 2.6 mmoL/L (< 100 mg/dL),
and<3.4 mmoL/L (< 130 mg/dL) in people at very high, high, and
moderate CV risk, respectively [121–123]; and (ii) ApoB<65 mg/dL,
< 80 mg/dL, and< 100 mg/dL in very-high, high, and moderate total
CV risk, respectively [121,123,124].
To date, no specific goals for HDL-C or TG levels have been de-
termined in clinical trials, although increases in HDL-C predict ather-
osclerosis regression, and low HDL-C is associated with excess events
and mortality in coronary artery disease (CAD) patients, even at low
LDL levels. Clinicians should use clinical judgment when considering
further treatment intensification in patients at high or very high total
CV risk.
7. Lifestyle modifications to improve the plasma lipid profile
The pivotal role of nutrition in the prevention of ASCVD has been
extensively reviewed [125–129]. Dietary factors influence the devel-
opment of CVD either directly or through their action on traditional risk
factors, such as plasma lipids, BP, or glucose levels.
Convincing evidence of the causal association between diet and
ASCVD risk is, nevertheless, available indirectly from randomized
‘metabolic ward’ studies showing that high saturated fat intake causes
increased LDL-C concentrations, and from cohort studies, genetic epi-
demiological studies, and randomized trials showing that higher LDL-C
levels cause ASCVD.
The lack of concordance between studies is due both to methodo-
logical problems (particularly inadequate sample sizes or short study
durations) and the difficulties of evaluating the impact of a single
dietary factor independently of any other changes in the diet [130]. In
fact, as foods are mixtures of different nutrients and other components,
it is not appropriate to attribute the health effects of a food to only one
of its components. Moreover, if energy intake must be kept constant,
eating less of one macronutrient implies necessarily eating more of
others. The quality of the replacement (for instance, unsaturated fat vs.
highly refined grains) can influence the effect observed, significantly
modifying the impact on health of the nutrient replaced. These
limitations suggest caution in interpreting the results of RCTs or even
meta-analyses of RCTs in relation to the effect of a single dietary change
on ASCVD [130].
To overcome, at least in part, these problems, in recent years nu-
trition research has focused on the relationship between ASCVD on the
one hand, and foods and dietary patterns—rather than single nu-
trients—on the other. Consistent evidence from epidemiological studies
indicates that higher consumption of fruit, non-starchy vegetables, nuts,
legumes, fish, vegetable oils, yoghurt, and wholegrains, along with a
lower intake of red and processed meats, foods higher in refined car-
bohydrates, and salt, is associated with a lower incidence of CV events
[131]. Moreover, it indicates that the replacement of animal fats, in-
cluding dairy fat, with vegetable sources of fats and polyunsaturated
fatty acids (PUFAs) may decrease the risk of CVD [132].
Dietary patterns that have been more extensively evaluated are the
Dietary Approaches to Stop Hypertension (DASH) diet—particularly in
relation to BP control—and the Mediterranean diet; both have proved
to be effective in reducing CV risk factors and, possibly, to contribute to
ASCVD prevention [133]. The most relevant difference between the
Mediterranean and the DASH diet is the emphasis of the former on
extra-virgin olive oil. The Mediterranean diet is associated with a re-
duced incidence of CV and other non-communicable diseases in epi-
demiological studies [134,135], and has been proved in RCTs to be
effective in reducing CV events in primary and secondary prevention
[136]. In particular, the Prevención con Dieta Mediterránea (PREDI-
MED) trial indicated that participants allocated to a Mediterranean-type
diet, supplemented with extra-virgin olive oil or nuts, had a sig-
nificantly lower (around 30%) incidence of major CV events compared
with those who were on a low-fat diet [137].
In summary, despite the results of PREDIMED and a few other in-
tervention studies with ASCVD endpoints that support a healthy life-
style for ASCVD prevention, RCTs cannot represent the sole grounds on
which dietary recommendations should rely. They also need to be based
on the combination of large observational cohort studies and relatively
short-term randomized trials having intermediate risk factors (such as
blood lipids) as outcomes.
Table 8 summarizes the currently available evidence on the influ-
ences of lifestyle changes and functional foods on lipoproteins, in-
dicating the magnitudes of the effects and the levels of evidence in
relation to the impacts on the specific lipoprotein class; for the reasons
outlined above, the levels of evidence are not based on RCTs with
ASCVD endpoints. Moreover, within the Guidelines on the management
of dyslipidaemias, information on the potential to improve plasma li-
poprotein profiles by dietary means is clinically relevant, even in the
absence of a clear demonstration of CV benefits.
Table 9
Food choices to lower low-density lipoprotein cholesterol and improve the overall lipoprotein profile.
To be preferred To be used in moderation To be chosen occasionally in limited amounts
Cereals Wholegrains Refined bread, rice, and pasta, biscuits, corn flakes Pastries, muffins, pies, croissants
Vegetables Raw and cooked vegetables Potatoes Vegetables prepared in butter or cream
Legumes Lentils, beans, fava beans, peas,
chickpeas, soybean
Fruit Fresh or frozen fruit Dried fruit, jelly, jam, canned fruit, sorbets, ice
lollies/popsicles, fruit juice
Sweets and sweeteners Non-caloric sweeteners Sucrose, honey, chocolate, sweets/candies Cakes, ice creams, fructose, soft drinks
Meat and fish Lean and oily fish, poultry without
skin
Lean cuts of beef, lamb, pork, and veal, seafood,
shellfish
Sausages, salami, bacon, spare ribs, hot dogs, organ
meats
Dairy food and eggs Skimmed milk and yoghurt Low-fat milk, low-fat cheese and other milk
products, eggs
Regular cheese, cream, whole milk and yoghurt
Cooking fat and dressings Vinegar, mustard, fat-free
dressings
Olive oil, non-tropical vegetable oils, soft
margarines, salad dressing, mayonnaise, ketchup
Trans fats and hard margarines (better to avoid them),
palm and coconut oils, butter, lard, bacon fat
Nuts/seeds All, unsalted (except coconut) Coconut
Cooking procedures Grilling, boiling, steaming Stir-frying, roasting Frying
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7.1. Influence of lifestyle on total cholesterol and low-density lipoprotein
cholesterol levels
Table 9 summarizes the possible choices of foods to lower TC and
LDL-C levels. Given the cultural diversity of the European populations,
they should be translated into practical behaviours, considering local
habits and socio-economic factors.
7.2. Influence of lifestyle on triglyceride levels
Weight reduction improves insulin sensitivity and decreases TG le-
vels. Regular physical exercise reduces plasma TG levels over and above
the effect of weight reduction [151,168,169]. Alcohol intake has a
major impact on TG levels, particularly in individuals with HTG
[153,170]. The detrimental effects of a high-carbohydrate diet on TGs
occur mainly when refined carbohydrate-rich foods are consumed,
while they are much less prominent if the diet is based largely on fibre-
rich, low-glycaemic index foods. This applies particularly to people
with DM or MetS [171,172].
Habitual consumption of significant amounts (> 10% energy) of
dietary fructose contributes to TG elevation, particularly in people with
HTG or abdominal obesity. These effects are dose-dependent; with a
habitual fructose consumption between 15 and 20% of total energy
intake, plasma TG increases by as much as 30–40%. Sucrose, a dis-
accharide containing glucose and fructose, represents an important
source of fructose in the diet [159,173,174].
7.3. Influence of lifestyle on high-density lipoprotein cholesterol levels
Weight reduction increases HDL-C levels; a 0.01 mmoL/L (0.4 mg/
dL) increase is observed for every kilogram decrease in body weight
when weight reduction has stabilized. Aerobic physical activity, such as
25–30 km of brisk walking per week (or any equivalent activity), may
increase HDL-C levels by 0.08–0.15 mmoL/L (3.1–6 mg/dL) [169].
Smoking cessation may also contribute to HDL-C elevation, provided
that weight gain is prevented [163].
7.4. Lifestyle recommendations to improve the plasma lipid profile
LDL-C lowering represents the primary target for reducing CV risk
and therefore deserves special emphasis in the evaluation of lifestyle
measures. The diet recommended to the general population, and par-
ticularly to people at increased CV risk, may also be able to modify
plasma TG and HDL-C levels (Table 9). This section focuses on dietary
and other lifestyle factors that may be implemented to improve the
overall lipoprotein profile.
7.4.1. Body weight and physical activity
Since overweight, obesity, and—in particular—abdominal adiposity
often contribute to dyslipidaemia, caloric intake should be reduced and
energy expenditure increased in those with excessive weight and/or
abdominal adiposity.
In the case of excess weight, body weight reduction, even if modest
(5–10% of basal body weight), improves lipid abnormalities and fa-
vourably affects the other CV risk factors often present in dyslipidaemic
individuals [148]. While the beneficial effects of weight reduction on
metabolic and surrogate markers have been demonstrated, the benefits
of weight loss on mortality and CV outcome are less clear [175].
Weight reduction can be achieved by decreasing the consumption of
energy-dense foods, inducing a caloric deficit of 300–500 kcaL/day.
The intervention should combine diet and exercise; this approach also
leads to the greatest improvement in physical performance and quality
of life, and mitigates reductions in muscle and bone mass, particularly
in older people [176]. It is always appropriate to advise people with
dyslipidaemia to engage in regular physical exercise of moderate in-
tensity for ≥30 min/day, even if they are not overweight [168].
7.4.2. Dietary fat
Avoiding any consumption of trans fat is a key measure of the
dietary prevention of CVD. The trans fatty acids produced in the partial
hydrogenation of vegetable oils account for 80% of total intake. Thanks
to efforts made in different parts of the world, the intake of trans fatty
acids has decreased substantially over the past 10–15 years.
As for saturated fat, its consumption should be< 10% of the total
caloric intake and should be further reduced (< 7% of energy) in the
presence of hypercholesterolaemia. For most individuals, a wide range
of total fat intakes is acceptable, and will depend upon individual
preferences and characteristics. However, fat intakes> 35–40% of
calories are generally associated with increased intakes of both satu-
rated fat and calories. Conversely, low intakes of fats and oils increase
the risk of inadequate intakes of vitamin E and of essential fatty acids,
and may contribute to a reduction of HDL-C [164].
Fat intake should predominantly come from sources of mono-
unsaturated fatty acids, including both n-6 and n-3 PUFAs. Not enough
data are available to make a recommendation regarding the optimal n-
3:n-6 fatty acid ratio [177,178]. The cholesterol intake in the diet
should be reduced (< 300 mg/day), particularly in people with high
plasma cholesterol levels.
7.4.3. Dietary carbohydrate and fibre
Dietary carbohydrate has a ‘neutral’ effect on LDL-C, although ex-
cessive consumption is represented by untoward effects on plasma TGs
and HDL-C levels [164]. Dietary fibre (particularly of the soluble
type)—which is present in legumes, fruits, vegetables, and wholegrain
cereals (e.g. oats and barley)—has a hypocholesterolaemic effect and
represents a good dietary substitute for saturated fat to maximize the
effects of the diet on LDL-C levels, and to minimize the untoward effects
of a high-carbohydrate diet on other lipoproteins [140,179].
Carbohydrate intake should range between 45 and 55% of total
energy intake, since both higher and lower percentages of carbohydrate
diets are associated with increased mortality [180,181]. A fat-modified
diet that provides 25–40 g per day of total dietary fibre, including
≥7–13 g of soluble fibre, is well tolerated, effective, and recommended
for plasma lipid control; conversely, there is no justification for the
recommendation of very low-carbohydrate diets [182].
Intake of added sugar should not exceed 10% of total energy (in
addition to the amount present in natural foods such as fruits and dairy
products); more restrictive advice concerning sugars may be useful for
those needing to lose weight or with high plasma TG values, MetS, or
DM. Soft drinks should be used with moderation by the general popu-
lation, and should be drastically limited in those individuals with ele-
vated TG values or visceral adiposity [158,159,174]. The Prospective
Urban Rural Epidemiology (PURE) study was a large, epidemiological
cohort study of 135 335 individuals enrolled in 18 countries with food
frequency questionnaires recorded. Total fat and types of fat were not
associated with CVD, MI, or CVD mortality, whereas saturated fat had
an inverse association with stroke [181]. However, a meta-analysis of
epidemiological studies including the PURE study showed a U-shaped
relationship between carbohydrate intake and mortality: diets asso-
ciated with the highest mortality rate had carbohydrate intakes> 70%
and<40% of energy, with minimal risk observed when carbohydrate
intake was between 45 and 55% of total energy intake [180].
7.4.4. Alcohol
Moderate alcohol consumption [≤10 g/day (1 unit) for men and
women] is acceptable for those who drink alcoholic beverages, if TG
levels are not elevated [183,184].
7.4.5. Smoking
Smoking cessation has clear benefits regarding overall CV risk, and
specifically on HDL-C levels [163].
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7.5. Dietary supplements and functional foods for the treatment of
dyslipidaemias
Nutritional evaluation of functional foods includes not only the
search for clinical evidence of beneficial effects relevant to improved
health or the reduction of disease risk, but also the demonstration of
good tolerability. Overall, the available evidence on functional foods so
far identified in this field is incomplete; the major gap is an absence of
diet-based intervention trials of enough duration to be relevant for the
natural history of dyslipidaemia and CVD.
7.5.1. Phytosterols
The principal phytosterols are sitosterol, campesterol, and stig-
masterol; they occur naturally in vegetable oils and in smaller amounts
in vegetables, fresh fruits, nuts, grains, and legumes. The dietary intake
of plant sterols ranges between an average of 250 mg/day in Northern
Europe to ∼500 mg/day in Mediterranean countries. Phytosterols
compete with cholesterol for intestinal absorption, thereby modulating
TC levels.
Daily consumption of 2 g of phytosterols can effectively lower TC
and LDL-C levels by 7–10% in humans (with a certain degree of het-
erogeneity among individuals), while it has little or no effect on HDL-C
and TG levels [143]. However, to date no studies have been performed
on the subsequent effect on CVD. Based on LDL-C lowering and the
absence of adverse signals, functional foods with plant sterols/stanols
(≥2 g/day with the main meal) may be considered: (i) in individuals
with high cholesterol levels at intermediate or low global CV risk who
do not qualify for pharmacotherapy; (ii) as an adjunct to pharmacolo-
gical therapy in high- and very-high-risk patients who fail to achieve
LDL-C goals on statins or could not be treated with statins; and (iii) in
adults and children (aged> 6 years) with FH, in line with current
guidance [142].
7.5.2. Monacolin and red yeast rice
Red yeast rice (RYR) is a source of fermented pigment that has been
used in China as a food colorant and flavour enhancer for centuries.
Hypocholesterolaemic effects of RYR are related to a statin-like me-
chanism—inhibition of hydroxymethylglutaryl-coenzyme A (HMG-
CoA) reductase—of monacolins, which represent the bioactive in-
gredient. Different commercial preparations of RYR have different
concentrations of monacolins, and lower TC and LDL-C levels to vari-
able extents, but the consumer is not able to make that distinction
[144,185]. Moreover, the long-term safety of the regular consumption
of these products has not been fully documented and safety issues due
to the possible presence of contaminants in some preparations have
been raised. Side effects like those observed with statins have also been
reported.
In the only available RCT in patients with ASCVD, a partially pur-
ified extract of RYR reduced recurrent events by 45% [146]. A clinically
relevant hypocholesterolaemic effect (up to a 20% reduction) has been
observed with RYR preparations providing an o.d. [once daily (omni
die)] dose of 5–10 mg monacolin K [145]. Nutraceuticals containing
purified RYR may be considered in people with elevated plasma cho-
lesterol concentrations who do not qualify for treatment with statins in
view of their global CV risk. However, there is a clear need for better
regulation of RYR supplements. Information regarding the precise
composition of these products, the quantities of their components, and
their purity should be implemented [185].
7.5.3. Dietary fibre
Available evidence consistently demonstrates a TC- and LDL-C-
lowering effect of β-glucan, a viscous fibre from oat and barley. Foods
enriched with these fibres or supplements are well tolerated, effective,
and recommended for LDL-C lowering [186]. However, the dosage
needed to achieve a clinically relevant reduction in levels of LDL-C of
3–5% varies from 3 to 10 g per day according to the specific type of
fibre [187].
7.5.4. Soy
The cholesterol-lowering effect of soy is generally attributed to its
isoflavone and phytoestrogen content, which decreases progressively
with the increasing degree of soybean processing. Soy protein has also
been indicated as being able to induce a modest LDL-C-lowering effect
when replacing animal protein foods. However, this was not confirmed
when changes in other dietary components were taken into account
[187,188].
7.5.5. Policosanol and berberine
Policosanol is a natural mixture of long-chain aliphatic alcohols
extracted primarily from sugarcane wax [189]. Studies show that po-
licosanol from sugarcane, rice or wheat germ has no significant effect
on LDL-C, HDL-C, TG, ApoB, Lp(a), homocysteine, high-sensitivity C-
reactive protein, fibrinogen, or blood coagulation factor levels [190].
As for berberine, a recent meta-analysis evaluated its effects on
plasma lipids in humans [191]. The comparative evaluation of ber-
berine and lifestyle intervention or placebo indicated that in the ber-
berine group, LDL-C and plasma TG levels were more effectively re-
duced than in the control group. However, due to the lack of high-
quality randomized clinical trials, the efficacy of berberine for treating
dyslipidaemia needs to be further validated. Moreover, the bioavail-
ability of the different berberine preparations is a matter of debate
[187].
7.5.6. n-3 unsaturated fatty acids
Observational evidence indicates that consumption of fish (at least
twice a week) and vegetable foods rich in n-3 fatty acids (α-linoleic acid
is present in walnuts, some vegetables, and some seed oils) is associated
with lower risk of CV death and stroke, but has no major effects on
plasma lipoprotein metabolism [178,192]. Pharmacological doses of
long-chain n-3 fatty acids (2–3 g/day) reduce TG levels by about 30%
and also reduce the post-prandial lipaemic response, but a higher do-
sage may increase LDL-C levels. α-Linolenic acid is less effective at al-
tering TG levels [156,193]. Recently, a significantly lower risk of
ischaemic events, including CV death, was observed in patients with
elevated TG levels despite the use of statins treated with 2 g of icosa-
pent ethyl b.i.d. [twice a day] [194].
Other features of a healthy diet contributing to CVD prevention are
presented in the Supplementary Data.
8. Drugs for treatment of dyslipidaemias
8.1. Statins
8.1.1. Mechanism of action
Statins reduce the synthesis of cholesterol in the liver by competi-
tively inhibiting the enzyme HMG-CoA reductase, the rate-limiting step
in cholesterol biosynthesis. The reduction in intracellular cholesterol
promotes increased LDL receptor (LDLR) expression at the surface of
the hepatocytes, which in turn results in increased uptake of LDL from
the blood, and decreased plasma concentrations of LDL- and other
ApoB-containing lipoproteins, including TG-rich particles.
8.1.2. Effects on lipids
8.1.2.1. Low-density lipoprotein cholesterol. The degree of LDL-C
reduction is dose-dependent and varies between the different statins.
A high-intensity regimen is defined as the dose of a statin that, on
average, reduces LDL-C by≥50%; moderate-intensity therapy is
defined as the dose expected to reduce LDL-C by 30–50%. Notably,
there is considerable interindividual variation in LDL-C reduction with
the same dose of drug [31]. Poor responses to statin treatment in
clinical studies are to some extent caused by poor compliance, but may
also be explained by genetic backgrounds [195,196]. Interindividual
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variations in statin responses warrant monitoring of responses on
initiation of therapy.
Among patients who cannot tolerate the recommended intensity of
a statin because of adverse effects or those who do not reach their goal,
the addition of a non-statin lipid-modifying agent to a maximally tol-
erated statin is recommended [197,198].
8.1.2.2. Triglycerides. Statins usually reduce TG levels by 10–20% from
baseline values [199]. More potent statins (atorvastatin, rosuvastatin,
and pitavastatin) demonstrate robust lowering of TG levels, especially
at high doses and in patients with elevated TGs (HTG), in whom the
absolute risk, and therefore the absolute risk reduction, is larger.
The mechanism of the TG-lowering effect has not been fully eluci-
dated, but it seems to be partly independent of the LDLR pathway. It
may involve the upregulation of VLDL uptake by hepatocytes, as well as
a reduction of the production rate of VLDLs; these effects seem to be
dependent on pre-treatment VLDL concentrations [200].
8.1.2.3. High-density lipoprotein cholesterol. In a meta-analysis [201],
elevations in HDL-C levels varied with dose among the respective
statins; such elevations ranged from 1 to 10%. However, given the
marked statin-mediated decrement in atherogenic ApoB-containing
lipoproteins, the extent to which the very modest effect on HDL-C
levels might contribute to the overall observed reductions in CV risk
consistently observed in statin intervention trials cannot reliably be
disentangled.
8.1.2.4. Lipoprotein(a). Statins only marginally affect Lp(a) plasma
levels. Previous studies have reported either no effect on or an
increase of Lp(a) levels after statin treatment [202,203]. The
mechanisms by which statins raise oxidized phospholipids on Lp(a)
require further investigation.
8.1.3. Other effects of statins
Although reduction of LDL-C levels is the major effect of statins, a
number of other, potentially important effects have been suggested
(pleiotropic effects of statins) [204,205]. Among such effects that are
potentially relevant for the prevention of CVD are the anti-in-
flammatory and antioxidant effects of statin treatment. These effects
have been shown in vitro and in experimental systems, but their clinical
relevance remains unproven [18,206].
8.1.3.1. Effect on cardiovascular morbidity and mortality. A large number
of meta-analyses have been performed to analyse the effects of statins in
populations and in subgroups [34–36,38,51,207–214]. In the
Cholesterol Treatment Trialists (CTT) meta-analysis of individual
participant data (IPD) from>170 000 participants in 26 RCTs of a
statin vs. control or a more vs. less intensive statin regimen [34], for
each 1 mmoL/L reduction in LDL-C, statin/more statin reduced major
vascular events (MI, CAD death, or any stroke or coronary
revascularization) by ∼22%, major coronary events by 23%, CAD
death by 20%, total stroke by 17%, and total mortality by 10% over 5
years. The proportional effects (per mmol/L reduction in LDL-C) on
major vascular events were similar in all subgroups examined, so the
absolute risk reduction was proportional to the absolute baseline risk.
The relative benefits were half as large in the first year as compared
with subsequent years. There was no increased risk for any non-CV
cause of death, including cancer, in those allocated statins. The absolute
benefit from statin treatment was lower in people in primary
prevention, who are typically at lower risk [36,38,214,215]. In the
CTT meta-analysis of treatment in people with a low-risk of vascular
disease [36], the relative risk reduction of major vascular events per
mmol/L reduction in LDL-C was at least as large in low-risk individuals
(i.e. in primary prevention). In those without a history of vascular
disease, statin therapy reduced the risk of all-cause mortality by 9% per
mmol/L reduction in LDL cholesterol. Similar results were reported in a
Cochrane review in 2013 [213]. The West of Scotland Coronary
Prevention Study (WOSCOPS) data were recently reanalysed, and
demonstrated that even people without DM and a 10 year predicted
ASCVD risk of< 7.5% benefit from statin treatment. There was also a
legacy effect with a mortality benefit of 18% in all-cause death over 20
years [216]. Statins are effective for the prevention of ASCVD in the
elderly, including those aged>75 years [217]. Statins are not effective
in a few specific groups, notably those with heart failure (HF) or
patients receiving haemodialysis [214,218–222].
Current available evidence from meta-analyses suggests that the
clinical benefit of statin treatment is largely a class effect, driven by the
absolute LDL-C reduction; therefore, the type of statin used should re-
flect the treatment goals for a given patient.
The following scheme may be proposed.
• Evaluate the total CV risk of the individual.• Determine the treatment goals (depending on current risk).• Involve the patient in decisions on CV risk management.• Choose a statin regimen and, where necessary, additional treatments
(e.g. ezetimibe or PCSK9 inhibitors) that can meet the treatment
goals (per cent and absolute value).• Response to statin treatment is variable, therefore uptitration of the
statin dose may be required before additional LDL-lowering treat-
ments are started.
These are general criteria for the choice of drug. Factors such as the
clinical condition of the patient, concomitant medications, drug toler-
ability, local treatment tradition, and drug cost will play major roles in
determining the final choice of drug and dose.
Furthermore, the effects of statins on a number of other clinical
conditions have been evaluated. For cancer, a meta-analysis of IPD from
randomized trials has shown that statins do not have any significant
effect on cancer, at least over a period of ∼5 years [223]. Other con-
ditions, such as dementia [224], hepatic steatosis [225], venous
thromboembolism [226], atrial fibrillation [227,228], and polycystic
ovary syndrome [229] have also been studied, and no effect of statins
on these conditions has been reliably demonstrated.
The suggested effect on Alzheimer's disease was recently reviewed
in a Cochrane analysis reporting no conclusive effect from statins [230].
Furthermore, neurocognitive functions were extensively investigated in
the Evaluating PCSK9 Binding Antibody Influence on Cognitive Health
in High Cardiovascular Risk Subjects (EBBINGHAUS) study [231] and
no excess risk was observed among patients on a statin regimen ran-
domized to a PCSK9 mAb.
8.1.4. Adverse effects and interactions of statins
Statins differ in their absorption, bioavailability, plasma protein
binding, excretion, and lipophilicity. Evening administration is usually
recommended. Lovastatin and simvastatin are prodrugs, whereas the
other available statins are administered in their active form. Their
bioavailability is relatively low, owing to a first-pass effect in the liver,
and many statins undergo significant hepatic metabolism via cyto-
chrome P450 (CYP) isoenzymes, except pravastatin, rosuvastatin, and
pitavastatin. These enzymes are expressed mainly in the liver and gut
wall. Although statins are generally very well tolerated, they do have
some specific adverse effects on muscle, glucose haemostasis, and
haemorrhagic stroke. However, there is also widespread misinforma-
tion about potential adverse effects, as reviewed recently [232,233].
8.1.4.1. Adverse effects on muscle. Myopathy is the most clinically
relevant adverse effect of statins. Among the risk factors for
myopathy, it is particularly important that interaction with
concomitant drug therapy is considered (see below). Rhabdomyolysis
is the most severe form of statin-induced muscle damage, characterized
by severe muscular pain, muscle necrosis, and myoglobinuria
potentially leading to renal failure and death. In rhabdomyolysis,
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creatine kinase (CK) levels are elevated by≥10 times, and often ≥40
times, the upper limit of normal (ULN) [234]. The frequency of
rhabdomyolysis has been estimated to represent 1–3 cases/100 000
patient-years [235]. Patients taking statin therapy frequently report
muscle symptoms [so-called ‘statin-associated muscle symptoms’
(SAMS)], and in non-randomized, observational studies, statins are
associated with muscular pain and tenderness (myalgia) without CK
elevation or major functional loss, with the reported frequency of SAMS
in such studies varying between 10 and 15% among statin-treated
individuals [236–238]. However, in part because individuals in
observational studies are not blind to the treatment they are
receiving, such studies are unreliable when used to assess the adverse
effects of statins [233]. In contrast, in blinded randomized trials of
statins vs. placebo there is no, or only a slightly, increased frequency of
muscle symptoms in statin-allocated groups [239,240]. The Anglo-
Scandinavian Cardiac Outcomes Trial – Lipid-Lowering Arm (ASCOT-
LLA) study addressed this issue by comparing the incidence of four
different adverse events, including muscle-related symptoms, during
both the blinded, placebo-controlled trial and its open-label extension
study [238]. They concluded that a nocebo effect (i.e. one caused by
negative expectations) may partly explain the higher frequency of
SAMS in observational studies compared with in trials. Suggested
practical management of muscular symptoms is shown in
Supplementary Fig. 6 [198,234,241]. Several studies have shown a
considerable LDL-C-lowering effect of alternative dosing, such as every
other day or twice a week, with atorvastatin or rosuvastatin [242].
Although no clinical endpoint trials are available, this strategy should
be considered in high-risk patients in whom statin treatment with daily
doses is not possible.
8.1.4.2. Adverse effects on the liver. The activity of alanine
aminotransferase (ALT) in plasma is commonly used to assess
hepatocellular damage. Mild elevation of ALT occurs in 0.5–2.0% of
patients on statin treatment, more commonly with potent statins or
high doses. The common definition of clinically relevant ALT elevation
has been an increase of three times the ULN on two consecutive
occasions. Mild elevation of ALT has not been shown to be associated
with true hepatotoxicity or changes in liver function. Progression to
liver failure is exceedingly rare, therefore routine monitoring of ALT
during statin treatment is no longer recommended [243]. Patients with
mild ALT elevation due to steatosis have been studied during statin
treatment and there is no indication that statins cause any worsening of
liver disease [244–246].
8.1.4.3. Increased risk of new-onset diabetes mellitus. Patients on statin
treatment have been shown to exhibit an increased risk of dysglycaemia
and development of type 2 diabetes mellitus (T2DM). Several studies
have shown that this is a consistent, dose-related effect [232]. A minor,
not clinically relevant elevation of glycated haemoglobin (HbA1c) has
also been observed. The number needed to cause one case of diabetes
has been estimated as 255 over 4 years of statin treatment [247].
However, the risk is higher with the more potent statins at high doses
[248], and is also higher in the elderly, and in the presence of other risk
factors for diabetes such as overweight or insulin resistance [249].
Overall, the absolute reduction in the risk of CVD in high-risk patients
clearly outweighs the possible adverse effects of a small increase in the
incidence of diabetes [233]. This effect is probably related to the
mechanism of action of statins, as Mendelian randomization studies
have confirmed the increased risk of DM in individuals with HMG-CoA
reductase polymorphisms that reduce cholesterol synthesis [250].
8.1.4.4. Increased risk of haemorrhagic stroke. In observational studies,
TC is negatively associated with haemorrhagic stroke, and in the CTT
meta-analysis, there was a 21% [95% confidence interval (CI) 5–41%;
P=0.01] relative increase per mmol/L lower LDL cholesterol in
haemorrhagic stroke [34,251,252]. However, other meta-analyses
have yielded conflicting findings and there is a need for further
exploration of the risk of haemorrhagic stroke in particular types of
patients. Note, however, that the overall benefit on other stroke
subtypes greatly outweighs this small (and uncertain) hazard [34,36].
8.1.4.5. Adverse effects on kidney function. There is no clear evidence
that statins have a clinically significant beneficial or adverse effect on
renal function [253]. An increased frequency of proteinuria has been
reported for all statins, but has been analysed in more detail for
rosuvastatin. With a dose of 80 mg, a frequency of 12% was reported.
With the approved doses of< 40 mg, the frequency is much lower and
in line with the frequency for other statins. The proteinuria induced by
statins is of tubular origin, usually transitory, and is believed to be due
to reduced tubular reabsorption and not to glomerular dysfunction
[254,255]. In clinical trials, the frequency of proteinuria is generally
low and, in most cases, is not higher than for placebo [256].
8.1.4.6. Interactions. A number of important drug interactions with
statins have been described that may increase the risk of adverse
effects. Inhibitors and inducers of enzymatic pathways involved in
statin metabolism are summarized in Table 10. All currently available
statins—except pravastatin, rosuvastatin, and pitavastatin—undergo
major hepatic metabolism via the CYPs. These isoenzymes are mainly
expressed in the liver and intestine. Pravastatin does not undergo
metabolism through the CYP system, but is metabolized by sulfation
and conjugation. CYP3A4 isoenzymes are the most abundant, but other
isoenzymes such as CYP2C8, CYP2C9, CYP2C19, and CYP2D6 are
frequently involved in the metabolism of statins. Thus, other
pharmacological substrates of these CYPs may interfere with statin
metabolism. Conversely, statin therapy may interfere with the
catabolism of other drugs that are metabolized by the same
enzymatic system.
Combination of statins with gemfibrozil enhances the risk of myo-
pathy, and its association with statins must be avoided. There is no or
very little increased risk for myopathy when combining statins with
other fibrates, such as fenofibrate, bezafibrate, or ciprofibrate
[259,260].
8.2. Cholesterol absorption inhibitors
8.2.1. Mechanism of action
Ezetimibe inhibits intestinal uptake of dietary and biliary choles-
terol at the level of the brush border of the intestine [by interacting
with the Niemann-Pick C1-like protein 1 (NPC1L1)] without affecting
the absorption of fat-soluble nutrients. By inhibiting cholesterol ab-
sorption, ezetimibe reduces the amount of cholesterol delivered to the
liver. In response to reduced cholesterol delivery, the liver reacts by
upregulating LDLR expression, which in turn leads to increased clear-
ance of LDL from the blood.
Table 10
Drugs potentially interacting with statins metabolized by cytochrome P450 3A4
leading to increased risk of myopathy and rhabdomyolysis.
Anti-infective agents Calcium antagonists Other
Itraconazole Verapamil Ciclosporin
Ketoconazole Diltiazem Danazol
Posaconazole Amlodipine Amiodarone
Erythromycin Ranolazine
Clarithromycin Grapefruit juice
Telithromycin Nefazodone
HIV protease inhibitors Gemfibrozil
Adapted from Egan and Colman [257], and Wiklund et al. [258].
HIV=human immunodeficiency virus.
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8.2.2. Effects on lipids
In clinical studies, ezetimibe in monotherapy at 10 mg/day reduces
LDL-C in hypercholesterolaemic patients by 15–22% with relatively
high interindividual variation [261]. A meta-analysis of RCTs that in-
cluded over 2700 people showed an 18.5% reduction in LDL-C as
compared with placebo [262]. In addition, there was a significant 3%
increase in HDL-C, a significant 8% reduction in TGs, and a 13% re-
duction in TC with ezetimibe as compared with placebo.
Ezetimibe added to ongoing statin therapy reduces LDL-C levels by
an additional 21–27% compared with placebo in patients with hy-
percholesterolaemia with or without established CHD. In statin-naïve
patients, ezetimibe and statin combination therapy has resulted in
around a 15% greater reduction in LDL-C when compared with the
same statins and doses in monotherapy. In other studies, this combi-
nation has also significantly improved reductions in LDL-C levels when
compared with doubling of the statin dose (13–20%), and after
switching from statin monotherapy to ezetimibe and statin combination
therapy (11–15%) [263].
Co-administration of ezetimibe and bile acid sequestrants (colese-
velam, colestipol, or cholestyramine) has been reported to result in an
additional reduction of LDL-C levels by 10–20% when compared with
the stable bile acid sequestrant regimen alone [264]. Co-administration
of ezetimibe with PCSK9 inhibitors also results in an additional effect
[265].
8.2.3. Effect on cardiovascular morbidity and mortality
The efficacy of ezetimibe in association with simvastatin has been
addressed in people with aortic stenosis in the Simvastatin and
Ezetimibe in Aortic Stenosis (SEAS) trial [266], and in patients with
CKD in the Study of Heart and Renal Protection (SHARP) trial [222]. In
both the SEAS and SHARP trials, a reduction in CV events was de-
monstrated in the simvastatin–ezetimibe arm vs. placebo [266,267].
In the Improved Reduction of Outcomes: Vytorin Efficacy
International Trial (IMPROVE-IT), ezetimibe was added to simvastatin
(40 mg) in patients after acute coronary syndrome (ACS) [33]. A total
of 18 144 patients were randomized to statin or statin plus ezetimibe,
and 5314 patients over 7 years experienced a CV event; 170 fewer
events (32.7 vs. 34.7%) were recorded in the group taking simvastatin
plus ezetimibe (P=0.016). The average LDL-C during the study was
1.8 mmoL/L (70 mg/dL) in the simvastatin group and 1.4 mmoL/L (55
mg/dL) in patients taking ezetimibe plus simvastatin. Also, ischaemic
stroke was reduced by 21% in this trial (P=0.008). There was no
evidence of harm caused by ezetimibe or the further LDL-C reduction.
In this group of patients already treated with statins to reach goals, the
absolute CV benefit from added ezetimibe was small, although sig-
nificant and in line with the CTT expectations [268]. Therefore, the
study supports the proposition that LDL-C lowering by means other
than statins is beneficial and safe. The beneficial effect of ezetimibe is
also supported by genetic studies of mutations in NPC1L1; naturally
occurring mutations that inactivate the protein were found to be as-
sociated with reduced plasma LDL-C and reduced risk for CAD
[55,269,270].
Taken together with other studies [271], IMPROVE-IT supports the
proposal that ezetimibe should be used as second-line therapy in as-
sociation with statins when the therapeutic goal is not achieved at the
maximal tolerated statin dose, or in cases where a statin cannot be
prescribed [272,273].
8.2.4. Adverse effects and interactions
Ezetimibe is rapidly absorbed and extensively metabolized to
pharmacologically active ezetimibe glucuronide. The recommended
dose of ezetimibe of 10 mg/day can be administered in the morning or
evening irrespective of food intake. There are no clinically significant
effects of age, sex, or race on ezetimibe pharmacokinetics, and no do-
sage adjustment is necessary in patients with mild hepatic impairment
or mild-to-severe renal insufficiency. Life-threatening liver failure with
ezetimibe as monotherapy or in combination with statins is extremely
rare. The addition of ezetimibe to statin therapy does not appear to
increase the incidence of elevated CK levels beyond what is noted with
statin treatment alone [261].
8.3. Bile acid sequestrants
8.3.1. Mechanism of action
Bile acids are synthesized in the liver from cholesterol and are re-
leased into the intestinal lumen, but most of the bile acid is returned to
the liver from the terminal ileum via active absorption. The two older
bile acid sequestrants, cholestyramine and colestipol, are both bile acid-
binding exchange resins. The synthetic drug colesevelam is also avail-
able in some countries. As bile acid sequestrants are not systemically
absorbed or altered by digestive enzymes, the beneficial clinical effects
are indirect. By binding the bile acids, the drugs prevent the re-
absorption of both the drug and cholesterol into the blood, and thereby
remove a large portion of the bile acids from the enterohepatic circu-
lation. The liver, depleted of bile, synthesizes more from hepatic cho-
lesterol, therefore increasing the hepatic demand for cholesterol and
increasing LDLR expression, which results in a decrease of circulating
LDL.
8.3.2. Effects on lipids
At the top daily dose of 24 g of cholestyramine, 20 g of colestipol, or
4.5 g of colesevelam, a reduction in LDL-C of 18–25% has been ob-
served. No major effect on HDL-C has been reported, while TGs may
increase in some predisposed patients [274]. Colesevelam can also re-
duce glucose levels in hyperglycaemic patients [275].
8.3.3. Effect on cardiovascular morbidity and mortality
In clinical trials, bile acid sequestrants have contributed greatly to
the demonstration of the efficacy of LDL-C lowering in reducing CV
events in hypercholesterolaemic people, with a benefit proportional to
the degree of LDL-C lowering. Of note, these studies were performed
before many of the modern treatment options were available
[276–278].
8.3.4. Adverse effects and interactions
Gastrointestinal (GI) adverse effects (most commonly flatulence,
constipation, dyspepsia, and nausea) are often present with these drugs,
even at low doses, which limits their practical use. These adverse effects
can be attenuated by beginning treatment at low doses and ingesting
ample fluid with the drug. The dose should be increased gradually.
Reduced absorption of fat-soluble vitamins has been reported.
Furthermore, these drugs may increase circulating TG levels in certain
patients.
Bile acid sequestrants have major drug interactions with several
commonly prescribed drugs, and must therefore be administered either
4 h before or 1 h after other drugs. Colesevelam is better tolerated and
has fewer interactions with other drugs, and can be taken together with
statins and several other drugs [279].
8.4. Proprotein convertase subtilisin/kexin type 9 inhibitors
8.4.1. Mechanism of action
Recently, a new class of drugs, PCSK9 inhibitors, has become
available that targets a protein (PCSK9) involved in the control of the
LDLR [280]. Elevated concentration or function of this protein in
plasma reduces LDLR expression by promoting, upon binding, LDLR
lysosomal catabolism and a subsequent increase in plasma LDL con-
centrations, while lower concentration or function of PCSK9 is related
to lower plasma LDL-C levels [281]. Therapeutic strategies have been
developed mainly using mAbs; the mechanism of action relates to the
reduction of the plasma level of PCSK9, which in turn is not available to
bind the LDLR. Since this interaction triggers the intracellular
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degradation of the LDLR, lower levels of circulating PCSK9 will result in
increased expression of LDLRs at the cell surface and therefore in a
reduction of circulating LDL-C levels [281]. Currently, the only ap-
proved PCSK9 inhibitors are two fully human mAbs, alirocumab and
evolocumab. Statin treatment increases circulating PCSK9 serum levels
[282], and thus the best effect of these mAbs has been demonstrated in
combination with statins.
8.4.2. Effects on lipids
8.4.2.1. Low-density lipoprotein cholesterol. In clinical trials, alirocumab
and evolocumab—either alone or in combination with statins, and/or
other lipid-lowering therapies—have been shown to significantly
reduce LDL-C levels on average by 60%, depending on dose. The
efficacy appears to be largely independent of any background therapy.
In combination with high-intensity or maximally tolerated statins,
alirocumab and evolocumab reduced LDL-C by 46–73% more than
placebo, and by 30% more than ezetimibe. Among patients in whom
statins cannot be prescribed, PCSK9 inhibition reduced LDL-C when
administered in combination with ezetimibe [283]. Both alirocumab
and evolocumab have also been shown to effectively lower LDL-C levels
in patients who are at high CV risk, including those with DM [284].
Given the mechanism of action, these drugs are effective at reducing
LDL-C in all patients capable of expressing LDLR in the liver. Therefore,
this pharmacological approach is effective in the vast majority of pa-
tients, including those with HeFH and, albeit to a lower level, those
with HoFH with residual LDLR expression. Receptor-deficient HoFH
responds poorly to the therapy [285].
8.4.2.2. Triglycerides and high-density lipoprotein cholesterol. These
highly efficacious LDL-lowering agents also lower TG levels, and
increase those of HDL-C and ApoA-I as a function of the dosing
regimen. In phase II trials, evolocumab lowered TG levels by 26%,
and raised HDL-C and ApoA-I by 9 and 4%, respectively; similar
findings have been reported for alirocumab [286,287]. However, the
TG effect must be confirmed in populations with higher starting plasma
TG levels.
8.4.2.3. Lipoprotein(a). In contrast to statins, inhibiting PCSK9 with
mAbs also reduces Lp(a) plasma levels. Pooled results of phase II trials
have shown that treatment leads to an Lp(a) reduction of about 30–40%
[288,289]. While recent investigations have attempted to unravel the
mechanism, it remains unclear. However, it appears to be distinct from
that of statins, which also enhance LDLR function but do not lower
circulating Lp(a) levels in humans. The relative contribution of this
effect to the reduction of risk remains to be addressed in appropriately
designed studies.
8.4.3. Effect on cardiovascular morbidity and mortality
Early preliminary data from phase III trials suggests a reduction of
CV events in line with the LDL-C reduction achieved [286,290,291].
Recently, two major studies were completed: the Further
Cardiovascular Outcomes Research with PCSK9 Inhibition in Subjects
with Elevated Risk (FOURIER) and the Evaluation of Cardiovascular
Outcomes After an Acute Coronary Syndrome During Treatment With
Alirocumab (ODYSSEY Outcomes) trials [119,120]. The designs of the
trials were similar with regard to the settings of secondary prevention
and background therapy; however, the populations enrolled had either
stable CHD, peripheral arterial disease (PAD), or stroke; or a recent
(median 2.6 months) ACS, respectively. The relative benefit ranged
from 15 to 20% reductions in the risk of the primary endpoints. Both
studies had relatively short follow-up periods and the evidence from
statin trials indicates that the clinical benefits of LDL-lowering may only
emerge after about 1 year [51], so these trials may have underestimated
the potential impact of longer-term treatment [120,290].
In the FOURIER trial [119], 27 564 patients with atherosclerotic
CVD, and LDL-C levels of 1.8 mmoL/L (70 mg/dL) or higher who were
receiving statin therapy, were randomly assigned to receive evolo-
cumab or placebo. Allocation to evolocumab reduced median LDL-C
from 2.38 mmoL/L (92 mg/dL) at baseline to a mean of 0.78 mmoL/L
(30 mg/dL) at 48 weeks. After a median follow-up of 2.2 years, evo-
locumab treatment significantly reduced the risk of the primary end-
point (composite of CV death, MI, stroke, hospitalization for unstable
angina, or coronary revascularization) by 15% [hazard ratio (HR) 0.85,
95% CI 0.79–0.92]. An analysis of the time to benefit also showed that
there was a lower benefit in the first year than in subsequent years,
consistent with the effects of statins observed within the CTT meta-
analysis [268]. In the FOURIER trial, allocation to evolocumab did not
reduce the risk of CV mortality (HR 1.05, 95% CI 0.88–1.25) or all-
cause mortality.
The ODYSSEY Outcomes trial randomized 18 924 patients after
hospitalization for acute MI or unstable angina, treated with statins,
and with LDL-C ≥1.8 mmoL/L (≥70 mg/dL), non-HDL cholesterol
≥2.6 mmoL/L (≥100 mg/dL), or ApoB ≥80 mg/dL, to receive injec-
tions of alirocumab or matching placebo. Allocation to alirocumab re-
duced the mean baseline LDL-C from 2.38 mmoL/L (92 mg/dL) to 1.24
mmoL/L (48 mg/dL) at 12 months. There was a 15% relative reduction
in the primary outcome (composite of CHD death, non-fatal MI,
ischaemic stroke, or unstable angina requiring hospitalization) (HR
0.85, 95% CI 0.78–0.93) after a median follow-up of 2.8 years [120].
Although there was a significant reduction in all-cause mortality in the
ODYSSEY trial, this was an exploratory outcome and was not supported
by a significant effect on CV death.
8.4.4. Adverse effects and interactions
Anti-PCSK9 mAbs are injected subcutaneously, every other week or
once a month, at different doses depending on the agent used. The
potential for interaction with orally absorbed drugs is absent, as they
will not interfere with pharmacokinetics or pharmacodynamics. Among
the most frequently reported side effects are itching at the site of in-
jection and flu-like symptoms [292]. In some studies, an increase of
patient-reported neurocognitive effects has been described [293].
However, the EBBINGHAUS trial [231], which was specifically de-
signed to detect neurocognitive function changes, was reassuring, as
were the safety reports in both the FOURIER and ODYSSEY trials.
Mendelian randomization studies have also suggested that PCSK9 in-
hibition may increase the risk of DM with an LDL-C-related effect, as
apparently occurs for statins [294]. To date, no signal has emerged
from RCTs [295–297]. Although large long-term trials of PCSK9 in-
hibitors are needed to rule out these and other potential side effects of
inhibition of PCSK9 [298], 7 year data from the IMPROVE-IT study
have shown that prolonged low LDL-C concentrations are not associated
with any clear adverse effects [299].
A potential problem of long-term antibody treatment is the occur-
rence of autoantibodies. Evolocumab and alirocumab are fully human
antibodies and, therefore, theoretically less likely to induce auto-
antibodies. To date, only very few cases of antidrug antibodies have
been reported, and no reduction of LDL-C lowering has been observed,
but long-term use needs to be monitored. Indeed, the development
programme for a third PCSK9 inhibitor, bococizumab, a humanized
antibody, was discontinued because of an increase of neutralizing an-
tibodies, which resulted in the attenuation of the LDL-C-lowering effect
over time, as well as a higher rate of injection site reactions [300].
However, although PCSK9 inhibitors are very effective drugs that can
reduce LDL-C and CV events on top of statin and/or ezetimibe treat-
ment, considering the costs of the treatments and the limited data on
long-term safety, these drugs are likely to be considered cost-effective
only in those patients at very high-risk of ASCVD, and their use may not
be possible in some countries with limited healthcare resources.
8.5. Lomitapide
The microsomal TG transfer protein (MTP) transfers TGs and
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phospholipids from the endoplasmic reticulum to ApoB, as a necessary
step in the formation of VLDL. MTP inhibition thus prevents the for-
mation of VLDL in the liver and of chylomicrons in the intestine.
Lomitapide is an MTP inhibitor designed for o.d. oral treatment of
HoFH. In an open-label, single-arm titration study evaluating lomita-
pide as adjunct therapy to statins, with or without apheresis and a low-
fat diet [301], LDL-C was reduced by 50% from baseline at 26 weeks
and by 44% at 56 weeks. Lomitapide was also shown to decrease the
frequency of apheresis in HoFH patients. It should be noted that the
drug's effect on CV outcomes has not yet been determined.
As a consequence of its mechanism of action, lomitapide has been
shown to be associated with increased aminotransferase levels, which
most likely reflects the increased fat in the liver, as well as poor GI
tolerability [301,302]. The GI side effects were the most frequent rea-
sons preventing a further increase in the dose of lomitapide in clinical
trials [301]. However, it has been noted that the frequency and in-
tensity of GI side effects generally decrease with time. Therefore, pre-
scription of lomitapide requires careful patient education and liver
function monitoring during therapy.
8.6. Mipomersen
Mipomersen is an antisense oligonucleotide able to bind the mes-
senger RNA (mRNA) of ApoB-100, which triggers the selective de-
gradation of mRNA molecules. After subcutaneous injection, the oli-
gonucleotide is preferentially transported to the liver, where it binds to
a specific mRNA preventing the translation of ApoB protein and, con-
sequently, reducing the production of atherogenic lipids and lipopro-
teins, including LDL and Lp(a) [303]. An adjunct to lipid-lowering
medications and diet, mipomersen is indicated to reduce LDL-C in pa-
tients with HoFH. Mipomersen is currently approved by the US Food
and Drug Administration (FDA), but not by the European Medicines
Agency (EMA).
Reactions at the injection site are the most common adverse effects
observed in patients treated with mipomersen [304]. However, the
main concerns regarding mipomersen's safety are related to liver toxi-
city. Mipomersen may lead to the development of steatosis. Treated
patients have shown a higher increase of liver fat from baseline com-
pared with patients randomized to placebo [303]. The efficacy and
safety of long-term mipomersen treatment are currently under evalua-
tion in patients with severe HeFH, and in statin-‘intolerant’ patients.
8.7. Fibrates
8.7.1. Mechanism of action
Fibrates are agonists of peroxisome proliferator-activated receptor-
α (PPAR-α), acting via transcription factors regulating, among other
things, various steps in lipid and lipoprotein metabolism. As a con-
sequence, fibrates have good efficacy in lowering fasting TG levels, as
well as post-prandial TGs and TG-rich lipoprotein (TRL) remnant par-
ticles.
8.7.2. Effects on lipids
Clinical impacts on lipid profiles vary among members of the fibrate
class, but are estimated to reach a 50% reduction of the TG level, a
≤20% reduction of the LDL-C level (but a paradoxical small LDL-C
increase may be observed with high TG levels), and an increase of the
HDL-C level of ≤20%. The magnitude of effect is highly dependent on
the baseline lipid levels [305]. Both the HDL-raising and TG-lowering
effects of fibrates have been reported to be markedly less (∼5 and
∼20%, respectively) in long-term intervention trials in people with
T2DM but without elevated levels of TGs [306,307].
8.7.3. Effect on cardiovascular morbidity and mortality
The clinical effects of fibrates have been primarily illustrated by six
RCTs: the Helsinki Heart Study (HHS), Veterans Affairs High Density
Lipoprotein Intervention Trial (VA-HIT), Bezafibrate Infarction
Prevention (BIP), Lower Extremity Arterial Disease Event Reduction
(LEADER), Fenofibrate Intervention and Event Lowering in Diabetes
(FIELD), and Action to Control Cardiovascular Risk in Diabetes
(ACCORD) trials; in the latter trial, fenofibrate was added to statin
therapy [306–311]. In CV outcome trials of fibrates, the risk reduction
appeared to be proportional to the degree of non-HDL-C lowering [50].
Although the HHS reported a significant reduction in CVD outcomes
with gemfibrozil, neither the FIELD nor the ACCORD studies involving
fenofibrate showed a reduction in total CVD outcomes. The LEADER
trial included male participants with lower-extremity arterial disease
and failed to show that bezafibrate could lead to a clinically important
reduction in CVD combined endpoints. Decreases in the rates of non-
fatal MI were reported, although often as a result of post hoc analyses.
The effect was most evident in people with elevated TG/low HDL-C
levels. However, the data on other outcome parameters have remained
equivocal. Only one study, ACCORD, has analysed the effect of a fibrate
as an add-on treatment to a statin. No overall benefit was reported in
two recent meta-analyses [312,313]. Results from other meta-analyses
suggest reduced major CVD events in patients with high TGs and low
HDL-C in fibrate-treated patients, but no decrease in CVD or total
mortality [314–316]. Thus, the overall efficacy of fibrates on CVD
outcomes is much less robust than that of statins. Recently, a new se-
lective PPAR-α modulator (pemafibrate) has been reported to have
marked efficacy in reducing TRLs [317]. The study, Pemafibrate to
Reduce Cardiovascular OutcoMes by Reducing Triglycerides IN Pa-
tiENts With DiabeTes (PROMINENT), is an ongoing CVD outcome trial
designed to evaluate the efficacy of pemafibrate in some 10 000 high-
risk diabetic patients with high TG and low HDL-C levels [318].
Overall, the potential CV benefits of fibrates require further confirma-
tion.
8.7.4. Adverse effects and interactions
Fibrates are generally well tolerated with mild adverse effects, GI
disturbances being reported in<5% of patients, and skin rashes in 2%
[319]. In general, myopathy, liver enzyme elevations, and cholelithiasis
represent the most well-known adverse effects associated with fibrate
therapy [319]. The risk of myopathy has been reported to be 5.5-fold
greater with fibrate monotherapy (mainly with gemfibrozil) compared
with a statin, and it varies with different fibrates and statins used in
combination. This is explained by the pharmacological interactions
between the metabolism of different fibrates and pathways of glucur-
onidation of statins. Gemfibrozil inhibits the metabolism of statins via
the glucuronidation pathway, which leads to marked increases in
plasma concentrations of statins [320]. As fenofibrate does not share
the same pharmacokinetic pathways as gemfibrozil, the risk of myo-
pathy is much less with this combination therapy [319].
As a class, fibrates have been reported to raise both serum creatinine
and homocysteine levels in both short- and long-term studies. The in-
crease of serum creatinine by fibrate therapy seems to be fully re-
versible when the drug is stopped. Data from meta-analyses suggest that
a reduction of calculated glomerular filtration rate (GFR) does not re-
flect any adverse effects on kidney function [315]. Fibrates are asso-
ciated with a slightly increased risk of pancreatitis [321]. The increase
in homocysteine levels caused by fibrates has been considered to be
relatively neutral with respect to CVD risk. However, a fibrate-induced
increase in homocysteine may blunt elevation of both HDL-C and
ApoA1 levels, and this effect may contribute to the smaller than esti-
mated benefits of fenofibrate in CV outcome parameters [322].
8.8. n-3 fatty acids
8.8.1. Mechanism of action
The n-3 (or omega-3) fatty acids [eicosapentaenoic acid (EPA) and
docosahexaenoic acid (DHA)] can be used at pharmacological doses to
lower TGs. n-3 fatty acids (2–4 g/day) affect serum lipids and
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lipoproteins, in particular VLDL concentrations. The underlying me-
chanism is poorly understood, although it may be related, at least in
part, to their ability to interact with PPARs and to decreased secretion
of ApoB.
8.8.2. Effects on lipids
n-3 fatty acids reduce TGs, but their effects on other lipoproteins are
trivial. More detailed data on clinical outcomes are needed to justify
wide use of prescription n-3 fatty acids [323]. The recommended doses
of total EPA and DHA to lower TGs have varied between 2 and 4 g/day.
Three recent studies in people with high TGs using EPA reported a
significant reduction in serum TG levels of up to 45% in a dose-de-
pendent manner [324–326]. The efficacy of omega-3 fatty acids in
lowering serum TGs has also been reported in meta-analyses [157].
Recently, the EpanoVa fOr Lowering Very high triglyceridEs II
(EVOLVE II) trial confirmed the efficacy of omega-3 fatty acids in
lowering serum TGs [327].
8.8.3. Effect on cardiovascular morbidity and mortality
A Cochrane meta-analysis, including 112 059 people from 79 trials,
reported no overall effect of omega-3 PUFAs on total mortality (relative
risk 0.98, 95% CI 0.90–1.03) or CV events (relative risk 0.99, 95% Cl
0.94–1.04), with only a suggestion that omega-3 fatty acids reduced
CHD events (relative risk 0.93, 95% Cl 0.88–0.97) [328]. Recently, the
A Study of Cardiovascular Events iN Diabetes (ASCEND) trial [329],
which randomly assigned 15 480 patients with DM but without ather-
osclerotic CV disease to n-3 fatty acids or placebo, showed no sig-
nificant difference in the risk of serious vascular events after a mean
follow-up of 7.4 years (relative risk 1.00, 95% Cl 0.91–1.09).
The data remain inconclusive and the clinical efficacy of omega-3
fatty acids appears to be related to non-lipid effects [330,331]. More-
over, studies with omega-3 fatty acids have suffered from the dose used
(1 g/day), which does not affect plasma lipids to a large extent, as the
dose required to decrease plasma TGs is > 2 g/day. The Reduction of
Cardiovascular Events with EPA-Intervention Trial (REDUCE-IT) [195]
aimed to evaluate the potential benefits of omega-3 oil (EPA) on ASCVD
outcomes in people with elevated serum TGs; the trial enrolled ∼8000
patients on statin therapy, with LDL-C levels between 1.0 and 2.6
mmoL/L (41–100 mg/dL) and various CV risk factors, including per-
sistent elevated TGs between 1.7 and 5.6 mmoL/L (150–499 mg/dL),
and either established ASCVD or DM, and at least one other CV risk
factor. Use of high doses (2 g b.i.d.) of EPA as compared with placebo
(mineral oil) resulted in a ∼25% relative risk reduction (P < 0.001) in
major adverse CV events (MACE). Another randomized placebo-con-
trolled trial, Outcomes Study to Assess STatin Residual Risk Reduction
with EpaNova in HiGh CV Risk PatienTs with Hypertriglyceridemia
(STRENGTH) [332], which aims to determine whether reduction of
TRLs and remnants in statin-treated patients will provide additional
ASCVD risk reduction, is ongoing. The VITamin D and OmegA-3 TriaL
(VITAL), which reported recently, was a 2× 2 factorial design study in
which healthy participants were randomized in a 1:1 fashion to either
vitamin D3 (at a dose of 2000 IU per day) vs. matching placebo, and n-3
fatty acids (1 g per day as a fish-oil capsule containing 840 mg of n-3
fatty acids, including 460 mg of EPA and 380 mg of DHA) vs. matching
placebo. It showed that supplementation with either n-3 fatty acids at a
dose of 1 g/day, or vitamin D3 at a dose of 2000 IU/day, was not ef-
fective for primary prevention of CV or cancer events among healthy
middle-aged men and women over 5 years of follow-up [333].
8.8.4. Safety and interactions
The administration of n-3 fatty acids appears to be safe and devoid
of clinically significant interactions. The most common side effect is GI
disturbance. The antithrombotic effects may increase the propensity for
bleeding, especially when given in addition to aspirin/clopidogrel.
Recently, data from one study have associated a risk of prostate cancer
with high dietary intake of n-3 PUFAs [334].
8.9. Nicotinic acid
Nicotinic acid has key action sites in both the liver and adipose
tissue. In the liver, nicotinic acid inhibits diacylglycerol acyltransferase-
2 resulting in decreased secretion of VLDL particles, which is also re-
flected in reductions of plasma levels of both IDL and LDL particles
[335]. Nicotinic acid primarily raises HDL-C and ApoA1 by stimulating
ApoA1 production in the liver [335]. Two large randomized trials with
nicotinic acid—one with extended-release niacin [66] and one with
niacin plus laropiprant [67]—have shown no beneficial effect and an
increased frequency of serious adverse effects. No medication con-
taining nicotinic acid is currently approved in Europe.
8.10. Cholesteryl ester transfer protein inhibitors
To date, the pharmacological approach that has led to the greatest
elevations in HDL-C levels has been direct inhibition of CETP by small-
molecule inhibitors, which may induce an increase in HDL-C
by≥ 100% on a dose-dependent basis. Torcetrapib was studied in the
Investigation of Lipid Level Management to Understand its Impact in
Atherosclerotic Events (ILLUMINATE) trial, which was stopped early
due to increased mortality [336]. Dalcetrapib raises HDL-C levels by
30–40% with no appreciable effect on LDL-C, offering specific insight
into pure HDL-C raising. However, dalcetrapib failed to show any
benefit in ACS patients in the dal-OUTCOMES trial. Evacetrapib, which
raises HDL-C levels by 130% and lowers LDL-C by 37%, was studied in
the ACCELERATE trial [63], which was terminated due to futility. Re-
cently, anacetrapib, which raises HDL-C and ApoA-I levels (by 104 and
36%, respectively), and lowers LDL-C and ApoB (by 17 and 18%, re-
spectively), was studied in the REVEAL trial. Anacetrapib reduced
major coronary events by 9% over a median of 4.1 years [64]. The
magnitude of the relative risk reduction appeared to be consistent with
the magnitude of LDL-C- or non-HDL-C-level lowering [337]. This drug
has not been submitted for regulatory approval.
8.11. Future perspectives
8.11.1. New approaches to reduce low-density lipoprotein cholesterol
An alternative approach targeting PCSK9 consists of RNA inter-
ference. In a phase I and a phase II trial, the small interfering RNA
(siRNA) molecule inclisiran—which inhibits the synthesis of
PCSK9—reduced LDL-C by up to 50% and the reduction was dose-de-
pendent. Reductions in PCSK9 and LDL-C levels were maintained for
≤6 months [338,339]. No specific serious adverse events were ob-
served. HPS4/TIMI65/ORION4, with a planned mean duration of 5
years, is currently comparing inclisiran vs. placebo among 15 000 pa-
tients with a prior MI or stroke.
Bempedoic acid is a novel, first-in-class, oral small molecule that
inhibits cholesterol synthesis by inhibiting the action of ATP citrate
lyase, a cytosolic enzyme upstream of 3-hydroxy-3-methylglutaryl-
coenzyme A reductase [340]. So far, it has been tested in diabetic pa-
tients, and patients with or without statin ‘intolerance’. In mono-
therapy, bempedoic acid reduces LDL-C levels by ∼30% and by about
50% in combination with ezetimibe. Bempedoic acid is currently being
tested in phase III trials and some trials have been completed
[341,342].
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8.11.2. New approaches to reduce triglyceride-rich lipoproteins and their
remnants
As genetic studies indicate that angiopoietin-like protein 3
(ANGPTL3) deficiency protects against atherosclerotic disease and that
this relationship is causal [343], an ANGPTL3 antibody (evinacumab) is
being developed. Evinacumab has been shown to decrease TGs, LDL-C,
and Lp(a) levels in HoFH patients [344]. Another approach that is
currently being investigated is the inhibition of ANGPTL3 production
by antisense oligonucleotides [345]. IONIS-ANGPTL3-LRx, an antisense
oligonucleotide targeting ANGPTL3, another critical protein in the
clearance of TRLs, reduces plasma TGs by about 85%. Thus, the future
may yield tools to improve TRL clearance that will be reflected in the
atherogenic load of the remnant particles.
The rapid development of gene-silencing technology has allowed
proteins (ApoC-III) that are critical in the regulation of TRL clearance
processes to be targeted. A second-generation antisense oligonucleotide
targeting ApoC-III mRNA has been developed [346]. Two phase III
trials have evaluated the safety and efficacy of volanesorsen in patients
with elevated TG levels [347,348]. Volanesorsen reduced plasma TGs
by ∼70% and ApoC-III by 80–90% [349]. The EMA recently issued a
marketing authorization for Waylivra (volanesorsen) as an adjunct to
diet in adult patients with genetically confirmed familial chylomicro-
naemia syndrome (FCS) who are at high-risk for pancreatitis, in whom
response to diet and TG-lowering therapy has been inadequate.
8.11.3. New approaches to increase high-density lipoprotein cholesterol
Although genetic studies suggest that low HDL-C levels are not a
cause of ASCVD, casting doubt on the possibilities of future treatment
options to raising HDL-C levels with attenuation of CVD, major devel-
opments in the search for efficacious agents to raise HDL-C and ApoA1
levels with concomitant benefits on atherosclerosis and CV events are
on the horizon. On the one hand, interest is focused on ApoA1 mimetic
peptides and recombinant forms of HDL possessing potential for in vivo
HDL particle remodelling and enhanced cardioprotective activity
[350]. On the other, agents that enhance catabolism of TG-rich lipo-
proteins, such as the antisense oligonucleotide to ApoC-III, and which
lead to a concomitant reduction in TGs (∼70%) and a marked elevation
in HDL-C (∼40%) in hypertriglyceridemia, are under development
[351]. Importantly, however, we currently lack understanding of the
relationship between the modality of raising HDL/ApoA-I levels and a
possible antiatherogenic function of HDL particles.
8.11.4. New approaches to reduce lipoprotein(a) levels
Another approach under study is the selective decrease of Lp(a)
concentrations. RNA-based therapies are now being evaluated in clin-
ical settings. Results from studies of an antisense oligonucleotide in
patients with normal Lp(a) values as well as in patients with elevated Lp
(a) concentrations have shown a reduction of> 90% [352]. These ap-
proaches are currently being evaluated in phase II–III studies and an
outcome trial is planned to study whether Lp(a) reduction translates
into risk reduction.
8.12. Strategies to control plasma cholesterol
Although LDL-C goals are attained with monotherapy in many pa-
tients, a significant proportion of patients at high-risk or with very high
LDL-C levels need additional treatment. In this case, combination
therapy is reasonable. In patients at very-high risk and with persistent
high-risk despite being treated with a maximally tolerated statin,
combination with ezetimibe is recommended and, if still not at goal, the
addition of a PCSK9 inhibitor is recommended (see Fig. 4 and Re-
commendations for pharmacological low-density lipoprotein cholesterol
lowering). Of note, addition of a PCSK9 inhibitor directly to a statin is
also feasible [120,290] (Fig. 4).
Recommendations for pharmacological low-density lipoprotein cholesterol lowering.
ASCVD= atherosclerotic cardiovascular disease; FH= familial hypercholesterolaemia; LDL-C= low-density lipoprotein cholesterol; PCSK9=proprotein convertase
subtilisin/kexin type 9.
a Class of recommendation.
b Level of evidence.
c For definitions see Table 7.
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As shown in Fig. 3, the expected clinical benefit of treatment to
lower the LDL-C level of any person can be estimated; it depends on the
intensity of therapy, the baseline LDL-C level, and the baseline esti-
mated risk of ASCVD. This simple algorithm can be used to help clin-
icians select the appropriate therapy and quantify the expected benefits
of LDL-C-lowering therapy to help inform discussions with patients. For
ease of reference, Supplementary Table 3 provides a summary of the
absolute LDL-C reductions that can be achieved with various ther-
apeutic approaches at particular baseline levels of LDL-C.
8.13. Strategies to control plasma triglycerides
Although CVD risk is increased when fasting TGs are> 1.7 mmoL/L
(> 150 mg/dL) [56], the use of drugs to lower TG levels may only be
considered in high-risk patients when TGs are> 2.3 mmoL/L (> 200
mg/dL) and TGs cannot be lowered by lifestyle measures. The available
pharmacological interventions include statins, fibrates, PCSK9 in-
hibitors, and n-3 PUFAs. A meta-analysis of 10 trials included people
treated with various agents that reduce serum TGs (fibrates, niacin, and
n-3 PUFAs) and reported a 12% reduction in CV outcomes [354]. Re-
cently, the REDUCE-IT trial [194] demonstrated that in statin-treated
patients with high CV risk with fasting TG levels between 135 and 499
mg/dL (1.52–1.63 mmoL/L), high-dose icosapent ethyl, a highly pur-
ified and stable EPA (2 g) taken b.i.d., significantly reduced the risk of
ischaemic events, including CV death, by about one-quarter over a
median follow-up of 4.9 years. In addition, the VITAL trial showed that
n-3 fatty acids at the lower dose of 1 g/day were not effective for pri-
mary prevention of CV or cancer events among healthy middle-aged
men and women over 5 years of follow-up [333]. Recommendations for
the treatment of HTG are shown below.
Fig. 3. Expected clinical benefits of low-density lipoprotein cholesterol-lowering therapies. The expected clinical benefits of treatment to lower low-density lipo-
protein cholesterol for any person can be estimated; it depends on the intensity of therapy, the baseline low-density lipoprotein cholesterol level, the expected
absolute achieved reduction in low-density lipoprotein cholesterol, and the baseline estimated risk of atherosclerotic cardiovascular disease. The intensity of therapy
should be selected to achieve the recommended proportional reduction in low-density lipoprotein cholesterol based on the person's estimated risk of atherosclerotic
cardiovascular disease. Multiplying the proportional reduction in low-density lipoprotein cholesterol by a person's baseline low-density lipoprotein cholesterol level
estimates the expected absolute reduction in low-density lipoprotein cholesterol that is likely to be achieved with that therapy. Because each 1.0 mmoL/L absolute
reduction in low-density lipoprotein cholesterol is associated with a 20% reduction in the risk of cardiovascular events, larger absolute reductions in low-density
lipoprotein cholesterol lead to larger proportional reductions in risk. Multiplying the proportional reduction in risk expected for the achieved absolute reduction in
low-density lipoprotein cholesterol by a person's estimated baseline risk of atherosclerotic cardiovascular disease determines the expected absolute risk reduction for
that person. LDL-C= low-density lipoprotein cholesterol; PCSK9=proprotein convertase subtilisin/kexin type 9.
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Fig. 4. Treatment goals and algorithm for low-density lipoprotein cholesterol lowering according to cardiovascular disease risk. (A) Treatment goals for low-density
lipoprotein cholesterol across categories of total cardiovascular disease risk. (B) Treatment algorithm for pharmacological low-density lipoprotein cholesterol
lowering. ASCVD= atherosclerotic cardiovascular disease; BP= blood pressure; CKD= chronic kidney disease; CV= cardiovascular; DM=diabetes mellitus;
eGFR=estimated glomerular filtration rate; FH= familial hypercholesterolaemia; LDL-C= low-density lipoprotein cholesterol; PCSK9=proprotein convertase
subtilisin/kexin type 9; SCORE = Systematic Coronary Risk Estimation; T1DM= type 1 DM; T2DM= type 2 DM; TC= total cholesterol.
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Recommendations for drug treatment of patients with hypertriglyceridaemia.
CVD= cardiovascular disease; LDL-C= low-density lipoprotein cholesterol;
PUFA=polyunsaturated fatty acids; TG= triglyceride.
a Class of recommendation.
b Level of evidence.
9. Management of dyslipidaemias in different clinical settings
9.1. Familial dyslipidaemias
Plasma lipid levels are, to a very large extent, determined by genetic
factors. In its more extreme forms this is manifested as familial dyslipi-
daemias. A number of monogenic lipid disorders have been identified;
among these, FH is the most common and is strongly related to CVD
(Table 11). In general, in a patient with dyslipidaemia, the pattern of
inheritance commonly does not suggest that there is a major single gene
(monogenic) disorder causing the abnormality; rather, it stems from the
inheritance of more than one gene variant affecting lipoprotein metabo-
lism that, on its own, might have relatively little effect, but in combina-
tion with another or others has a greater influence on TC, TGs, or HDL-C.
The pattern of inheritance is polygenic [357]. It is common to find that
high LDL-C, high TG, or low HDL-C levels affect several family members.
9.1.1. Familial combined hyperlipidaemia
Familial combined hyperlipidaemia (FCH) is a highly prevalent
mixed dyslipidaemia (1:100–200) characterized by elevated levels of
LDL-C, TGs, or both, and is an important cause of premature CAD. FCH
is a complex disease, and the phenotype is determined by the interac-
tion of multiple susceptibility genes and the environment. It has con-
siderable overlap with the dyslipidaemic phenotypes of T2DM and
MetS. Even within a family, the phenotype shows high inter- and in-
trapersonal variability based on lipid values (TGs, LDL-C, HDL-C, and
ApoB). FCH has no monogenic component and is not linked to a single
genetic cause, but the phenotype is high LDL-C and/or high TGs
[358,359]. Therefore, the diagnosis is commonly missed in clinical
practice; the combination of ApoB>120 mg/dL and TGs>1.5 mmoL/
L (> 133 mg/dL) with a family history of premature CVD can be used
to identify people who most probably have FCH [360].
The concept of mixed dyslipidaemia is also valuable clinically in
assessing CV risk. It emphasizes both the importance of considering
family history in deciding how rigorously to treat dyslipidaemia and
that elevated LDL-C levels portend a higher risk when HTG is also
present. Statin treatment decreases CV risk by the same relative amount
in people with HTG as in those without. Because the absolute risk is
often greater in those with HTG, they may therefore benefit greatly
from LDL-lowering therapy.
9.1.2. Familial hypercholesterolaemia
9.1.2.1. Heterozygous familial hypercholesterolaemia. FH is a common
codominant monogenic dyslipidaemia causing premature CVD due to
lifelong elevation of plasma levels of LDL-C. If left untreated, men and
women with HeFH typically develop early CAD before the ages of 55
and 60 years respectively. The risk of CHD among individuals with
definite or probable HeFH is estimated to be increased at least 10-fold.
However, early diagnosis and appropriate treatment can dramatically
reduce the risk for CAD.
The prevalence of HeFH in the population is estimated to be 1/
200–250,361 translating to a total number of cases between 14 and 34
million worldwide [362,363]. Only a minor fraction of these cases is
identified and properly treated.
FH is a monogenic disease caused by loss-of-function mutations in
the LDLR or apoB genes, or a gain-of-function mutation in the PCSK9
gene; around 95% of FH cases are caused by mutations in LDLR. More
than 1000 different mutations that cause FH have been identified in
LDLR. The different mutations cause reduced function or complete loss-
of-function, the latter being associated with more severe hypercholes-
terolaemia and CVD.
The diagnosis of FH is usually based on clinical presentation. The
commonly used criteria from the Dutch Lipid Clinic Network are shown
in Table 12. Other criteria are the Simon Broome register or the WHO
criteria [364,365].
The diagnosis can be verified by showing causative mutations in the
pathogenic genes. However, in most studies, the frequency of detect-
able mutations in patients with a clinically definite or probable HeFH is
between 60 and 80%. This suggests that a considerable proportion of
patients with FH have either a polygenic cause of the disease or that
other genes, yet to be identified, are involved.
Genetic testing and cascade screening. Probands (index cases) should
be identified according to the following criteria:
• TC≥8 mmoL/L (≥310 mg/dL) without treatment in an adult or
adult family member (or> 95th percentile by age and gender for
country);• Premature CHD in the patient or a family member;• Tendon xanthomas in the patient or a family member; or• Sudden premature cardiac death in a family member.
Cascade screening of family members of a known index case allows
for the efficient identification of new cases. Cascade screening is best
performed by a lipid clinic. In most families, the cases may be identified
with TC or LDL-C analysis; however, genetic testing is recommended
when the causative mutation is known.
Cholesterol-lowering treatment should be initiated as soon as possible
after a diagnosis has been made. To improve risk assessment, the use of
imaging techniques to detect asymptomatic atherosclerosis is re-
commended. The concept of cumulative cholesterol burden illustrates the
importance of early treatment (for children, see below). Treatment should
be initiated with high-intensity statin therapy, in most cases in combination
with ezetimibe. In FH patients at very-high risk of ASCVD due to a prior
history of ASCVD or another major risk factor, LDL-C goals are a ≥50%
reduction of LDL-C from baseline and an LDL-C<1.4 mmoL/L (<55 mg/
dL). In the absence of ASCVD or another major risk factor, patients with FH
are categorized as high-risk, and LDL-C goals are a ≥50% reduction of
LDL-C from baseline and an LDL-C<1.8 mmoL/L (<70 mg/dL).
PCSK9 inhibitors lower LDL-C levels by up to 60% on top of statins.
Two RCTs have reported a beneficial effect on clinical endpoints in
ASCVD patients without FH [119,120]. PCSK9 inhibitors are re-
commended in very-high-risk patients with FH if the treatment goal is
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not achieved on maximal tolerated statin plus ezetimibe. PCSK9 in-
hibitors are also recommended in FH patients who cannot tolerate
statins [366,367].
Recommendations for the detection and treatment of patients with
HeFH are shown below.
Recommendations for the detection and treatment of patients with hetero-
zygous familial hypercholesterolaemia.
ASCVD= atherosclerotic cardiovascular disease; CHD= coronary heart dis-
ease; CVD= cardiovascular disease; FH= familial hypercholesterolaemia;
HoFH=homozygous FH; LDL-C= low-density lipoprotein cholesterol;
PCSK9=proprotein convertase subtilisin/kexin type 9.
a Class of recommendation.
b Level of evidence.
9.1.2.2. Homozygous familial hypercholesterolaemia. HoFH is a rare and
life-threatening disease. The clinical picture is characterized by
extensive xanthomas, marked premature and progressive CVD, and
TC > 13 mmoL/L (> 500 mg/dL). Most patients develop CAD and
aortic stenosis before the age of 20 years and die before 30 years of age.
The frequency of HoFH is estimated to be 1/160 000–1/320 000. The
early identification of these children and prompt referral to a
specialized clinic is crucial. The patients should be treated with
intensive LDL-lowering drug therapy and, when available, with
lipoprotein apheresis. This treatment (every 1–2 weeks) can decrease
plasma LDL-C levels by 55–70%. The procedure frequency may be
adjusted for each patient as lipid levels, symptoms, and other disease-
related parameters change. Maximally tolerated pharmacological
therapy must be maintained [368]. For a more detailed discussion on
HoFH, see the EAS consensus statements [366,368].
9.1.2.3. Familial hypercholesterolaemia in children. FH is diagnosed in
children based on phenotypic criteria including elevated LDL-C plus a
family history of elevated LDL-C, premature CAD, and/or positive
genetic testing [369]. Testing during childhood is optimal to
discriminate between FH and non-FH using LDL-C. In children with a
family history of high cholesterol or premature CHD, an accepted cut-
off is≥ 4.0 mmoL/L (≥160 mg/dL). If a parent has a known genetic
defect, the diagnostic level for the child is≥ 3.5 mmoL/L (≥130 mg/
dL). If possible, genetic testing of the child is suggested.
Although there have been no placebo-controlled trials in children,
observational studies have suggested that early treatment can reduce
LDL-C burden, improve endothelial function, substantially attenuate
the development of atherosclerosis, and improve coronary outcomes
[369–371]. Treatment of children with FH includes a healthy lifestyle
and statin treatment. A heart-healthy diet should be adopted early in
life and statin treatment should be considered at 6–10 years of age.
Statin treatment should be started with low doses and the dose should
be increased to reach goals [372]. The goal in children>10 years of
age is an LDL-C< 3.5 mmoL/L (< 135 mg/dL) and at younger ages a
≥50% reduction of LDL-C.
9.1.3. Familial dysbetalipoproteinaemia
Familial dysbetalipoproteinaemia (i.e. type III hyperlipoprotei-
naemia; remnant removal disease) is rare and is generally inherited as
an autosomal recessive disorder with variable penetrance. Familial
dysbetalipoproteinaemia produces a characteristic clinical syndrome in
which both TC and TGs are elevated before treatment, usually both in
the range of 7–10 mmoL/L. In severe cases, patients develop tuber-
oeruptive xanthomas, particularly over the elbows and knees, and
palmar xanthomata in the skin creases of the hands and wrists. The risk
of CAD is very high, and accelerated atherosclerosis of the femoral and
tibial arteries is also prevalent. The syndrome is usually not expressed
at a young age or in women before menopause. The majority of cases
are homozygous for the E2 isoform of ApoE. ApoE is important for the
hepatic clearance of chylomicron remnants and IDL. ApoE2 binds less
readily than the E3 and E4 isoforms to hepatic receptors. However,
without some coincidental cause of dyslipidaemia such as dyslipi-
daemia associated with HTG, DM, obesity, or hypothyroidism
[373–375], ApoE2 homozygosity does not generally cause familial
dysbetalipoproteinaemia.
The detection of ApoE2 homozygosity in a dyslipidaemic patient is
diagnostic and analysis of ApoE isoforms is now available in most
clinical laboratories. The presence of cholesterol remnants character-
istic of familial dysbetalipoproteinaemia can be reliably predicted on
the basis of plasma levels of cholesterol, TGs, and ApoB [376]. If sus-
picion is confirmed, ApoE genotyping can be performed. In older pa-
tients with xanthomata resembling those of familial dysbetalipopro-
teinaemia who prove not to be homozygous for ApoE2, a paraprotein
should be sought. The treatment of familial dysbetalipoproteinaemia
should be undertaken in a specialist clinic. Most cases respond well to
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treatment with a statin or, if dominated by high TGs, a fibrate; often a
combination of a statin and a fibrate may be needed.
9.1.4. Genetic causes of hypertriglyceridaemia
Although the genetic aetiology for HTG seems to be very complex,
recent data have extended our genetic understanding of HTG, in par-
ticular that of chylomicronaemia [37,226,377]. Moderate elevation of
TG levels (between 2.0 and 10.0 mmoL/L) is caused by the polygenic
effect of multiple genes influencing both VLDL production and removal.
Monogenic severe HTG causes chylomicronaemia, pancreatitis, and
lipid deposits. Thus far, mutations in six genes (LPL, apoC2, apoA5,
LMF1, GPIHBP1, and GPD1) with monogenic effects have been re-
cognized to lead to severe elevation of serum TGs due to disruption of
the chylomicron removal pathways. These mutations are inherited as
autosomal recessive traits and are rare. The profound defect in the
catabolism of chylomicrons and VLDL results in chylomicronaemia and
TG levels> 11.2 mmoL/L (> 1000 mg/dL), with turbid and milky
serum. Severe HTG is seen in patients who are homozygous or com-
pound heterozygous for mutations of the enzyme LPL, and in other
genes linked to the catabolism of TG-rich lipoproteins. Heterozygous
carriers of these same gene mutations commonly express moderate
elevations of serum TG levels that expose them to increased CVD risk
[378]. Recently, gene therapy for LPL deficiency has been developed
and tested in clinical trials [379], and the alipogene tiparvovec was
approved by the EMA in 2013. However, this therapy is no longer
available. A gain-of-function mutation in apoC3 that leads to high
ApoC-III levels can also cause severe HTG by inhibiting the activity of
LPL, whereas loss-of-function mutations are associated with a favour-
able lipid profile with low TG levels [380]. These findings have raised
the possibility of ApoC-III being a novel lipid drug target.
9.1.4.1. Action to prevent acute pancreatitis in severe
hypertriglyceridaemia. The risk of pancreatitis is clinically significant if
TGs are> 10 mmoL/L (880 mg/dL), particularly when occurring in
association with familial chylomicronaemia, and actions to prevent
acute pancreatitis are mandatory [381,382]. Notably, HTG is the cause
of ∼10% of all cases with pancreatitis, and patients can develop
pancreatitis even when their TG concentration is 5–10 mmoL/L
(440–880 mg/dL). Recent data from a prospective cohort study
reported that the risk of acute pancreatitis increased significantly
over the quartiles of serum TGs, highlighting the fact that, as a risk
factor, serum TGs may have been underestimated [383]. Any factor that
increases VLDL production can aggravate the risk of pancreatitis, with
alcohol consumption being the most common contributing factor.
Either a patient should be admitted to hospital if symptomatic, or
careful and close follow-up of the patient's TG values should be
undertaken. Restriction of calories and fat content (10–15%
recommended) in the diet, and alcohol abstinence are obligatory.
Fibrate therapy (fenofibrate) should be initiated, with n-3 fatty acids
(2–4 g/day) as adjunct therapy. Lomitapide may also be considered in
severe cases [37]. In patients with DM, insulin therapy should be
initiated to achieve good glycaemic control. In general, a sharp
decrease of TG values is seen within 2–5 days. In the acute setting,
plasmapheresis is able to rapidly lower TG levels [384]. Volanesorsen
has been recently approved by the EMA as an adjunct to diet in adult
patients with genetically confirmed FCS who are at high-risk for
pancreatitis.
Table 11
Genetic disorders of lipoprotein metabolism.
Disorder Prevalence Gene(s) Effect on lipoproteins
HeFH 1 in 200–250 LDLR
APO B
PCSK9
↑LDL-C
HoFH 1 in 160 000–320 000 LDLR
APO B
PCSK9
↑↑LDL-C
FCH 1 in 100/200 USF1 + modifying genes ↑LDL-C ↑VLDL-C ↑ApoB
Familial dysbetalipoproteinaemia 1 in 5000 APO E ↑↑ IDL and chylomicron remnants (βVLDL)
Familial lipoprotein lipase deficiency (familial chylomicron syndrome) 2 in 106 LPL
APO C2
ApoAV, GPIHBP1
LMF1
↑↑ chylomicrons and VLDL-C
Tangier disease (analphalipoproteinaemia) 1 in 106 ABCA1 ↓↓HDL-C
Familial LCAT deficiency 1 in 106 LCAT ↓HDL-C
Apo= apolipoprotein; FCH= familial combined hyperlipidaemia; HDL-C=high-density lipoprotein cholesterol; HeFH=heterozygous familial hypercholester-
olaemia; HoFH=homozygous familial hypercholesterolaemia; IDL= intermediate-density lipoprotein; LCAT= lecithin cholesterol acyltransferase; LDL-C= low-
density lipoprotein cholesterol; VLDL=very low-density lipoprotein cholesterol.
Table 12
Dutch Lipid Clinic Network diagnostic criteria for familial hypercholester-
olaemia.
Criteria Points
1) Family history
First-degree relative with known premature (men aged < 55 years;
women <60 years) coronary or vascular disease, or first-degree
relative with known LDL-C above the 95th percentile
1
First-degree relative with tendinous xanthomata and/or arcus cornealis,
or children aged < 18 years with LDL-C above the 95th percentile
2
2) Clinical history
Patient with premature (men aged < 55 years; women <60 years)
CAD
2
Patient with premature (men aged < 55 years; women <60 years)
cerebral or peripheral vascular disease
1
3) Physical examinationa
Tendinous xanthomata 6
Arcus cornealis before age 45 years 4
4) LDL-C levels (without treatment)
LDL-C ≥8.5 mmoL/L (≥325 mg/dL) 8
LDL-C 6.5–8.4 mmoL/L (251–325 mg/dL) 5
LDL-C 5.0–6.4 mmoL/L (191–250 mg/dL) 3
LDL-C 4.0–4.9 mmoL/L (155–190 mg/dL) 1
5) DNA analysis
Functional mutation in the LDLR, apoB, or PCSK9 genes 8
Choose only one score per group, the highest applicable; diagnosis is based on the total
number of points obtained
A ‘definite’ FH diagnosis requires > 8 points
A ‘probable’ FH diagnosis requires 6–8 points
A ‘possible’ FH diagnosis requires 3–5 points
CAD= coronary artery disease; FH= familial hypercholesterolaemia; LDL-
C= low-density lipoprotein cholesterol; PCSK9=proprotein convertase sub-
tilisin/kexin type 9.
a Exclusive of each other (i.e. maximum 6 points if both are present).
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9.1.5. Other genetic disorders of lipoprotein metabolism
Sometimes patients are encountered with extremely low levels of
LDL-C or HDL-C. The most common form of genetic hypolipidaemia is
hypobetalipoproteinaemia, which is dominantly inherited and often
due to truncation of ApoB. Serum LDL-C is typically between 0.5 and
1.5 mmoL/L (20–60 mg/dL). A more profound deficiency of ApoB oc-
curs in abetalipoproteinaemia when steatorrhoea, and neurological or
other complications require specialist treatment. Almost absent levels
of HDL-C occur in Tangier disease (analphalipoproteinaemia) and very
low levels of HDL-C occur in lecithin cholesterol acyltransferase (LCAT)
deficiency. Both these conditions are associated with distinct clinical
syndromes and require specialist investigation. Very high levels of HDL-
C are detected in patients with CETP deficiency. In the heterozygous
form, levels of 2.0–2.3 mmoL/L (80–90 mg/dL) are typically observed,
and levels ≥5 mmoL/L (≥200 mg/dL) are observed in homozygotes.
This is not associated with atherosclerotic disease and may be asso-
ciated with reduced risk.
Lysosomal acid lipase deficiency or cholesterol ester storage disease
(in children with Wolman disease) is a rare cause (recessive transmis-
sion) of elevated LDL-C and low HDL-C, accompanied by hepatomegaly
and microvesicular hepatosteatosis. Statin treatment does decrease
LDL-C levels and could therefore prevent ASCVD in these patients, but it
cannot stop the progression of liver damage. Treatment with a PCSK9
inhibitor may lead to an even greater overload of lysosomes [385].
Enzyme replacement therapy with sebelipase alfa might offer a treat-
ment solution in the near future [386].
9.2. Women
Few randomized trials of statin therapy have reported in-
dependently significant CV benefits in women [387,389], chiefly be-
cause women have not been adequately represented in statin trials.
9.2.1. Effects of statins in primary and secondary prevention
There has previously been controversy over whether statins are ef-
fective for primary prevention in women. Using published data, a 2013
Cochrane analysis showed that statin therapy reduced all-cause mor-
tality, vascular events, and revascularizations in primary prevention,
and the proportional effects in women were similar to those in men
[213]. The CTT collaboration has provided a more complete assessment
of the evidence through a comprehensive analysis of IPD from 22 trials
of statins vs. control and five trials of more-vs. less-intensive statin
therapy [35]. Overall, 46 675 (27%) of 174 149 participants were
women, and after adjustment for non-gender differences, the propor-
tional reductions per mmol/L reduction in LDL-C in major vascular
events, major coronary events, coronary revascularization, and stroke
were similar in women and men [35].
9.2.2. Non-statin lipid-lowering drugs
Definitive evidence of the cardioprotective effects of non-statin
drugs that lower LDL-C is now available, and the beneficial effects are
similar in both women and men. In the IMPROVE-IT study [33], the
relative benefit of adding ezetimibe to simvastatin was similar in
women and men [33]. In the ACCORD lipid study, there was no evi-
dence that fenofibrate added to the effects of simvastatin in patients
with T2DM [306], but an analysis of the FIELD study showed consistent
CV event reduction in both women and men [389]. Several outcome
trials assessing the effects of adding a PCSK9 inhibitor to high-intensity
statin therapy have now been reported, with similar proportional re-
ductions in major vascular events in women and men [120,286,290].
9.2.3. Hormone therapy
Currently prescribed third-generation, low-dose oestrogen–pro-
gestin oral contraceptives do not appear to increase adverse coronary
events [390] and can be used, after baseline lipid profile assessment, in
women with acceptable TC levels. In contrast, alternative contraceptive
measures should be recommended in women with hypercholester-
olaemia [LDL-C> 4 mmoL/L (> 160 mg/dL)] or with multiple risk
factors, and in those at high-risk of thrombotic events [391]. Oestrogen
replacement therapy, despite some favourable effects on lipid profiles,
has not been demonstrated to reduce CV risk and cannot be re-
commended for CVD prevention in women [392]. No lipid-lowering
drugs should be administered during pregnancy and the period of
breastfeeding because data on possible adverse effects are lacking.
However, bile acid sequestrants may be considered.
Box 6 lists the main measures in the management of dyslipidaemia
in women.
9.3. Older people
The proportion of older people (defined herein as those aged>65
years) in society is increasing and, as a consequence,> 80% of in-
dividuals who die from CVD are> 65 years of age. The proportion of
patients with MI > 85 years of age has increased several-fold [393].
Box 6
Management of dyslipidaemia in women
Statin treatment is recommended for primary prevention of ASCVD in high-risk women [34,35].
Statins are recommended for secondary prevention in women with the same indications and goals as in men [34,35].
Lipid-lowering drugs should not be given when pregnancy is planned, during pregnancy, or during the breastfeeding period. However, for
severe FH patients, bile acid sequestrants (which are not absorbed) and/or LDL apheresis may be considered.
ASCVD=atherosclerotic cardiovascular disease; FH= familial hypercholesterolaemia; LDL= low-density lipoprotein.
Box 7
Summary of dyslipidaemia in metabolic syndrome and type 2 diabetes mellitus
Dyslipidaemia represents a cluster of lipid and lipoprotein abnormalities, including elevation of both fasting and post-prandial TG, ApoB, and
small dense LDL, and low HDL-C and ApoA1 levels.
Non-HDL-C or ApoB are good markers of TRLs and remnants, and are a secondary objective of therapy. Non-HDL-C<2.6 mmoL/L (< 100
mg/dL) and ApoB<80 mg/dL are desirable in those at high-risk, and non-HDL-C< 2.2 mmoL/L (< 85 mg/dL) and ApoB<65 mg/dL in
those at very high-risk. For those at very high-risk with recurrent ASCVD events, a goal of non-HDL-C<1.8 mmoL/L (< 70 mg/dL) and
ApoB<55 mg/dL may be considered.
Atherogenic dyslipidaemia is one of the major risk factors for CVD in people with type 2 diabetes, and in people with abdominal obesity
and insulin resistance or impaired glucose tolerance.
Apo= apolipoprotein; ASCVD= atherosclerotic cardiovascular disease; CVD= cardiovascular disease; HDL-C=high-density lipoprotein choles-
terol; LDL-C= low-density lipoprotein cholesterol; TG= triglyceride; TRLs= triglyceride-rich lipoproteins.
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A meta-analysis of observational studies has shown that higher TC is
associated with increased CAD mortality at all ages [62,394]. However,
since the absolute risk of CAD is higher in older persons, the associated
absolute increase in risk for a given increment in TC is larger with in-
creasing age [217].
9.3.1. Effects of statins in primary and secondary prevention
The use of statin therapy declines with increasing age, reflecting
differences in both prescription and compliance [395,396]. This trend
is even more prominent among older patients who do not have evidence
of occlusive vascular disease [396]. One explanation for this pattern
may be uncertainty about the effects of statins in older people due to
the relatively small number of people aged>75 years who have been
included in statin trials [233,397,398]. The CTT collaboration recently
provided a comprehensive assessment of the randomized evidence on
the effects of statin therapy at different ages [217]. Among 186 854
participants in 28 trials, 14 483 (8%) were aged>75 years at rando-
mization. Overall, statin therapy produced a 21% relative reduction in
major vascular events (relative risk 0.79, 95% CI 0.77–0.81) per 1.0
mmoL/L reduction in LDL-C, and there was direct evidence of benefit
among those aged> 75 years. The relative reduction in major vascular
events was similar, irrespective of age, among patients with pre-existing
vascular disease, but appeared smaller among older individuals not
known to have vascular disease. Therefore, the available evidence from
trials indicates that statin therapy produces significant reductions in
major vascular events irrespective of age. However, there is less direct
evidence of benefit among patients aged> 75 years who do not already
have evidence of occlusive vascular disease, and this limitation is cur-
rently being addressed by the STAtin therapy for Reducing Events in the
Elderly (STAREE) trial in Australia.
9.3.2. Adverse effects, interactions, and adherence
The safety and adverse effects of statins are a matter of special
concern in older adults because they often have comorbidities, take
multiple medications, and have altered pharmacokinetics and phar-
macodynamics. Statin–drug interactions are a concern, primarily be-
cause of their potential to increase muscle-related statin-associated
adverse effects such as myalgia without CK elevation, myopathy with
CK elevation, and the rare but serious rhabdomyolysis. It is re-
commended that a statin is started at a low dose if there is significant
renal impairment and/or the potential for drug interactions, and then
titrated upwards to achieve LDL-C treatment goals.
The recommendations for the treatment of dyslipidaemias in older
people are shown below.
9.4. Diabetes and metabolic syndrome
The number of people with DM will increase from ∼415 million
today up to 550 million by 2030, but the situation may get even worse
[399]. Despite significant advantages in the management strategies that
lessen atherosclerotic CVD risk factors, CVD has remained the leading
cause of morbidity and mortality in patients with T2DM. The good news
is that fatal CVD outcomes have declined significantly in both T1DM
and T2DM between 1998 and 2014 [400]. DM itself is an independent
risk factor for CVD and is associated with a higher risk of CVD, even
more so in women. The difference in CVD risk between individuals with
and without DM has narrowed substantially over the last few decades
[401], and there are strong associations between DM and vascular
outcomes [402,403]. Recent data indicate that DM per se increases CVD
risk about two-fold on average, but the risk is subject to wide variation
depending on the population and current aggressive prophylactic
therapy [401,404]. Importantly, those with DM and CAD are at sub-
stantially higher CVD risk for future events. In T2DM, the risk of ASCVD
is strongly determined by the presence of target organ damage—in-
cluding nephropathy (microalbuminuria), neuropathy, or re-
tinopathy—with the risks increasing in relation to the number of con-
ditions present [405]. Hypertension, dyslipidaemia, abdominal obesity,
and non-alcoholic fatty liver disease (NAFLD) commonly coexist with
T2DM and further aggravate the risk, which is highest in people with
T2DM and multiple cardiometabolic risk factors [406–408]. Im-
portantly, DM confers excess mortality risk following ACS despite
modern therapies, highlighting the poor prognosis of coronary patients
with T2DM and the need for intensive therapy [409].
How to capture the extra risk beyond the traditional risk factors in
clinical practice is a debated issue. A practical approach is that if one
component is identified, a systematic search should be made for the
others [410].
9.4.1. Specific features of dyslipidaemia in insulin resistance and type 2
diabetes mellitus
Diabetic dyslipidaemia is a cluster of plasma lipid and lipoprotein
abnormalities that are metabolically interrelated. The increase in large
VLDL particles in T2DM initiates a sequence of events that generates
atherogenic remnants, small dense LDL, and small TG-rich dense HDL
particles [411]. These components are not isolated abnormalities but
are closely linked to each other. Both LDL and HDL particles show
variable compositional changes that are reflected in their functions.
Notably, ApoC-III levels are increased in people with T2DM [412]. High
ApoC-III concentrations prevent the clearance of both TRLs and rem-
nants, resulting in prolonged residence times of these particles in the
circulation [413,414]. In fact, the defective catabolism of TRLs seems to
be a more important contributor to the elevation of plasma TGs than the
increased production rate leading to an excess of remnant particles.
Together, TRL remnants, small dense LDL, and small dense HDL com-
prise the atherogenic lipid profile, which is also characterized by an
increase in ApoB concentration due to an increased number of ApoB-
containing particles. Importantly, TRLs—including chylomicrons,
Recommendations for the treatment of dyslipidaemias in older people (aged> 65 years).
ASCVD= atherosclerotic cardiovascular disease; LDL-C= low-density lipoprotein cholesterol.
a Class of recommendation.
b Level of evidence.
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VLDL, and their remnants—carry a single ApoB molecule, also like LDL
particles. Therefore, the malignant nature of diabetic dyslipidaemia is
not always revealed by the lipid measures used in clinical practice, as
LDL-C levels may remain within the normal range. It may be better
revealed by non-HDL-C levels [415]. Elevation of TGs or low HDL-C
levels in the fasting or post-prandial state is seen in about one-half of all
people with T2DM [416,417], and is also often present in people with
abdominal adiposity, insulin resistance or impaired glucose tolerance
[413].
Box 7 summarizes dyslipidaemia in MetS and T2DM.
9.4.2. Evidence for lipid-lowering therapy
9.4.2.1. Low-density lipoprotein cholesterol. LDL-C is the primary target
of lipid-lowering therapy in patients with DM. Trials specifically
performed in people with T2DM, as well as subsets of individuals
with DM in major statin trials, have consistently demonstrated
significant benefits of statin therapy on CVD events in people with
T2DM [418]. Statin therapy reduces the 5 year incidence of major CVD
events by 23% per 1 mmoL/L reduction in LDL-C, regardless of the
initial LDL-C level or other baseline characteristics based on meta-
analysis [418]. The CTT meta-analysis further indicates that people
with T2DM will have a relative risk reduction that is comparable to that
seen in non-diabetic patients; however, being at higher absolute risk,
the absolute benefit will be greater, resulting in a lower number needed
to treat (NNT). Thus, statin therapy is the first-line treatment for LDL-C
lowering and for the reduction of CVD burden [419].
Ezetimibe lowers LDL-C by ∼24% and, when added to statin
therapy, decreases the risk of major vascular events [33]. The relative
risk reduction in major vascular events is proportional to the absolute
degree of LDL-C lowering and consistent with the relationship seen for
statins. The subset of patients with DM in IMPROVE-IT had, as ex-
pected, a higher rate of major vascular events than patients without DM
(46 vs. 31% 7 year Kaplan–Meier rate in the placebo arm). Ezetimibe
appeared particularly efficacious in patients with DM, with a relative
risk reduction of 15% (95% CI 6–22%) and an absolute risk reduction of
5.5% [299].
The mAb PCSK9 inhibitors evolocumab and alirocumab lower LDL-
C levels by ∼60% and, when added to statin therapy, decrease the risk
of major vascular events [119]. In the FOURIER study, the relative risk
reduction for major vascular events was similar in patients with and
without DM; however, given the higher baseline risk in patients with
DM, the absolute risk reductions tended to be greater in patients with
DM (2.7% absolute decrease in major vascular events over 3 years)
[297]. Of note, the achieved LDL-C in the evolocumab arm was 0.8
mmoL/L. The same benefits were also recently demonstrated for dia-
betic patients after ACS in the ODYSSEY trial [420].
Recent studies have suggested an increased incidence of DM in
patients treated with statins [247]. These observations have been seen
in Mendelian randomization studies and in clinical trials, although the
effect appears greatest in patients already at high risk for DM (e.g. those
with pre-diabetes). These observations should not lessen our attention
to the treatment of patients, as the overall benefits in CV event reduc-
tion remain and greatly outweigh the increased incidence of DM. In
RCTs, neither ezetimibe nor the PCSK9 inhibitors have been reported to
increase the risk of DM [297].
9.4.2.2. Triglycerides and high-density lipoprotein cholesterol. Lifestyle
modification provides the first option to improve atherogenic
dyslipidaemia due to its multifaceted effects. Weight loss is, in most
cases, the most effective measure since it is associated with very
pronounced effects on plasma TG and HDL levels, together with a
modest decrease in TC and LDL-C levels. Moderate-to-heavy aerobic
exercise is also associated with improvement of the plasma lipid profile
by reducing TG levels and increasing HDL-C concentrations. In relation
to diet composition, besides the need to eliminate trans fat, the
available evidence supports the reduction of saturated fat intake and
its substitution with unsaturated fat, as well as the replacement of a
major proportion of refined starchy foods and simple sugars with fibre-
rich foods like fruits, vegetables, and wholegrains [179].
The clinical benefits achieved by the treatment of high TG and low
HDL-C levels (frequently seen with DM) are still a matter of debate, as
the effects of fenofibrate therapy on the major outcome (MACE) re-
mained negative in both the FIELD and the ACCORD studies performed
in T2DM cohorts [306,307]. In a post hoc analysis of the FIELD study,
fenofibrate reduced CVD events by 27% in those with elevated TGs
[∼2.3 mmoL/L (200 mg/dL)] and increased HDL-C levels (NNT=23)
[416]. The ACCORD trial confirmed the following: patients who had
both TG levels in the higher third [∼2.3 mmoL/L (200 mg/dL)] and an
HDL-C level in the lower third [≤0.4 mmoL/L (≤34 mg/dL)], re-
presenting 17% of all participants, appeared to benefit from the addi-
tion of fenofibrate to simvastatin [306].
Recently, post-trial follow-up of the ACCORD lipid trial participants
reported the beneficial effect of fenofibrate in people with HTG and low
HDL-C levels at baseline [421]. Consistent with these findings, a meta-
analysis of fibrates in the prevention of CVD in 11 590 people with
T2DM showed that fibrates significantly reduced the risk of non-fatal
MI by 21%, but had no effect on the risk of overall mortality or cor-
onary mortality [422]. In CV outcome trials of fibrates, the risk re-
duction has appeared to simply be proportional to the degree of non-
HDL-C lowering [50].
Overall, available data indicate that diabetic patients with athero-
genic dyslipidaemia may derive clinical benefits from TG-lowering
therapy as an add-on to statin treatment [354]. The ongoing PROMI-
NENT trial is exploring the efficacy of pemafibrate, a new selective
PPAR-α modulator, in reducing CVD outcomes in ∼10 000 diabetic
patients with atherogenic dyslipidaemia on a statin [317,423].
There are limited data on the impacts on CVD of adding omega-3
fatty acids to statin therapy in patients with high plasma TG levels who
are treated with statins. The REDUCE-IT trial examined the effects of
icosapent ethyl 2 g b.i.d. on CV events in 8179 high-risk patients with
HTG who were taking a statin. Over a median of 4.9 years, there was a
significant (P < 0.001) 25% reduction in the composite primary out-
come of CV death, non-fatal MI, non-fatal stroke, coronary revascular-
ization, or unstable angina, corresponding with an absolute reduction
of 4.8%, which was offset by a 1% increased absolute risk of hospita-
lization for atrial fibrillation or flutter [194]. The STRENGTH trial is
investigating the effect of omega-3 fatty acids, in addition to a statin, in
individuals with HTG and low HDL-C levels who are at high-risk for
CVD. The ASCEND trial was a randomized 2× 2 factorial design study
of aspirin and omega-3 fatty acid supplements for the primary pre-
vention of CV events in people with DM, but not specifically with HTG.
Among 15 480 people randomized to omega-3 fatty acid supplements
vs. placebo over a mean follow-up of 7.4 years, there was no significant
effect (HR 0.97, 95% CI 0.87–1.08) on serious vascular events [non-
fatal MI, non-fatal stroke, transient ischaemic attack (TIA), or vascular
death] [329,424–426].
9.4.3. Type 1 diabetes mellitus
T1DM is associated with high CVD risk, in particular in patients
with microalbuminuria and renal disease [427]. Conclusive evidence
supports the proposition that hyperglycaemia accelerates athero-
sclerosis. Emerging evidence highlights the frequent coexistence of
MetS with T1DM, resulting in the so-called double diabetes increasing
CVD risk [428].
The lipid profile in T1DM patients with good glycaemic control is
‘supernormal’, and is characterized by subnormal TG and LDL-C levels,
whereas HDL-C levels are usually within the upper normal range or
slightly elevated. This is explained by subcutaneous administration of
insulin that increases LPL activity in adipose tissue and skeletal muscle,
and consequently the turnover rate of VLDL particles [429]. However,
there are potentially atherogenic changes in the compositions of both
HDL and LDL particles.
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Consistent data have demonstrated the efficacy of statins in pre-
venting CV events and reducing CV mortality in patients with DM, with
no evidence of sex differences [430,431]. A meta-analysis including
18 686 patients with DM demonstrated that a statin-induced reduction
of LDL-C yielded a 9% reduction in all-cause mortality and a 21% re-
duction in the incidence of major CV events per 1.0 mmoL/L (40mg/dL)
lower LDL cholesterol [418]. Similar benefits were seen in patients with
T1DM and T2DM. In diabetic patients with ACS, intensive statin
treatment led to a reduction in all-cause mortality and CV death, and
contributed to a reduction in atheroma progression [432].
9.4.4. Management of dyslipidaemia for pregnant women with diabetes
In both T1DM and young-onset T2DM patients, there is a paucity of
evidence to indicate the age at which statin therapy should be initiated.
To guide an approach, statins are not indicated in pregnancy [433], and
should be avoided in both T1DM and T2DM individuals who are
planning pregnancy. If diabetic individuals aged ≤30 years have no
evidence of vascular damage and, in particular, microalbuminuria, it
seems reasonable to delay statin therapy in asymptomatic patients until
the age of 30. Below this age, statin therapy should be managed on a
case-by-case basis, taking into account the presence of micro-
albuminuria, end organ damage, and ambient LDL-C levels.
Recommendations for the treatment of dyslipidaemias in DM are
shown in the table below.
Recommendations for the treatment of dyslipidaemias in diabetes mellitus.
LDL-C= low-density lipoprotein cholesterol; T1DM= type 1 diabetes mellitus;
T2DM= type 2 diabetes mellitus.
a Class of recommendation.
b Level of evidence.
c See Table 6.
9.5. Patients with acute coronary syndromes and patients undergoing
percutaneous coronary intervention
Patients who present with ACS are at increased risk of experiencing
recurrent CV events. For these patients, lipid management should be
undertaken in the context of a comprehensive global risk reduction
strategy including lifestyle adaptations, risk factor management, and
the implementation of cardioprotective drug strategies. Ideally, patients
should be signed up to cardiac rehabilitation programmes to enhance
the control of lipid levels [434] and improve overall survival following
ACS [435]. Despite the acknowledged clinical benefits of lowering LDL-
C in patients with ACS [436], attainment of LDL-C target values remains
suboptimal in this very high-risk setting [437].
9.5.1. Lipid-lowering therapy in patients with acute coronary syndromes
LDL-C levels tend to decrease during the first days of ACS and
therefore a lipid profile should be obtained as soon as possible after
admission for ACS. Patients do not have to be fasting as this has little
impact on LDL-C levels [100]. Lipid-lowering treatment should be in-
itiated as early as possible to increase patient adherence after discharge.
Lipid levels should be re-evaluated 4–6 weeks after ACS to determine
whether treatment goals have been achieved and to check for any safety
issues; the therapeutic regimen can then be adapted accordingly.
9.5.1.1. Statins. Data from RCTs and meta-analyses indicate that
routine early use of high-intensity statin therapy is associated with
rapid and sustained clinical benefits [438–442]. We recommend the
initiation of high-intensity statin therapy in all statin-naïve ACS
patients with no contraindication, regardless of initial LDL-C values;
the treatment goal is to reach a 50% LDL-C reduction from baseline and
an LDL-C goal of< 1.4 mmoL/L (< 55 mg/dL). In those with recurrent
events within 2 years while taking maximally tolerated statin therapy, a
goal of< 1.0 mmoL/L (< 40 mg/dL) for LDL-C should be considered.
The intensity of statin therapy should be increased in those patients
receiving low- or moderate-intensity statin treatment at presentation,
unless there is a definite history of intolerance to high-intensity statin
therapy. The use of lower-intensity statin therapy should be considered
in patients at increased risk of adverse effects with high-intensity statin
therapy, such as in the elderly, patients diagnosed with hepatic or renal
impairment, or in the case of a potential risk of drug–drug interactions
with other essential concomitant therapies.
Regarding the timing of statin treatment initiation, the Statins
Evaluation in Coronary Procedures and Revascularization (SECURE-
PCI) randomized, placebo-controlled trial recently assessed the impact
of peri-procedural loading with atorvastatin [two loading doses of 80
mg, before and 24 h after the planned percutaneous coronary inter-
vention (PCI)] on MACE at 30 days in 4191 patients with ACS and
planned invasive management [443]. All patients received atorvastatin
40 mg per day starting 24 h after the second loading dose. The authors
found no significant treatment benefit in the overall study population.
In a pre-specified analysis, a significant 28% relative risk reduction in
MACE was observed among patients who underwent PCI (65% of all
patients). The benefit was even more pronounced (46% relative risk
reduction) in a post hoc analysis including 865 ST-elevation MI (STEMI)
patients undergoing reperfusion by primary PCI [443]. Based on cur-
rent evidence, we recommend the initiation of high-intensity statin
therapy during the first 1–4 days of hospitalization for the index ACS
[438–442]. Moreover, pre-treatment (or loading dose for patients al-
ready on a statin) with a high-intensity statin should be considered in
ACS patients with planned invasive management [443].
9.5.1.2. Ezetimibe. In the IMPROVE-IT trial, the addition of ezetimibe to
simvastatin therapy provided an additional benefit (6.4% relative risk
reduction in the composite clinical endpoint) to post-ACS patients [33].
The clinical benefit of adding ezetimibe was consistent across patient
subgroups [299,444] and also led to a reduction of total CV events [445],
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stroke [446], and rehospitalizations [447]. Patients at higher
atherothrombotic risk [as assessed by the TIMI (Thrombolysis In
Myocardial Infarction) risk score for secondary prevention] benefitted
the most from the addition of ezetimibe [448]. In another randomized,
open-label trial including 1734 patients with ACS, the addition of
ezetimibe to moderate-intensity statin (pitavastatin 2 mg) therapy failed
to improve outcomes overall, but did reduce the composite primary
endpoint (death, MI, stroke, unstable angina, and ischaemia-driven
revascularization) during 3.9-year follow-up in patients with increased
intestinal absorption of cholesterol (as assessed by elevated levels of
sitosterol) [449]; however, this finding requires further confirmation.
9.5.1.3. Proprotein convertase subtilisin/kexin type 9 inhibitors. In the
FOURIER trial, which included 27 564 patients with atherosclerotic CV
disease, the addition of evolocumab to statin therapy (69% high-intensity
therapy) resulted in a 15% relative risk reduction of the composite
primary endpoint throughout a 2.2 year follow-up. Results were
consistent in the subgroup of patients with a history of MI (81% of all
patients) [119,450]. A subanalysis of the FOURIER trial showed that
patients who achieved the lowest LDL-C values under PCSK9 treatment
also had the lowest risk of future MACE [451]. In the ODYSSEY
Outcomes trial, which included 18 924 patients with recent ACS (1–12
months prior to enrolment, median 2.6 months), alirocumab added to
statin therapy (89% high-intensity therapy) also resulted in a 15%
relative risk reduction in the primary composite endpoint and was
associated with a 15% relative reduction in all-cause mortality
throughout a 2.8 year follow-up [120]. No serious side effects or safety
concerns were reported in these two large trials. The optimal timing of
initiating PCSK9 inhibition after ACS and its impact on clinical outcomes
remain to be determined. Regarding the timing of PCSK9 inhibitor
treatment initiation, post hoc analyses from the FOURIER trial have
shown that the closer to the event this is done, the better. Treatment
initiation with PCSK9 inhibitors during the acute phase of ACS is under
investigation in the EVOlocumab for Early Reduction of LDL-cholesterol
Levels in Patients With Acute Coronary Syndromes (EVOPACS) trial
[452]. Based on current evidence, we recommend the initiation of
treatment with PCSK9 inhibitors in patients with ACS who do not
reach their respective LDL-C goals (as outlined in Table 7) after 4–6
weeks of maximum tolerated statin and ezetimibe therapy. In patients
who present with an ACS and whose LDL-C levels are not at goal, despite
already taking a maximally tolerated statin dose and ezetimibe prior to
the event, the addition of a PCSK9 inhibitor early after the event (during
the hospitalization for the ACS event if possible) should be considered.
9.5.1.4. n-3 polyunsaturated fatty acids. Oral supplementation with
highly purified n-3 PUFAs reduced mortality in survivors of MI in one
study [Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto
Miocardico-Prevenzione (GISSI-P)] but failed to affect clinical outcomes
in subsequent trials using contemporary secondary prevention therapies.
A recent meta-analysis of available RCTs showed no reduction in
mortality, MI, or major vascular events associated with n-3 PUFAs,
including the subgroup of patients with known CAD [453]. Therefore,
routine treatment with n-3 PUFAs cannot be recommended.
9.5.1.5. Cholesteryl ester transfer protein inhibitors. In 2007, a large
prospective study using the CETP inhibitor torcetrapib failed to show
any clinical benefit in more than 15 000 high-risk patients, and was
potentially harmful [336]. The CETP inhibitors dalcetrapib
(in> 30 000 patients with recent ACS [65]) and evacetrapib
(in> 12 000 high-risk patients [63]) were investigated in 2012 and
2017, respectively. Neither clinical study was able to show any clinical
benefit associated with CETP inhibitors [65]. More recently, the
REVEAL study investigated anacetrapib in>30 000 patients with
atherosclerotic vascular disease and resulted in a lower incidence of
MACE compared with placebo after 4 years, with no safety concerns
[64]. However, this compound was not filed for marketing
authorization.
9.5.2. Lipid-lowering therapy in patients undergoing percutaneous coronary
intervention
In a meta-analysis of 13 randomized studies including 3341 patients
who were planned to undergo PCI, pre-treatment with a high-dose
statin (statin-naïve patients, 11 studies) or a high-dose statin loading
dose reduced the risk of MACE (death, MI, or target vessel revascular-
ization) by 44% both for peri-procedural MI and MACE at 30 days
[454]. In all but one study, PCI was performed in the setting of stable
angina or in a non-emergency setting in non-ST elevation ACS (NSTE-
ACS). One of the studies that was included in the meta-analysis showed
an improvement in coronary flow when primary PCI was used for the
treatment of STEMI [455]. A routine strategy of either short pre-treat-
ment or loading (on the background of pre-existing therapy) with a
high-dose statin before PCI should be considered in elective PCI or
NSTE-ACS [454,456,457].
In addition, pre-treatment with a statin has also been shown to re-
duce the risk of contrast-induced acute kidney injury after coronary
angiography or intervention [458].
Recommendations for lipid-lowering therapy in patients with ACS
and patients undergoing PCI are summarized below.
Recommendations for lipid-lowering therapy in very-high-risk patients with
acute coronary syndromes.
ACS= acute coronary syndrome; LDL-C= low-density lipoprotein cholesterol;
PCSK9=proprotein convertase subtilisin/kexin type 9.
a Class of recommendation.
b Level of evidence.
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Recommendations for lipid-lowering therapy in very-high-risk patients under-
going percutaneous coronary intervention.
ACS= acute coronary syndrome; PCI= percutaneous coronary intervention.
a Class of recommendation.
b Level of evidence.
9.6. Stroke
Stroke has a heterogeneous aetiology, including cardiac throm-
boembolism [often associated with atrial fibrillation, but also of un-
certain source (embolic stroke of undetermined source)], carotid artery
and proximal aortic atherosclerosis and thromboembolism, small-vessel
CVD, and intracranial haemorrhage (including intracerebral and sub-
arachnoid haemorrhage). Dyslipidaemia may play a variable role in the
pathogenesis of stroke according to the particular aetiology. The re-
lationship between dyslipidaemia and atherothrombotic events, in-
cluding ischaemic stroke and TIA, is well recognized, while the asso-
ciation of dyslipidaemia with other types of stroke is uncertain.
Notwithstanding, concomitant control of other aetiological factors,
such as hypertension, is of paramount importance.
Following ischaemic stroke or TIA, patients are at risk not only of
recurrent cerebrovascular events, but also of other major CV events,
including MI. Secondary prevention therapy with statins reduces the
risk of recurrent stroke (by 12% per mmol/L reduction in LDL choles-
terol), MI, and vascular death [459,460]. Statin pre-treatment at TIA
onset was associated with reduced recurrent early stroke risk in patients
with carotid stenosis in a pooled data analysis, supporting as-early-as-
possible initiation of statins after stroke [460–462]. Statin therapy may
yield a small increase in the risk of haemorrhagic stroke, but the evi-
dence regarding this risk is uncertain [34,36,251,252].
Recommendations for lipid-lowering therapy for the prevention of athero-
sclerotic cardiovascular disease events in patients with prior ischaemic stroke.
ASCVD= atherosclerotic cardiovascular disease; LDL-C= low-density lipo-
protein cholesterol; TIA= transient ischaemic attack.
a Class of recommendation.
b Level of evidence.
9.7. Heart failure and valvular diseases
9.7.1. Prevention of incident heart failure in coronary artery disease
patients
Cholesterol lowering with statins reduces the incidence of HF in
patients with CAD (stable CAD or a history of ACS) without previous
HF; this has been shown consistently in RCTs that have compared statin
vs. no statin treatment [463,464] as well as more-intensive vs. less-
intensive statin therapy [465–468]. A large-scale meta-analysis of pri-
mary and secondary prevention RCTs with statins showed a modest
(10%) reduction in first non-fatal HF hospitalizations with statin
treatment, with no effect on HF death within the limited RCT period
[469]. There is no evidence that statins can prevent HF of non-
ischaemic origin.
9.7.2. Chronic heart failure
Two large RCTs [466,470] (mainly including patients with systolic
HF), as well as a meta-analysis of 24 RCTs, have shown no benefit of
statin treatment on CV mortality or stroke [471]; a reduction in HF
hospitalizations [218,471], as well as a small reduction in MI, was
observed in a pooled analysis of the Controlled Rosuvastatin Multi-
national Trial in Heart Failure (CORONA) and GISSI-HF trials [472].
Based on current evidence, routine administration of statins in patients
with HF without other indications for their use (e.g. CAD) is not re-
commended. Because there is no evidence of harm in patients on statin
treatment after the occurrence of HF, there is no need for statin dis-
continuation for patients already on treatment.
There is no evidence regarding the effect of PCSK9 inhibition in
patients with chronic HF. In the recent PCSK9 clinical outcomes trials,
FOURIER [119] and ODYSSEY Outcomes [120], PCSK9 inhibition in
patients with atherosclerotic CVD or after an ACS did not reduce the
risk of HF hospitalization. In the BIOlogy Study to TAilored Treatment
in Chronic Heart Failure (BIOSTAT-CHF) study of 2174 patients with
worsening HF, multivariable analysis revealed a positive linear asso-
ciation between PCSK9 levels and the risk of mortality, and the com-
posite of mortality and unplanned HF hospitalization [473]. Similarly,
there was a negative association between LDLR levels and mortality,
indicating a potential relationship between the PCSK9–LDLR axis and
outcomes among patients with HF that requires further investigation
[473,474].
Treatment with n-3 PUFAs 1 g o.d. may confer a small benefit in
patients with chronic HF, as shown by a significant 9% relative risk
reduction for mortality in the GISSI-HF RCT [475].
9.7.3. Valvular heart diseases
Aortic stenosis increases the risk of CV events and mortality, and
frequently coexists with atherosclerotic CVD. Life-long high levels of
LDL-C [476] and Lp(a) [477] have been associated with incident aortic
valve stenosis and aortic valve calcification in genetic Mendelian ran-
domization studies. Observational studies have suggested possible
beneficial effects of intensive lipid lowering in slowing the progression
of native valve aortic stenosis [478]. However, this has not been con-
firmed in RCTs [266,479–481], or in meta-analyses of observational
and randomized trials [482,483]. Three modestly sized trials
[479–481] and one large randomized trial (SEAS, which included 1873
patients treated with simvastatin 40 mg plus ezetimibe 10 mg or pla-
cebo) [266] failed to show a reduction in the clinical progression of
aortic stenosis in patients with mild-to-moderate native valve aortic
stenosis. In a post hoc analysis of the SEAS trial, the efficacy of lipid-
lowering therapy in impeding the progression of aortic stenosis in-
creased with higher pre-treatment LDL-C levels and lower peak aortic
jet velocity (i.e. milder stenosis at baseline) [484]. Similarly, a post hoc
analysis of three RCTs, including patients without known aortic valve
stenosis at baseline [Treating to New Targets (TNT), Incremental De-
crease In End-points Through Aggressive Lipid-lowering (IDEAL), and
Stroke Prevention by Aggressive Reduction in Cholesterol Levels
(SPARCL)] showed no impact of high-dose vs. usual-dose statin therapy
on the incidence of aortic valve stenosis [485]. In patients who un-
derwent transcatheter aortic valve replacement, statin therapy was as-
sociated with improved outcomes in a small observational study [486].
Aortic valve sclerosis (calcification of the aortic leaflets without
significant transvalvular pressure gradient) is associated with an in-
creased risk of CAD even in the absence of increased risk profiles.
Whether or not statins may be useful both for aortic valve disease and
CAD progression in such patients warrants further investigation [487].
Recommendations for lipid-lowering therapy in patients with HF
and valvular diseases are shown below.
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Recommendations for the treatment of dyslipidaemias in chronic heart failure
or valvular heart diseases.
CAD= coronary artery disease; HF=heart failure.
a Class of recommendation.
b Level of evidence.
9.8. Chronic kidney disease
CKD is defined as abnormalities of kidney structure or function,
present for> 3 months, with implications for health. CKD is classified
on the basis of the cause, GFR category, and category of albuminuria
[488]. In the adult population, decreasing GFR is associated with in-
creased CVD risk, independent of other CV risk factors [489–492].
There is an increased risk of both atherosclerotic vascular disease and
structural heart disease [492]. Patients with CKD and established CVD
have a much higher mortality rate compared with patients with CVD
and normal renal function [493]. Therefore, patients with CKD are
considered to be at high (stage 3 CKD) or very-high risk (stage 4–5 CKD
or on dialysis) of CVD, and there is no need to use risk estimation
models in these patients.
9.8.1. Lipoprotein profile in chronic kidney disease
In the initial stages of CKD, TG levels are specifically elevated and
HDL-C levels are lowered. LDL subclasses display a shift to an excess of
small dense LDL particles. Studies suggest that the kidney has a role in
Lp(a) catabolism and that Lp(a) levels are increased in association with
kidney disease. Such acquired abnormalities can be reversed by kidney
transplantation or remission of nephrosis.
9.8.2. Evidence for risk reduction through statin-based therapy in patients
with chronic kidney disease
In the Die Deutsche Diabetes Dialyse Studie (4D) trial, which in-
volved 1200 patients with diabetes on haemodialysis, atorvastatin had
no significant effect on risk of CVD [220]. Similar results were obtained
in the AURORA (A study to evaluate the Use of Rosuvastatin in subjects
On Regular haemodialysis: an Assessment of survival and cardiovas-
cular events) trial, which involved 2776 patients on haemodialysis
[221].
In the SHARP study [222], simvastatin and ezetimibe combination
therapy reduced the risk for major atherosclerotic events (coronary
death, MI, non-haemorrhagic stroke, or any revascularization) com-
pared with placebo in persons with CKD stage 3A–5. The trial did not
have sufficient power to separately assess the effects on the primary
outcome in dialysis and non-dialysis patients. Although statin-based
therapy is clearly effective in mild-to-moderate CKD, a major con-
troversy that remained after the publication of the 4D, AURORA, and
SHARP studies was whether statin therapy is effective in more ad-
vanced CKD, particularly dialysis patients. By combining data from the
three CKD trials with other trials in the existing database, the CTT in-
vestigators found that, even after adjusting for the smaller LDL-C re-
ductions achieved among patients with more advanced CKD and for
differences in outcome definitions between dialysis trials, there was a
trend towards smaller relative reductions per mmol/L reduction in LDL-
C in major atherosclerotic events as estimated GFR (eGFR) declines
(with little evidence of benefit among dialysis patients) [214]. This
diminution in relative risk reduction as GFR declines implies that, at
least in non-dialysis patients, more intensive LDL-lowering regimens
are required to achieve the same benefit.
9.8.3. Safety of lipid management in patients with chronic kidney disease
Safety issues and dose adjustments are important in advanced stages
of CKD (stages 3–5), as adverse events are commonly dose-related and
due to increased blood concentrations of compounds. Although it has
been suggested that preference should be given to regimens and doses
that have been shown to be beneficial in RCTs conducted specifically in
such patients [494], the CTT meta-analysis makes clear that the
goal—as in patients without CKD—should be to achieve the largest
possible absolute reduction in LDL-C safely. Although there were no
specific safety concerns raised by the 4D, AURORA, or SHARP trials,
statins metabolized via CYP3A4 may result in adverse effects due to
drug–drug interactions and caution is required.
Based on the evidence for lipid management in patients with CKD,
the Kidney Disease: Improving Global Outcomes (KDIGO) organization
has developed an updated clinical practice guideline for lipid man-
agement in CKD [494]. In line with this, but with a focus on those
patients at high or very-high risk for developing CVD, recommendations
are summarized below.
Recommendations for lipid management in patients with moderate-to-severe
(Kidney Disease Outcomes Quality Initiative stages 3–5) chronic kidney disease.
ASCVD=atherosclerotic cardiovascular disease; CKD= chronic kidney dis-
ease; eGFR= estimated glomerular filtration rate.
a Class of recommendation.
b Level of evidence.
c Defined as eGFR<60ml/min/1.73m2 on two measurements more than 3
months apart.
9.9. Transplantation
Dyslipidaemias are very common in patients who have undergone
heart, lung, liver, kidney, or allogenic haematopoietic stem cell trans-
plantation, and predispose such patients to an increased risk of devel-
oping ASCVD and transplant arterial vasculopathy [497–501]. In pa-
tients with CKD undergoing renal transplantation, the risk of ASCVD
may be determined, at least in part, by the increased risk resulting from
CKD itself.
Immunosuppressive drug regimens may have adverse effects on
lipid metabolism leading to increases in TC, VLDL, and TGs, and in the
size and density of LDL particles. These effects vary with different
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immunosuppressive drugs [497,498,502–506].
The management of dyslipidaemias in transplant recipients is
comparable to what is recommended for patients at high or very high
ASCVD risk, although more attention is needed regarding the causes of
the lipid disturbances and possible side effects due to drug–drug in-
teractions (see Recommendations for low-density lipoprotein in solid organ
transplant patients below).
The clinical effectiveness of statins in renal transplant patients is
uncertain owing to a lack of randomized trials in this population. A
systematic review of the benefits and harms of statins in patients with a
functioning kidney transplant included 3465 patients, free of CHD,
from 22 studies. Although the authors concluded that statins may re-
duce CV events, they also suggested a need for additional studies [253].
However, in patients with a functioning renal transplant at increased
risk of CVD, it may be appropriate to extrapolate from the clear evi-
dence of benefit from statin therapy, without safety concerns, in people
with moderate reductions in GFR [214].
Several potential drug interactions must also be considered, espe-
cially with ciclosporin, which is metabolized through CYP3A4, and may
increase systemic statin exposure and the risk of myopathy. Ciclosporin
increases the blood levels of all statins.
Fluvastatin, pravastatin, pitavastatin, and rosuvastatin are metabo-
lized through different CYP enzymes than the others and have less
potential for interaction [507].
Tacrolimus is also metabolized by CYP3A4, but appears to have less
potential for harmful interaction with statins than ciclosporin. Other
drugs that influence CYP3A4 activity should be avoided if possible, and
used with extreme caution in patients receiving both calcineurin in-
hibitors and statins.
For transplant patients with dyslipidaemia, ezetimibe could be
considered as an alternative for patients unable to take a statin or added
to the highest tolerated statin dose [507–509]. No outcome data are
available for this drug, which should generally be reserved for second-
line use. Ciclosporin can induce a 2–12-fold increase in the ezetimibe
level.
Care is required with the use of fibrates, as they can decrease ci-
closporin levels and have the potential to cause myopathy. Extreme
caution is required if fibrate therapy is planned in combination with a
statin. Cholestyramine is not effective as monotherapy in heart trans-
plant patients and has the potential to reduce absorption of im-
munosuppressants; this potential is minimized by separate adminis-
tration.
Recommendations for low-density lipoprotein lowering in solid organ trans-
plant patients.
a Class of recommendation.
b Level of evidence.
9.10. Peripheral arterial disease
PAD encompasses all vascular sites, including carotid, vertebral,
upper extremity, mesenteric, renal, and lower extremity arteries. The
aorta is often included in the term [510]. PAD is a common manifes-
tation of atherosclerosis and such patients are at elevated risk of cor-
onary events, with PAD representing an independent risk factor for MI
and CV death [510,511]. Patients with PAD are at very-high risk and
should be managed according to the recommendations in Table 7.
Elevated CV risk has led to the inclusion of PAD among the list of ‘risk
equivalent’ conditions, and therapeutic strategies of secondary pre-
vention should be implemented [see Recommendations for lipid-lowering
drugs in patients with peripheral arterial disease (including carotid artery
disease) below]. Yet, despite the high CV morbidity and mortality risk,
PAD patients are usually inadequately managed compared with CAD
patients [511].
9.10.1. Lower extremity arterial disease
A low ABI (0.90) is diagnostic for lower extremity arterial disease
(LEAD). Either a low (0.90) or high (1.40, related to stiffened arteries)
ABI is predictive of CV morbidity and mortality. Lowering LDL-C levels
reduces the risk of ischaemic CV events and worsening of claudication,
while it also improves walking performance. As for cardiac events, a
systematic review of 18 trials including 10 000 patients, with choles-
terol levels ranging from normal to elevated, reported that lipid-low-
ering therapy in people affected by atherosclerosis of the lower limbs
was associated with a 20% reduction in total CV events, together with a
non-significant 14% reduction of all-cause mortality [512]. In the Heart
Protection Study, the need for non-coronary revascularization was re-
duced by 16% with statin therapy [513].
In addition to statins, PSCK9 inhibitors have also been shown to
reduce CV events in PAD patients. In a pre-specified subgroup analysis
of the FOURIER trial, evolocumab significantly reduced the primary
endpoint in patients with PAD [514]. PAD had larger absolute risk re-
ductions for the primary endpoint (3.5% with PAD and 1.6% without
PAD). Evolocumab also reduced the risk of major adverse limb events
by 42% in patients, with consistent effects in those with and without
known PAD. In the FIELD trial, fenofibrate reduced the risk of ampu-
tations, particularly minor amputations without known large-vessel
disease, probably through non-lipid mechanisms [515].
9.10.2. Carotid artery disease
While there are currently no randomized studies that have assessed
whether lipid-lowering treatments reduce the incidence of CV events in
patients enrolled on the basis of carotid atherosclerotic disease and
without previous CV events, lipid-lowering therapy had reduced stroke
in numerous studies. In a meta-analysis of RCTs enrolling> 90 000
patients, statin therapy did lead to a 21% reduction in the incidence of
all strokes in different populations; this effect was mainly driven by the
extent of LDL-C reduction [460].
9.10.3. Retinal vascular disease
Atherosclerotic changes of retinal arteries correlate with TC, LDL-C,
TG, and apoB levels and also with CAD [516]. Fenofibrate reduces the
progression of diabetic retinopathy [517,518].
9.10.4. Secondary prevention in patients with abdominal aortic aneurysm
The presence of an abdominal aortic aneurysm represents a risk-
equivalent condition for CAD and is associated with age, male gender,
personal history of atherosclerotic CVD, smoking, hypertension, and
dyslipidaemia [519]; in contrast, diabetic patients are at decreased risk.
There are currently no available clinical trials on the reduction of
CV risk with lipid-lowering therapy in patients affected by this condi-
tion. Systematic reviews [520], mostly based on retrospective non-
randomized studies, have reported that there is still inconclusive evi-
dence that statin therapy reduces peri-operative CV morbidity and
mortality. In an RCT comparing atorvastatin 20 mg with placebo, the
composite endpoint of cardiac death, MI, stroke, and unstable angina
was significantly reduced in 100 patients undergoing vascular non-
cardiac surgery, including abdominal aortic aneurysm repair [521]. In
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another double-blind, placebo-controlled trial in 497 patients under-
going vascular surgery, peri-operative fluvastatin therapy (80 mg/day)
was associated with an improvement in post-operative cardiac outcome
[522].
9.10.5. Renovascular atherosclerosis
Lipid-lowering therapy has never been tested in an RCT in patients
affected by renovascular atherosclerosis; however, a recent non-ran-
domized population-based study showed that in patients older than 65
years of age with atherosclerotic renovascular disease raised the hy-
pothesis that such treatment may yield cardiorenal benefits; the risk of
a major cardiorenal composite endpoint (MI, stroke, HF, acute renal
failure, dialysis, and death) was significantly lower in statin users than
in non-users [523].
Recommendations for lipid-lowering drugs in patients with peripheral arterial
disease (including carotid artery disease).
ASCVD= atherosclerotic cardiovascular disease; PAD=peripheral arterial
disease; PCSK9=proprotein convertase subtilisin/kexin type 9.
a Class of recommendation.
b Level of evidence.
9.11. Other special populations at risk of atherosclerotic cardiovascular
disease
In general, the effects of lowering LDL-C are determined by the
absolute risk of ASCVD and the achieved reduction in LDL-C, so it is
important to identify and treat all those at increased risk of ASCVD.
There are a few specific groups of patients in whom an underlying
disease confers such increased risk, and in addition in whom the stan-
dard treatments may themselves cause dyslipidaemia that may con-
tribute to the risk of ASCVD. These include: (i) chronic immune-medi-
ated inflammatory disease, (ii) patients with human immunodeficiency
virus (HIV), and (iii) patients with severe mental illness. The manage-
ment principles are the same in these patient groups, but their man-
agement may need to address specific issues related to individual dys-
lipidaemias and drug safety. Details are provided in the Supplementary
Data document.
10. Inflammation
Recent advances in basic science have established a fundamental
role for low-degree chronic inflammation in mediating all stages of
atherosclerosis, from initiation through progression and, ultimately, to
the rupture of plaque and ensuing thrombotic complications of ather-
osclerosis. The cellular and molecular interactions involved during
atherogenesis are fundamentally not different from those in chronic
inflammatory–fibroproliferative diseases, such as rheumatoid arthritis
(RA), glomerulosclerosis, or pulmonary fibrosis [525]. Almost all cell
types of the immuno-inflammatory system, such as macrophages, and
T- and B-cells, as well as many pro- and anti-inflammatory cytokines
and chemokines, have been identified during the process of athero-
sclerosis [526].
Interestingly, cholesterol accumulation in cells triggers the in-
flammasome response and results in the production of inflammatory
mediators such as interleukin (IL)-1β. Numerous animal studies, using
the knockout model, have demonstrated that inflammation and the
immune system both play crucial roles during atherogenesis [527].
During inflammatory processes, large numbers of acute-phase pro-
teins have been identified, and several clinical studies have reported C-
reactive protein [528] to be the most useful serum marker of in-
flammation, even though it has poor specificity for any particular in-
flammation process, including atherosclerosis. The high-sensitivity C-
reactive protein diagnostic test was developed to detect very low levels
of C-reactive protein, and thereby enable a more accurate and precise
measure of chronic inflammation compared with standard C-reactive
protein [529]. This diagnostic tool differs only in the range of C-re-
active protein levels that it can detect. Several studies have found that
elevated levels of high-sensitivity C-reactive protein in the blood are
associated with an increased risk of CV events and could be used to
predict clinical outcomes independently of cholesterol levels [530,531].
Other studies have not been able to show any relationship between low-
grade chronic inflammation, as indicated by high-sensitivity C-reactive
protein levels, and increased risk of CV [532–535]. Finally, genetic
studies of large population cohorts have not demonstrated that chronic
elevated high-sensitivity C-reactive protein increases the risk of ather-
osclerotic events [536]. Nevertheless, in some guidelines, high-sensi-
tivity C-reactive protein has been added to traditional risk factors for
prognostic information, especially for patients at intermediate risk
[537,538].
Statins have been shown to reduce C-reactive protein secretion by
hepatocytes [539], and a series of clinical trials and post hoc analyses
have found that beneficial outcomes after statin therapy relate both to a
reduction in cholesterol levels and reduced inflammation [540–544].
The Justification for the Use of Statins in Prevention: an Intervention
Trial Evaluating Rosuvastatin (JUPITER) trial [542] demonstrated that
in primary prevention for individuals with chronically elevated C-re-
active protein (> 2 mg/L), statin treatment markedly reduced CV
events [545]. It is of note that other lipid-lowering agents, such as
ezetimibe and more recently the anti-PCSK9 mAbs, do not influence
high-sensitivity C-reactive protein levels [546,547], but lead to further
significant reductions in CV events when added to statin therapy.
Specific anti-inflammatory treatment was tested in the
Canakinumab Antiinflammatory Thrombosis Outcome Study (CANTOS)
trial [548]. In patients with previous MI and chronic elevated high-
sensitivity C-reactive protein levels, all on optimal medical treatment,
including statins, the anti-IL-1β mAb canakinumab dose-dependently
reduced high-sensitivity C-reactive protein and significantly lowered
the rate of recurrent CV events compared with placebo, independently
of the level of lipid lowering. Not surprisingly, there was a slight in-
crease in the risk of severe and fatal infections associated with cana-
kinumab. This study was the first to highlight the positive correlation
between high-sensitivity C-reactive protein and CV events, where lower
achieved high-sensitivity C-reactive protein values were directly cor-
related with a lower risk of future CV events [548]. Nevertheless, the
FDA declined to approve canakinumab for CV risk reduction on the
strength of data from the CANTOS study. As canakinumab treatment
has not been tested against anti-PCSK9 mAb and/or ezetimibe added to
statin therapy, the question of residual risk remains for patients with
elevated high-sensitivity C-reactive protein despite achieving very low
(below goal) LDL-C values, and whether patients with very low LDL-C
would benefit from anti-IL-1β treatment or other anti-inflammatory
agents. In addition, all currently recommended lipid-lowering drugs,
including anti-PCSK9 mAbs, have demonstrated beneficial effects on
atherosclerotic plaque composition as well as plaque volume regres-
sion; such results are still missing for anti-inflammatory treatment.
Another anti-inflammatory approach using methotrexate was tested in
the Cardiovascular Inflammation Reduction Trial (CIRT) [549]. Very
low-dose methotrexate (10 mg weekly), a proven anti-inflammatory
regimen that reduces tumour necrosis factor (TNF), IL-6, and C-reactive
protein levels and is widely used in the treatment of RA, was allocated
vs. placebo to 7000 stable CAD patients. This study was stopped pre-
maturely due to futility. Interestingly, this regimen of methotrexate had
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no effect on either IL-6 or high-sensitivity C-reactive protein blood le-
vels in this population, which could explain the neutral results of this
trial [550]. Based on the current level of evidence, no further re-
commendations on the use of anti-inflammatory agents can be made
[551].
11. Monitoring of lipids and enzymes in patients on lipid-lowering
therapy
Evidence concerning which tests should be carried out to monitor
lipids in patients on treatment is limited. Similar limited evidence ap-
plies to tests of possible toxicity, such as ALT and CK.
Recommendations stem from consensus rather than evidence-based
medicine.
Fig. 5. Health impact pyramid.
Fig. 6. Absolute reductions in major vascular events with statin therapy [233].
LDL= low-density lipoprotein. Reproduced from The Lancet, 388/10059, Col-
lins et al., ‘Interpretation of the evidence for the efficacy and safety of statin
therapy’, 2532–2561, 2016, with permission from Elsevier.
Table 13
Summary of recommendations for monitoring lipids and enzymes in patients,
before and on lipid-lowering therapy.
Testing lipids
How often should lipids be tested?• Before starting lipid-lowering drug treatment, at least two measurements should be
made, with an interval of 1–12 weeks, with the exception of conditions where
prompt drug treatment is suggested, such as ACS and very high-risk patients.
How often should a patient's lipids be tested after starting lipid-lowering
treatment?• After starting treatment: 8 (± 4) weeks.• After adjustment of treatment: 8 (± 4) weeks until the goal is achieved.
How often should lipids be tested once a patient has achieved the target or
optimal lipid level?• Annually (unless there are adherence problems or other specific reasons for more
frequent reviews).
Monitoring liver and muscle enzymes
How often should liver enzymes (ALT) be routinely measured in patients on
lipid-lowering drugs?• Before treatment.• Once, 8–12 weeks after starting a drug treatment or after dose increase.• Routine control of ALT thereafter is not recommended during statin treatment,
unless symptoms suggesting liver disease evolve. During treatment with fibrates,
control of ALT is still recommended.
What if liver enzymes become elevated in a person taking lipid-lowering drugs?
If ALT <3×ULN:• Continue therapy.• Recheck liver enzymes in 4–6 weeks.
If ALT rises to ≥3×ULN• Stop lipid-lowering therapy or reduce dose and recheck liver enzymes within 4–6
weeks.• Cautious reintroduction of therapy may be considered after ALT has returned to
normal.• If ALT remains elevated check for the other reasons.
How often should CK be measured in patients taking lipid-lowering drugs?
Pre-treatment
o Before starting therapy.
o If baseline CK is > 4×ULN, do not start drug therapy; recheck.
Monitoring:
o Routine monitoring of CK is not necessary.
o Check CK if patient develops myalgia.
Be alert regarding myopathy and CK elevation in patients at risk, such as: elderly
patients, those on concomitant interfering therapy, multiple medications, liver or
renal disease, or athletes.
What if CK becomes elevated in a person taking lipid-lowering drugs? Re-
evaluate indication for statin treatment. If≥ 4×ULN:• If CK > 10×ULN: stop treatment, check renal function, and monitor CK every 2
weeks.• If CK < 10×ULN: if no symptoms, continue lipid-lowering therapy while
monitoring CK between 2 and 6 weeks.• If CK < 10×ULN: if symptoms present, stop statin and monitor normalization of
CK, before rechallenge with a lower statin dose.• Consider the possibility of transient CK elevation for other reasons such as exertion.• Consider myopathy if CK remains elevated.• Consider combination therapy or an alternative drug.
○ If < 4×ULN:• If no muscle symptoms, continue statin (patient should be alerted to report
symptoms; check CK).• If muscle symptoms, monitor symptoms and CK regularly.• If symptoms persist, stop statin and re-evaluate symptoms after 6 weeks; re-evaluate
indication for statin treatment.• Consider rechallenge with the same or another statin.• Consider low-dose statin, alternate day or once/twice weekly dosing regimen, or
combination therapy.
○ For details on CK elevation and treatment of muscular symptoms during statin
treatment see algorithm in Supplementary Fig. 4. In which patients should
HbA1c or blood glucose be checked?• Regular checks of HbA1c or glucose should be considered in patients at high-risk of
developing diabetes, and on high-dose statin treatment.• Groups to be considered for glucose control are the elderly and patients with
metabolic syndrome, obesity, or other signs of insulin resistance.
ACS= acute coronary syndromesyndrome; ALT= alanine aminotransferase;
CK= creatine kinase; ULN=upper limit of normal.
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Response to therapy can be assessed at 6–8 weeks from initiation of
therapy, but response to lifestyle may take longer. Standard practice for
subsequent follow-up monitoring is 6–12 months, but such monitoring
intervals are arbitrary. As a minimum, LDL-C should be assessed
whenever available, but better management decisions will probably
occur if a full lipid profile is performed, including HDL-C and TGs. Non-
HDL-C or ApoB should also be analysed, and used as a secondary
treatment target. A separate issue is the impact of regular lipid mon-
itoring in promoting patient adherence to lifestyle changes or drug
regimens that impact positively on their health, as found in a range of
studies. It is unclear whether only the process of monitoring is critical in
achieving this or whether a combination of education, regular contact,
and adherence assessment is required.
Where pharmacological lipid-lowering therapy is implemented,
safety blood tests are advised, including ALT and CK at baseline, to
identify the limited number of patients where treatment is contra-
indicated. CK should be checked in patients at high-risk for myopathy,
such as the very elderly with comorbidities, patients with antecedents
of muscle symptoms, or patients receiving interacting drugs. A mild and
typically transient elevation of ALT is seen in about 2% of patients and
normalization is seen with continuing therapy [240,244,552]. Recent
reviews are encouraging regarding the safety of long-term statin
therapy and statin-induced liver injury is reported to be very un-
common [243,244,553–555]. ALT is recommended before the start of
statin therapy; routine control of ALT during treatment is not re-
commended but should be performed, if indicated, based on clinical
observations. During fibrate therapy, regular ALT control is still re-
commended. In patients whose liver function tests increase to above
three times the ULN, explanations such as alcohol ingestion or NAFLD
should be sought, and the levels monitored. If levels remain elevated
then lipid-lowering therapy should be stopped, but may be cautiously
reintroduced under monitoring after levels have returned to normal.
There is no predictive value of routine repeat CK testing for rhab-
domyolysis since the level can increase for many reasons, including
muscle injury or excess muscular exercise. However, CK must be as-
sessed immediately in patients who present with muscle pain and
weakness, and especially in the elderly, and treatment stopped if CK
rises to> 10 times the ULN. Strategies to handle CK elevations are
given in Table 13.
Due to the increased frequency of DM during statin treatment
[247,249,556,557], regular checks of HbA1c should be considered in
patients at high-risk of developing DM and under high-dose statin
treatment. Groups to be considered for glucose control are the elderly
or those with MetS, obesity, or signs of insulin resistance.
12. Cost-effectiveness of cardiovascular disease prevention by
lipid modification
In 2015, there were>85 million people in Europe living with CVD
[558]. Aging populations [559], unhealthy diets, smoking, sedentary
lifestyles, increasing obesity, and diabetes [560–563] are the main
contributors. CVD cost the European Union about €210 billion in 2015,
one-half of which was in healthcare costs (∼8% of total healthcare
expenditure), and the other half in productivity losses and informal care
[558].
In these Guidelines, the Joint Task Force recommends a range of
actions to reduce CVD by targeting plasma lipids, ranging from popu-
lation-wide initiatives to promote healthy lifestyles to individual-level
interventions to reduce CVD risk factors, such as unhealthy diets and
high lipid levels. Cost-effectiveness analysis can help target resources
for interventions where the net health gain is greatest in relation to the
net resources, and is increasingly required across Europe [564].
However, cost-effectiveness depends on available resources, the costs of
services, and disease risk in the population, and results obtained in one
country might not be valid in another [565]. In addition, to fully cap-
ture the long-term effects of interventions, cost-effectiveness studies
combining evidence from RCTs with modelling and limitations in both
could affect the reliability of findings. Here, the evidence for the cost-
effectiveness of ASCVD preventive interventions with respect to lipid
modification is summarized; further scrutiny in view of local circum-
stances is recommended.
The health impact pyramid summarizes the evidence on the relative
efforts and costs in relation to health impact (Fig. 5), with interventions
with the broadest impact on populations at the base and interventions
requiring considerable individual effort at the top [566]. There is
consensus that all the levels of the pyramid should be targeted but that
emphasis should be placed on the lower levels. This would address the
persistent socio-economic divide in CV health despite major improve-
ments in ASCVD treatment [558].
More than one-half of the reduction in CV mortality over the last
three decades has been attributed to population-level changes in CV risk
factors, primarily reductions in plasma cholesterol, BP levels, and
smoking [560–563,567]. Lifestyle changes at the population level may
be more cost-effective than lifestyle and drug interventions at the in-
dividual level, particularly when targeted to populations at increased
risk. Awareness and knowledge of how lifestyle risk factors lead to CVD
has increased in recent decades. Moreover, legislation promoting a
healthy lifestyle, such as reduced salt intake and smoking bans, has
been reported to be cost-effective in preventing CVD [568–573], and
initiatives to improve infrastructure and promote physical activity have
shown promise [574,575]. A number of structural strategies at inter-
national, national, and regional levels combined can substantially re-
duce CVD morbidity and mortality [576,577]. Individual-level inter-
ventions to improve diet [578,579], increase physical activity [580],
and stop smoking [581] could also be cost-effective [582]. However,
suboptimal adherence limits benefits [583,584], and interventions to
improve adherence, such as electronic device reminders to reinforce
favourable health behaviours, are increasingly being investigated
[585].
All statin regimens and ezetimibe are now generically available
across Europe. There is strong evidence that lowering blood cholesterol
levels using low-cost statins is widely cost-effective [586–590] in many
categories of patients. For secondary prevention of CVD, the evidence
suggests that statin treatments are highly cost-effective [586,590,591],
and adding low-cost ezetimibe to high-intensity statin therapy further
reduces LDL-C and CVD risk cost-effectively [592]. In primary ASCVD
prevention, the evidence indicates that generic statin-based treatments
are cost-effective for people at least down to 1% annual total CVD risk
and could be cost-effective at even lower risk [589], with the highest
tolerated statin dose likely the most cost-effective [591,593,594]. Im-
portantly, many patients on statin treatment fail to take their medica-
tions adequately and/or to reach their therapeutic goals [595], with
clinical and economic consequences [596,597]. Reinforcing measures
aimed at improving adherence to treatment is cost-effective [598–600].
Studies have shown that at mid-2018 prices PCSK9 inhibitors were
largely not cost-effective.601−604 Their cost-effectiveness is improved in
selected high-risk patients, such as those with clinical CVD or FH, other
comorbidities, and high LDL-C levels.605,606 However, at lower prices,
PCSK9 inhibitors would become cost-effective in a wider range of high-
risk patients; recent price reductions may therefore lead to increased
use.607 Cost-effectiveness evidence for other lipid-modifying therapies
is lacking.
Effective interventions to prevent ASCVD, including statins, typi-
cally exhibit similar relative risk reductions across categories of
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patients, including by ASCVD risk; therefore, health benefits and cost-
effectiveness are greater among people at higher ASCVD risk (Fig. 6)
[36,233]. Consequently, increased efforts and higher-intensity inter-
ventions should be aimed at individuals and populations at higher
ASCVD risk.
Box 8 lists the key messages regarding the cost-effectiveness of CVD
prevention by lipid modification, and Box 9 highlights gaps in the
evidence.
13. Strategies to encourage adoption of healthy lifestyle changes
and adherence to lipid-modifying therapies
Helping patients to change to healthier lifestyle habits is most ef-
fectively achieved through formal programmes of preventive care,
possibly because of the intensive follow-up and multidisciplinary ex-
pertise they provide.608 However, in everyday care, adherence to both
healthy lifestyle changes and medication regimens is a challenge to
patients and professionals.
A comprehensive patient- and family-centred approach located in
one healthcare setting is recommended rather than addressing single
risk factors with more than one intervention in different locations. Box
10 includes some useful techniques when counselling patients for
behavioural change.
A comprehensive approach to improving adherence to medication is
described in the Supplementary Data document.
14. Key messages
1. Cholesterol and risk. Prospective studies, randomized trials, and
Mendelian randomization studies have all shown that raised LDL-C
is a cause of ASCVD. Throughout the range of LDL-C levels, ‘lower
is better’ with no lower threshold, at least down to ∼1 mmoL/L.
Lowering LDL-C may yield worthwhile benefits in patients with
average or below average LDL-C who are already receiving LDL-C-
lowering treatment. The proportional reduction in ASCVD risk
achieved by lowering LDL-C (e.g. with a statin, ezetimibe, or
PCSK9-inhibitor) depends on the absolute reduction in LDL-C, with
each 1 mmoL/L reduction corresponding to a reduction of about
one-fifth in ASCVD.
2. PCSK-9 inhibitors. Large trials have shown that PCSK9 inhibitors
further reduce ASCVD risk when given on top of statin-based
therapy and their use may need to be restricted to those at the
highest risk for ASCVD.
3. Use of cardiac imaging for risk stratification. CAC score
Box 8
Key messages
Prevention of CVD by lifestyle changes, medication, or both is cost-effective in many scenarios, including population-based approaches and
actions directed at individuals at increased CVD risk.
Cost-effectiveness depends on several factors, including baseline CVD risk and LDL levels, cost of treatment, and uptake of preventive
strategies.
Interventions to prevent CVD are more cost-effective among individuals and populations at higher CVD risk.
Cost-effectiveness analyses are importantly informed by assumptions about long-term disease prognosis and treatment effects.
Strengthening of the evidence to inform these assumptions is encouraged.
CVD= cardiovascular disease; LDL= low-density lipoprotein.
Box 9
Gaps in the evidence
Cost-effectiveness requires evidence for effects of interventions on health and healthcare over a long time period; modelling techniques fill
gaps. More data are needed from RCTs and observational studies.
Direct evidence of effects of lipid-modifying treatments on overall mortality, particularly among people at low-to-moderate CVD risk, older
people, and for newer interventions, is lacking. Long-term post-trial follow-up in RCTs should be encouraged.
The cost-effectiveness of using lifetime CVD risk and more precise CVD risk scores to target interventions needs further investigation.
CVD= cardiovascular disease; RCT= randomized controlled trial.
Box 10
Methods for enhancing adherence to lifestyle changes
1. Explore motivation and identify ambivalence. Weigh pros and cons for change, assess and build self-efficacy and confidence, and avoid
circular discussion.
2. Offer support, and establish an alliance with the patient and his/her family.
3. Involve the partner, other household members, or caregiver who may be influential in the lifestyle of the patient.
4. Use the OARS method (Open-ended questions, Affirmation, Reflective listening, Summarising when discussing behaviour changes (www.
smartrecovery.org/wp-content/uploads/2017/03/UsingMIinSR.pdf).
5. Tailor advice to an individual patient's culture, habits, and situation.
6. Use SMART goal setting (negotiate goals for change that are Specific,Measurable, Achievable, Realistic, and Timely). Follow-up on goals and
record progress on a shared record.
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assessment with CT may be helpful in reaching decisions about
treatment in people who are at moderate risk of ASCVD. Obtaining
such a score may assist in discussions about treatment strategies in
patients where the LDL-C goal is not achieved with lifestyle inter-
vention alone and there is a question of whether to institute LDL-C-
lowering treatment. Assessment of arterial (carotid or femoral)
plaque burden on ultrasonography may also be informative in these
circumstances.
4. Use of ApoB in risk stratification. ApoB may be a better measure
of an individual's exposure to atherosclerotic lipoproteins, and
hence its use may be particularly helpful for risk assessment in
people where measurement of LDL-C underestimates this burden,
such as those with high TG, DM, obesity, or very low LDL-C.
5. Use of Lp(a) in risk stratification. A one-off measurement of Lp(a)
may help to identify people with very high inherited Lp(a) levels
who may have a substantial lifetime risk of ASCVD. It may also be
helpful in further risk stratification of patients at high risk of
ASCVD, in patients with a family history of premature CVD, and to
determine treatment strategies in people whose estimated risk is on
the border of risk categories.
6. Intensification of treatment goals. It is important to ensure that
treatment of the highest-risk patients achieves the largest LDL-C
reduction possible. These Guidelines aim to support this by setting
both a minimum percentage LDL-C reduction (50%) and an abso-
lute LDL-C treatment goal of< 1.4 mmoL/L (< 55 mg/dL) for
very-high-risk patients, and<1.8 mmoL/L (< 70 mg/dL) for high-
risk patients. It is recommended that FH patients with ASCVD or
who have another major risk factor are treated as very-high risk,
and those with no prior ASCVD or other risk factors as high-risk.
7. Treatment of patients with recent ACS. New randomized trials
support a strategy of intensification of LDL-C-lowering therapy in
very-high-risk patients with ACS (MI or unstable angina). If the
specified LDL-C treatment goal is not achieved after 4–6 weeks with
the highest tolerated statin dose and ezetimibe, it is appropriate to
add a PCSK9 inhibitor.
8. Safety of low LDL cholesterol concentrations. There are no
known adverse effects of very low LDL-C concentrations [e.g.< 1
mmoL/L (40 mg/dL)].
9. Management of statin ‘intolerance’. While statins rarely cause
serious muscle damage (myopathy, or rhabdomyolysis in the most
severe cases), there is much public concern that statins may com-
monly cause less serious muscle symptoms. Such statin ‘intolerance’
is frequently encountered by practitioners and may be difficult to
manage. However, placebo-controlled randomized trials have
shown very clearly that true statin intolerance is rare, and that it is
generally possible to institute some form of statin therapy (e.g. by
changing the statin or reducing the dose) in the overwhelming
majority of patients at risk of ASCVD.
10. Statin treatment for older people. A meta-analysis of randomized
trials has shown that the effects of statin therapy are determined by
the absolute reduction in LDL-C as well as the baseline ASCVD risk,
and are independent of all known risk factors, including age. Statin
therapy in older people should therefore be considered according to
the estimated level of risk and baseline LDL-C, albeit with due re-
gard to an individual's underlying health status and the risk of drug
interactions. There is less certainty about the effects of statins in
individuals aged>75 years, particularly in primary prevention.
Statin therapy should be started at a low dose if there is significant
renal impairment and/or the potential for drug interactions, and
then titrated upwards to achieve LDL-C treatment goals.
15. Gaps in the evidence
• Prospective studies are needed to investigate the incremental value
of reclassifying total CV risk and defining eligibility for lipid-low-
ering therapy based on CAC scores in individuals at moderate or
high-risk.• Outcome-based comparisons of CAC scores vs. assessment of arterial
(carotid or femoral) plaque burden by ultrasonography for CV risk
reclassification in people at moderate or high-risk are needed.• Although calibrated country-specific versions of the SCORE system
are available for many European countries, risk charts based on
country-specific cohort data are missing for most countries.
Regional total event charts (vs. mortality-only charts) are needed.• Total CV risk estimation by means of the SCORE system and, ac-
cordingly, recommendations on eligibility for statins as well as
treatment goals are based on TC, whereas LDL-C is the primary lipid
analysis method for screening, diagnosis, and management.• There are no outcome-based comparisons of LDL-C vs. ApoB as
primary measurement methods for screening, diagnosis, and man-
agement.• Against a background of genetic and randomized clinical trial evi-
dence showing no significant effect of increasing HDL levels on the
risk of CVD events, the clinical impact of therapies altering the
function of HDL particles is unknown. More evidence is needed re-
garding the apparently adverse association of extremely high levels
of HDL-C with clinical outcomes.• Dedicated studies assessing outcomes with specific Lp(a)-lowering
therapies are warranted.• More evidence is needed for PCSK9 inhibitors in specific popula-
tions, including patients with severe CKD and on dialysis, patients
with HIV infection, in children and adolescents with FH, after heart
transplantation, and during pregnancy.• The effects of PCSK9 inhibition in all body compartments (as with
siRNA or antisense) or only within plasma (as with monoclonal
antibodies) remain to be established.• How early should a PCSK9 inhibitor be initiated in patients with
ACS or stroke? In view of evidence of sustained clinical benefit as-
sociated with the early initiation of statin treatment in the acute
phase of ACS or stroke, the optimal timing of PCSK9 inhibitor
treatment in ACS and stroke patients remains to be addressed in
outcome studies.• Whether very low LDL-C levels achieved with the combination of
statin, ezetimibe, and PCSK9 inhibitor reduce the need for further
PCI remains to be addressed in outcome studies.• In patients with chronic HF, a small benefit of n-3 PUFAs has been
shown in one RCT and merits further investigation.• What is the optimal screening programme for detecting FH?• In view of limited access to genetic testing in several environments,
more evidence is needed regarding outcomes with only clinical vs.
genetic screening and diagnosis of FH.• More RCT evidence is required to support the use of statin-based
treatment in older people (aged ≥75 years, but particularly in those
aged ≥80 years).• More RCT evidence is needed for statin treatment in kidney trans-
plant recipients.• There are no data on the effects of statins, ezetimibe, or fibrates on
CV events in dyslipidaemic HIV-infected patients.• More evidence is needed regarding attainment of recommended LDL
goals among very high-risk patients in real-world practice in the era
of increasingly prescribed combination therapies for LDL lowering.
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16. ‘What to do’ and ‘what not to do’ messages from the guidelines
F. Mach, et al. Atherosclerosis 290 (2019) 140–205
187
F. Mach, et al. Atherosclerosis 290 (2019) 140–205
188
ESC entities having participated in the development of this
document
Associations: Acute Cardiovascular Care Association (ACCA),
Association of Cardiovascular Nursing & Allied Professions (ACNAP),
European Association of Cardiovascular Imaging (EACVI), European
Association of Preventive Cardiology (EAPC), European Association of
Percutaneous Cardiovascular Interventions (EAPCI).
Councils: Council for Cardiology Practice, Council on Hypertension,
Council on Stroke.
Working Groups: Aorta and Peripheral Vascular Diseases,
Atherosclerosis and Vascular Biology, Cardiovascular Pharmacotherapy,
e-Cardiology, Thrombosis.
The content of these European Society of Cardiology (ESC)
Guidelines has been published for personal and educational use only.
No commercial use is authorized. No part of the ESC Guidelines may be
translated or reproduced in any form without written permission from
the ESC. Permission can be obtained upon submission of a written re-
quest to Oxford University Press, the publisher of the European Heart
Journal and the party authorized to handle such permissions on behalf
of the ESC (journals.permissions@oxfordjournals.org).
Disclaimer. The ESC/EAS Guidelines represent the views of the ESC
and EAS, and were produced after careful consideration of the scientific
and medical knowledge, and the evidence available at the time of their
publication. The ESC and EAS is not responsible in the event of any
contradiction, discrepancy, and/or ambiguity between the ESC/EAS
Guidelines and any other official recommendations or guidelines issued
by the relevant public health authorities, in particular in relation to
good use of healthcare or therapeutic strategies. Health professionals
are encouraged to take the ESC/EAS Guidelines fully into account when
exercising their clinical judgment, as well as in the determination and
the implementation of preventive, diagnostic, or therapeutic medical
strategies; however, the ESC/EAS Guidelines do not override, in any
way whatsoever, the individual responsibility of health professionals to
make appropriate and accurate decisions in consideration of each pa-
tient's health condition and in consultation with that patient and, where
appropriate and/or necessary, the patient's caregiver. Nor do the ESC/
EAS Guidelines exempt health professionals from taking into full and
careful consideration the relevant official updated recommendations or
guidelines issued by the competent public health authorities, in order to
manage each patient's case in light of the scientifically accepted data
pursuant to their respective ethical and professional obligations. It is
also the health professional's responsibility to verify the applicable rules
and regulations relating to drugs and medical devices at the time of
prescription.
Appendix A. Supplementary data
Supplementary Data with additional Supplementary Tables, Boxes,
and text complementing the full text—as well as sections on other
features of a healthy diet contributing to cardiovascular disease pre-
vention, chronic immune-mediated inflammatory diseases, HIV pa-
tients, severe mental illness, and adhering to medications along with
the related references—are available on the European Heart Journal
website and via the ESC website at www.escardio.org/guidelines.
Supplementary data to this article can be found online at https://
doi.org/10.1016/j.atherosclerosis.2019.08.014.
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